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1. What is cardiovascular disease prevention?  185 
1.1 Definition and rationale 186 
Cardiovascular disease (CVD) prevention is defined as a coordinated set of actions, at 187 
the population level or targeted at an individual, that are aimed at eliminating or 188 
minimizing the impact of CVDs and their related disabilities.1 CVD remains a leading 189 
cause of morbidity and mortality, despite improvements in outcomes: age-adjusted 190 
coronary artery disease (CAD) mortality has declined since the 1980s, particularly in 191 
high-income regions.2 CAD rates are now less than half what they were in the early 192 
1980s in many countries in Europe, due to preventive measure including the success of 193 
smoking legislation. However inequalities between countries persist and many risk 194 
factors, particularly obesity3 and diabetes (DM),4 have been increasing substantially. If 195 
prevention was practiced as instructed it would markedly reduce the prevalence of 196 
CVD. It is thus not only prevailing risk factors that are of concerns but poor 197 
implementation of preventive measures as well.5, 6 Prevention should be delivered (i) at 198 
the general population level by promoting healthy lifestyle behaviour7 and (ii) at the 199 
individual level, i.e. in those subjects at moderate to high risk of CVD or patients with 200 
established CVD, by tackling an unhealthy lifestyle (e.g. poor-quality diet, physical 201 
inactivity, smoking), and by optimising risk factors. Prevention is effective: the 202 
elimination of health risk behaviours would make it possible to prevent at least 80% of 203 
CVDs and even 40% of cancers.8, 9 204 
 205 
1.2 Development of the 6th Joint Task Force guidelines 206 
The present guidelines represent an evidence-base consensus of the Sixth European 207 
Joint Task Force involving 10 professional societies.  208 
By appraising the current evidence and identifying remaining knowledge gaps in 209 
managing CVD prevention, the Task Force formulated recommendations to guide 210 
actions to prevent CVD in clinical practice. The Task Force followed the quality criteria 211 
for development of guidelines, which can be found at 212 
www.escardio.org/knowledge/guidelines/rules. For simplification and in keeping with 213 
other European Society of Cardiology (ESC) guidelines, the ESC grading system based 214 
on classes of recommendation and levels of evidence has been maintained, recognising 215 
that this may be less suitable to measure the impact of prevention strategies, particularly 216 
those related to behavioural issues and population based interventions.  217 
This document has been developed to support healthcare professionals communicating 218 
with individuals about their cardiovascular (CV) risk and the benefits of a healthy 219 
lifestyle and early modification of their CV risk. In addition, the guidelines provide 220 
tools for healthcare professionals to promote population-based strategies and integrate 221 
these into national or regional prevention frameworks and to translate these in locally 222 
delivered healthcare services, in line with the recommendations of the World Health 223 
Organization (WHO) global status report on non-communicable diseases 2010.10 224 
As in the present guidelines, the model presented in the previous document from the 225 
Fifth European Joint Task Force11 has been structured around four core questions: 1. 226 
What is CVD prevention? 2. Who will benefit from prevention? 3. How to intervene? 4. 227 
Where to intervene?  228 
Compared to the previous guidelines, greater emphasis has been put on a population-229 
based approach, on disease-specific interventions, and on female specific conditions, 230 
younger individuals and ethnic minorities. Due to space restriction for the paper 231 
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version, the chapter on disease-specific intervention is on the web, together with a few 232 
tables and figures for more detail [add link to website].  233 
A lifetime approach to CV risk is important since both CV risk and prevention are 234 
dynamic and continuous as patients age and/or accumulate comorbidities. This implies 235 
that apart from improving lifestyle and reducing risk factor levels in patients with 236 
established CVD and those at increased risk of developing CVD, healthy people of all 237 
ages should be encouraged to adopt a healthy lifestyle. Healthcare professionals play an 238 
important role in achieving this in their clinical practice.  239 
1.3 Cost effectiveness of prevention 240 
Key messages 241 
• Prevention of CVD, either by implementation of lifestyle changes or use of 242 
medication, is cost-effective in many scenarios, including population-based 243 
approaches and actions directed at high-risk individuals. 244 
• Cost-effectiveness depends on several factors, including baseline CV risk, cost of 245 
drugs or other interventions, reimbursement procedures, and implementation of 246 
preventive strategies. 247 
Recommendations for cost-effective prevention of cardiovascular disease 248 
Recommendations Classa Levelb Refc 
Measures aimed at promoting healthy lifestyles at the 
population level should be considered. 
IIa B 12, 13 
aClass of recommendation. 249 
bLevel of evidence. 250 
cReference(s) supporting recommendations. 251 
 252 
In 2009, costs related to CVD amounted to €106 billion, representing approximately 9% 253 
of the total healthcare expenditure across the European Union (EU).14 Thus, CVD 254 
represents a considerable economic burden to society, and effective preventive 255 
measures are necessary. There is consensus in favour of an approach combining 256 
strategies to improve CV health across the population at large from childhood onwards, 257 
with specific actions to improve CV health in individuals at increased risk of CVD or 258 
with established CVD. 259 
Most studies assessing cost-effectiveness of CVD prevention combine evidence from 260 
clinical research with simulation approaches, while cost-effectiveness data from 261 
randomized controlled trials (RCTs) are relatively scarce.15, 16 Cost-effectiveness 262 
strongly depends on parameters such as the target population’s age, the overall 263 
population risk of CVD, and the cost of interventions. Hence, results obtained in one 264 
country may not be valid in another. Furthermore, changes such as the introduction of 265 
generic drugs can considerably change cost-effectiveness.17 According to the WHO, 266 
policy and environmental changes could reduce CVD in all countries for less than US$1 267 
per person per year.18 A report from the National Institute for Health and Care 268 
Excellence (NICE) estimated that a UK national programme reducing population CV 269 
risk by 1% would prevent 25,000 CVD cases and generate savings of €40 million per 270 
year. Coronary artery disease (CAD) mortality rates could be halved by only modest 271 
risk factor reduction and it has been suggested that eight dietary priorities alone could 272 
halve CVD death.13 273 
In the last three decades, over half of the reduction in CV mortality has been attributed 274 
to changes in risk factor levels in the population, primarily the reduction in cholesterol 275 
and blood pressure (BP) levels and smoking. This favourable trend is partly off-set by 276 
an increase in other risk factors, mainly obesity and type 2 DM.19, 20 Aging of the 277 
population also increases CVD events.21  278 
Several population interventions have efficiently modified the lifestyle of individuals. 279 
For example, increased awareness of how healthy lifestyles prevent CVD has helped to 280 
reduce smoking and cholesterol levels. Lifestyle interventions act on several CV risk 281 
factors and should be applied prior to or in conjunction with drug therapies. Also, 282 
legislation aimed at decreasing salt and trans fatty acid content of foods and smoking 283 
habits is cost-effective in preventing CVD 12, 13, 19.  284 
Cholesterol lowering using statins15, 16 and improvement in BP control are cost-effective 285 
if targeted at persons with high CV risk.22 Importantly, a sizable portion of patients on 286 
lipid lowering drugs or BP lowering drug treatment fails to take their treatment 287 
adequately or to reach therapeutic goals 23, 24, with clinical and economic consequences. 288 
 289 
Gaps in evidence 290 
• Most cost-effectiveness studies rely on simulation. More data, mainly from RCTs, 291 
are needed. 292 
 293 
2. Who will benefit from prevention? When and how to assess risk and 294 
prioritize  295 
2.1 Estimation of total cardiovascular risk  296 
All current guidelines on the prevention of CVD in clinical practice recommend the 297 
assessment of total CVD risk because atherosclerosis is usually the product of a number 298 
of risk factors. Prevention of CVD in an individual should be adapted to his or her total 299 
CV risk: the higher the risk, the more intense the action should be.  300 
The importance of total risk estimation in apparently healthy people before management 301 
decisions are made is illustrated in Table 1 derived from the high risk SCORE chart 302 
[http://www.escardio.org/Guidelines-&-Education/Practice-tools/CVD-prevention-303 
toolbox/SCORE-Risk-Charts]. This shows that a person with a cholesterol level of 7 304 
mmol/L can be at 10 times lower risk than someone with a cholesterol level of 5 305 
mmol/L if the former is a female and the latter is a male hypertensive smoker. 306 
 307 
Table 1 Impact of combinations of risk factors on risk 308 
Gender Age 
(years) 
Cholesterol 
(mmol/l) 
SBP 
(mmHg) 
Smoker Risk (10 year 
risk of fatal 
CVD) 
F 60 7 120 No 2% 
F 60 7 140 Yes 5% 
M 60 6 160 No 9% 
M 60 5 180 Yes 21% 
CVD = cardiovascular disease; F = female; M = male; SBP = systolic blood pressure. 309 
 310 
A recent meta-analysis on CV risk reduction by treatment with BP lowering drugs does, 311 
however, support the concept that absolute risk reduction is larger in those at higher 312 
baseline risk.25 This was confirmed in a further meta-analysis which also showed a 313 
greater residual risk during treatment in those at higher baseline risk, supporting earlier 314 
intervention 26, 27.  315 
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Although clinicians often ask for decisional thresholds to trigger intervention, this is 316 
problematic since risk is a continuum and there is no exact point above which, for 317 
example, a drug is automatically indicated, nor below which lifestyle advice may not 318 
usefully be offered.  319 
The risk categories presented later in this section are to assist the physician in dealing 320 
with individual people. They acknowledge that although individuals at the highest 321 
levels of risk gain most from risk factor interventions, most deaths in a community 322 
come from those at lower levels of risk, simply because they are more numerous 323 
compared to high risk individuals. Thus a strategy for individuals at high risk must be 324 
complemented by public health measures to encourage a healthy lifestyle and to reduce 325 
population levels of CV risk factors.  326 
It is essential for clinicians to be able to assess CV risk rapidly and with sufficient 327 
accuracy. This realization led to the development of the risk chart used in the 1994 and 328 
1998 Guidelines. This chart, developed from a concept pioneered by Anderson,28 used 329 
age, sex, smoking status, blood cholesterol and systolic BP (SBP) to estimate the 10 330 
year risk of a first fatal or non-fatal CAD event. There were several problems with this 331 
chart, which are outlined in the Fourth Joint European Guidelines on prevention.11, 29 332 
This led to the presently recommended Systematic Coronary Risk Estimation (SCORE) 333 
system, estimating an individual’s 10 year risk of fatal CVD. 30 The SCORE charts have 334 
been developed to estimate risk in both high and low risk European populations, but its 335 
applicability to non-Caucasian populations has not been examined. 336 
2.2 When to assess total cardiovascular risk? 337 
 338 
Recommendations for cardiovascular risk assessment 339 
BP = blood pressure; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus. 340 
aClass of recommendation. 341 
bLevel of evidence. 342 
 343 
Screening is the identification of unrecognized disease or, in this case, of an unknown 344 
increased risk of CVD in individuals without symptoms. CV risk assessment or 345 
screening can be done opportunistically or systematically. Opportunistic screening 346 
means without a predefined strategy, but is done when the opportunity arises (e.g. when 347 
the individual is consulting his or her general practitioner (GP) for some other reason). 348 
Systematic screening can be done in the general population as part of a screening 349 
programme or in targeted subpopulations, such as subjects with a family history of 350 
premature CVD or familial hyperlipidemia.  351 
Recommendations Classa Levelb 
Systematic CV risk assessment is recommended in individuals at 
increased CV risk, i.e. with family history of premature CVD, familial 
hyperlipidaemia, major CV risk factors (such as smoking, high BP, 
DM or raised lipid levels) or comorbidities increasing CV risk. 
I C 
It is recommended to repeat CV risk assessment every 5 years, and 
more often for individuals with risks close to thresholds mandating 
treatment. 
I C 
Systematic CV risk assessment may be considered in men > 40 years 
of age and in women >50 years of age or post-menopausal with no 
known CV risk factors. 
IIb C 
Systematic CV risk assessment in men < 40 and women < 50 years of 
age with no known CV risk factors is not recommended. 
III C 
While the ideal scenario would be for all adults to have their risk assessed, this is not 352 
practical in many societies. The decision about who to screen must be made by 353 
individual countries and will be resource-dependent.  354 
In a meta-analysis, GP based health checks on cholesterol, BP, body mass index (BMI) 355 
and smoking were effective in improving surrogate outcomes, especially in high-risk 356 
patients.31 A large study of CV risk assessment in the general population found that 357 
although there were overall improvements in risk factors, there was no impact on CV 358 
outcomes at population level32. A Cochrane review of RCTs using counselling or 359 
education to modify CV risk factors in adults from the general population, occupational 360 
groups or those with specific risk factors (i.e. DM, hypertension) concluded that risk 361 
factor improvements were modest and interventions did not reduce total or CV 362 
mortality in general populations but reduced mortality in high-risk hypertensive and 363 
DM populations.33 Although the benefits of treating asymptomatic conditions such as 364 
hypertension, DM and dyslipidemia on morbidity and mortality outcomes have been 365 
documented, a Cochrane review of the existing trials concluded that general health 366 
checks (including screening for these conditions) do not reduce all cause or CV 367 
morbidity or mortality.34 However, most studies were performed 3 to 4 decades ago, 368 
and thus risk factor interventions were not contemporary. Perhaps application of 369 
medical treatment in addition to the lifestyle interventions that were the core component 370 
of most trials would improve efficacy.  371 
Most guidelines recommend a mixture of opportunistic and systematic screening.11, 35-38 372 
Screening in people at relatively low risk of CVD is not particularly effective in 373 
reducing the risk of CV events. The costs of such screening interventions are high and 374 
these resources may be better used in people at higher CV risk, or with established 375 
CVD. In many countries GPs have a unique role in identifying individuals at risk of, but 376 
without established, CVD and assessing their eligibility for intervention (see section 377 
4a.1.1). A modelling study based on the European Prospective Investigation of Cancer-378 
Norfolk (EPIC-Norfolk) cohort data concluded that, compared with the National Health 379 
Service (NHS) national strategy to screen all adults aged 40–74 years for CV risk, 380 
Inviting the 60% of the population at the highest risk according to an integrated risk 381 
score was equally effective in preventing new cases of CVD and had potential cost 382 
savings.39  383 
A general concern in screening, including CV risk assessment, is its potential to do 384 
harm. False positive results can cause unnecessary concern and medical treatment. 385 
Conversely, false negative results may lead to inappropriate reassurance and lack of 386 
lifestyle changes. However, current data suggest that participating in CV screening in 387 
general does not cause worry in the screeners.40-43 More research is needed on how 388 
certain subgroups, such as older people, the socially deprived and ethnic minorities, 389 
react to screening. 390 
Despite limited evidence, these guidelines recommend a systematic approach to CV risk 391 
assessment targeting populations likely to be at higher CV risk, such as those with a 392 
family history of premature CVD. Thus systematic CV risk assessment in men younger 393 
than 40 and women younger than 50 years of age with no known CV risk factors is not 394 
recommended. Additionally, screening of specific groups with jobs that place other 395 
people at risk, e.g. bus drivers and pilots, may be reasonable, as is screening for CV risk 396 
factors in women before prescribing combined oral contraception, although there is no 397 
data to support the beneficial effects. Beyond this, systematic CV risk assessment in 398 
adults below the age of 40 years with no known CV risk factors is not recommended as 399 
a main strategy due to the low cost-effectiveness. Systematic CV assessment may be 400 
considered in adult men > 40 years of age and in women > 50 years of age or post-401 
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menopausal with no known CV risk factors. Risk assessment is not a one-time event; it 402 
should be repeated, for example every 5 years. 403 
2.3 How to estimate total cardiovascular risk? 404 
Key messages 405 
• In apparently healthy persons, CV risk in general is the result of multiple, 406 
interacting risk factors. This is the basis for the total CV risk approach to 407 
prevention. 408 
• SCORE, which estimates 10-year risk of fatal CVD, is recommended for risk 409 
assessment and can assist in making logical management decisions, and may help to 410 
avoid both under- and over-treatment. Validated local risk estimation systems are 411 
useful alternatives to SCORE. 412 
• Individuals automatically at high to very high CV risk (table 5) do not need the use 413 
of a risk score and require immediate attention to risk factors. 414 
• In younger persons, a low absolute risk may conceal a very high relative risk and 415 
use of the relative risk chart or calculation of their “risk age” may help in advising 416 
them of the need for intensive preventive efforts.  417 
• While women are at lower CV risk than men, their risk is deferred by about 10 years 418 
rather than avoided. 419 
• The total risk approach allows flexibility; if perfection cannot be achieved with one 420 
risk factor, trying harder with others can still reduce risk. 421 
 422 
Recommendations for how to estimate cardiovascular risk  423 
 Recommendations Classa Levelb Refc 
Total CV risk estimation, using a risk estimation system such 
as SCORE, is recommended for adults >40 years of age, unless 
they are automatically categorised as being at high risk or very 
high risk based on documented CVD, DM (> 40 years of age), 
kidney disease or highly elevated single risk factor (table 5). 
1 C 11, 25 
CV = cardiovascular; DM = diabetes mellitus; SCORE = Systematic Coronary Risk Estimation. 424 
aClass of recommendation. 425 
bLevel of evidence. 426 
cReference(s) supporting recommendations. 427 
2.3.1 Ten-year cardiovascular risk 428 
Many CV risk assessment systems are available for use in apparently healthy 429 
individuals (Table 2), including Framingham,44 SCORE,30 ASSIGN (CV risk estimation 430 
model from the Scottish Intercollegiate Guidelines Network),45 Q-Risk,46, 47 PROCAM 431 
(Prospective Cardiovascular Munster Study),48 CUORE,49 the Pooled Cohort 432 
equations,50 Arriba51 and Globorisk.52 In practice, most risk estimation systems perform 433 
rather similarly when applied to populations recognizably comparable to those from 434 
which the risk estimation system was derived. Since 2003, the European Guidelines on 435 
CVD prevention in clinical practice recommend the use of the SCORE system because 436 
it is based on large, representative European cohort datasets. The SCORE risk function 437 
has been externally validated.53 438 
Table 3 lists the advantages of the SCORE risk charts. 439 
 Framingham44 SCORE30 ASSIGN – 
SCORE45 
QRISK146 & 
QRISK247 
PROCAM48 Pooled Cohort 
Studies 
Equations50 
CUORE 
49 
Globorisk52 
 
Data: Prospective studies: 
Framingham Heart Study and 
Framingham offspring study. 
Latest version includes both 
12 pooled 
prospective studies  
 
SHHEC 
Prospective 
study 
QRESEARCH 
database 
Prospective study 4 Pooled prospective 
studies 
ARIC 
CHS 
CARDIA 
Framingham (original 
and offspring 
studies) 
CUORE Derivation cohort: Eight 
pooled prospective studies - 
Atherosclerosis Risk in 
Communities, Cardiovascular 
Health Study, Framingham 
Heart Study original cohort 
and offspring cohort, 
Honolulu Program, Multiple 
Risk Factor Intervention Trial, 
Puerto Rico Heart Health 
Program, and Women's 
Health Initiative Clinical Trial 
Population: General population, 
Framingham, 
Massachusetts, USA. 
Baselines: 1968-1971, 
1971-1975, 1984-1987 
12 prospective 
studies from 11 
European 
countries. 
Baselines: 1972 to 
1991 
Random 
sample from 
general 
population 
in Scotland, 
baseline 
1984-1987 
 
Data collected from 
1993 to 2008 from 
GP databases – 
imputation of 
missing data 
Healthy 
employees. 
Baseline: 1978 to 
1995 
 
Baselines 1987-89 
(ARIC), 1990 and 
1992-3 (CHS), 1985-
6 (CARDIA), 1968-
1971, 1971-1975, 
1984-1987 
(Framingham) 
1980s and 1990s 8 prospective studies from 
North America.  
Baselines: 1948 - 1993 
Sample size: 3969 men and 4522 women 117,098 men and 
88,080 women 
6540 men 
and 6757 
women 
1.28 million 
(QRISK1) 
2.29 million 
(QRISK2) 
 
18,460 men and  
8515 women 
11,240 white 
women, 9098 white 
men, 2641 African-
American women 
and 1647 African-
American men 
 
7520 men and 13,127 
women 
33,323 men and 16,806 
women 
Calculates: 10-year risk of CAD 
events originally. 
Latest version: 
10-year risk of CVD events 
NCEP ATP III version: 10 
year risk of hard coronary 
events 
10-year risk of 
CVD mortality 
10-year risk 
of CVD 
events 
10-year risk of 
CVD events. 
 
Lifetime risk 
Two separate 
scores 
calculate 10-year 
risks 
of major 
coronary events 
and cerebral 
ischaemic 
events 
10-year risk for a 
first atherosclerotic 
CVD (ASCVD) 
event. 
 
Lifetime risk 
10-year probability of 
developing a first major 
CV event (myocardial 
infarction or stroke) 
10 year risk of fatal 
cardiovascular disease 
Age range 
(years): 
30–75 40–65 30–74 35–74 20–75 20–79 35–69  40-84 
Variables: Sex, age, total cholesterol, 
HDL-C, SBP, 
smoking status, DM, 
hypertensive treatment 
Sex, age, total 
cholesterol 
or total 
cholesterol/HDL-C 
ratio, SBP, 
smoking status. 
Versions for use in 
high and low risk 
countries 
Sex, age, 
total 
cholesterol, 
HDL-C, SBP, 
smoking – no. 
cigs, 
DM, area 
based index 
of 
deprivation, 
family history 
QRISK1 - sex, age, 
total cholesterol to 
HDL-C ratio, SBP, 
smoking status, 
DM, 
area based index of 
deprivation, 
family history, BMI, 
BP treatment, 
ethnicity and 
chronic diseases 
Age, sex, LDL-C, 
HDL-C, DM, 
smoking, SBP 
Age, sex, race (white 
or other/African 
American), total 
cholesterol, HDL-C, 
SBP, 
antihypertensive 
treatment, DM, 
smoking 
Age, sex, SBP, total 
cholesterol, HDL-C, 
antihypertensive therapy 
and smoking habit 
Age, sex, smoking, total 
cholesterol, DM, systolic BP 
Comments/ 
developments: 
Latest version includes 
version based on 
non-laboratory values only, 
substituting BMI from 
lipid measurements 
National, updated 
recalibrations 
 QRISK2 includes 
interaction 
terms to adjust for 
the 
interactions 
between age and 
some of the 
variables 
Recent change in 
the 
methods 
(Weibull) 
allows extension 
of risk 
estimation to 
women and 
broader age 
Race specific beta 
coefficients for risk 
factors have been 
incorporated. 
Calculator shown to 
overestimate risk in 
external validations – 
this may indicate the 
need for recalibration 
 Recalibrations have been 
undertaken for 11 countries 
6JTF_Mastercopy 20160125 CONFIDENTIAL DOCUMENT 13 
 
range in certain 
populations 
Recommended 
by guidelines 
NCEP guidelines,54 Canadian 
CV guidelines,55 other 
national guidelines 
recommend adapted versions 
including New Zealand56 
European 
guidelines on CVD 
prevention29 
SIGN37 NICE guidelines on 
lipid modification,57 
QRISK Lifetime 
recommended by 
JBS3 guidelines58 
International Task 
Force for 
Prevention of 
Coronary Disease 
guidelines 
2013 AHA ACC 
guideline on the 
assessment of CVD 
risk50 
  
 
Table 2 Current cardiovascular disease risk estimation systems for use in apparently healthy persons, updated from 59 60 
ACC = American College of Cardiology; AHA = American Heart Association; ARIC = Atherosclerosis Risk in Communities; ATP = Adult Treatment Panel; BMI = body 
mass index; BP = blood pressure; CAD = coronary artery disease; CARDIA = Coronary Artery Risk Development in Young Adults; CHS = Cardiovascular Health Study; 
CVD = cardiovascular disease; DM = diabetes mellitus; HDL-C = high-density lipoprotein cholesterol; JBS = Joint British Societies; LDL-C = low-density lipoprotein 
cholesterol; NCEP = National Cholesterol Education Program; NICE = National Institute for Health and Care Excellence; no. cigs = number of cigarettes; PROCAM = 
Prospective Cardiovascular Munster Study; SBP = systolic blood pressure; SIGN = Scottish Intercollegiate Guidelines Network; SHHEC = Scottish Heart Health Extended 
Cohort  
 
The SCORE system estimates the 10-year risk of a first fatal atherosclerotic event. All ICD 440 
(International Classification of Diseases) codes that could reasonably be assumed to be 441 
atherosclerotic are included, including CAD, stroke and aneurysm of the abdominal aorta. 442 
Traditionally most systems estimated CAD risk only; however, more recently a number of 443 
risk estimation systems have changed to estimate risk of all CVD.44, 47, 50, 58 444 
The choice of CV mortality rather than total (fatal plus non-fatal) events was deliberate 445 
although not universally popular. Non-fatal event rates are critically dependent upon 446 
definitions and the methods used in their ascertainment. Critically, the use of mortality allows 447 
re-calibration to allow for time-trends in CV mortality. Any risk estimation system will over-448 
predict in countries in which mortality has fallen and under-predict in those in which it has 449 
risen. Recalibration to allow for secular changes can be undertaken if good quality, up-to-date 450 
mortality and risk factor prevalence data are available. Data quality does not permit this for 451 
non-fatal events. For these reasons, the CV mortality charts were produced and have indeed 452 
been recalibrated for a number of European countries.  453 
Naturally, the risk of total fatal and non-fatal events is higher, and clinicians frequently ask 454 
for this to be quantified. The SCORE data indicate that the total CV event risk is about three 455 
times higher than the risk of fatal CVD for men, so that a SCORE risk of fatal CVD of 5% 456 
translates approximately into a fatal plus non-fatal CV risk of 15%; the multiplier is about 457 
four in women and somewhat lower than three in older persons, in whom a first event is more 458 
likely to be fatal. 61  459 
As noted in the introduction, thresholds to trigger certain interventions are problematic 460 
since risk is a continuum and there is no threshold at which, for example, a drug is 461 
automatically indicated. Obviously, decisions on whether treatment is initiated should 462 
also be based on patient preferences.  463 
A particular problem relates to young people with high levels of risk factors, where a low 464 
absolute risk may conceal a very high relative risk requiring intensive lifestyle advice. Several 465 
approaches to communicating about risk to younger people are presented below (refer also to 466 
section 2.5.1). These include use of the relative risk chart or “risk age” or “lifetime risk”. The 467 
aim is to communicate that lifestyle changes can reduce the relative risk substantially as well 468 
as reduce the increase in risk that will occur with ageing. 469 
Another problem relates to older people. In some age categories the vast majority, especially 470 
of men, will have estimated CV death risks exceeding the 5–10% level, based on age (and 471 
gender) only, even when other CV risk factor levels are low. This could lead to excessive use 472 
of drugs in the elderly. This issue is dealt with later (see section 2.3.5). It should be noted that 473 
randomised controlled trial evidence to guide drug treatments in older persons is limited (refer 474 
to section 2.5.2). 475 
The role of high-density lipoprotein cholesterol (HDL-C) in risk estimation has been 476 
systematically re-examined using the SCORE database.62-64 HDL-C can contribute 477 
substantially to risk estimation if entered as an independent variable. For example, HDL-C 478 
modifies risk at all levels as estimated from the SCORE cholesterol charts,63 and this effect is 479 
seen in both genders and in all age groups.64 This is particularly important at levels of risk just 480 
below the threshold for intensive risk modification of 5%, where many of these subjects will 481 
qualify for intensive advice if their HDL-C is low.63 This point is illustrated in supplementary 482 
figures A and B (see web addenda). In these charts HDL-C is used categorically. The 483 
electronic version of SCORE, HeartScore (www.HeartScore.org), has been modified to take 484 
HDL-C into account on a continuous basis, and is therefore more accurate. 485 
The role of a plasma triglyceride as a predictor of CVD has been debated for many years. 486 
Fasting triglycerides relate to risk in univariable analyses but the effect is attenuated by 487 
adjustment for other factors, especially HDL-C.65  488 
Dealing with the impact of additional risk factors such as body weight, family history and 489 
newer risk markers is difficult within the constraint of a paper chart. It should be stressed, 490 
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however, that although many other risk factors have been identified, their contribution is 491 
generally very modest to both absolute CV risk estimations and in terms of reclassification of 492 
an individual to another risk category66 (Table 4). 493 
 494 
Table 3 Advantages and limitations in using the SCORE risk charts 
Advantages 
• Intuitive, easy to use tool 
• Establishes a common language of risk for healthcare professionals 
• Allows a more objective assessment of risk 
• Takes account of the multifactorial nature of CVD 
• Allows flexibility in management; if an ideal risk factor level cannot be achieved, total 
risk can still be reduced by reducing other risk factors 
• Deals with the problem of a low absolute risk in young people with multiple risk factors: 
the relative risk chart helps to illustrate how a young person with a low absolute risk may 
be at a substantially high and reducible relative risk; calculation of an individual’s “risk 
age” may also be of use in this situation 
Limitations 
• Estimates risk of fatal but not total (fatal + non-fatal) CV risk for reasons outlined in text 
• Adapted to suit different European populations, but not different ethnic groups within 
these populations 
• Limited to the major determinants of risk 
• Other systems have more functionality, although applicability to multiple countries is 
uncertain 
• Limited age range (40-65) 
CVD = cardiovascular disease; SCORE = Systematic Coronary Risk Estimation. 495 
 496 
The SCORE risk charts are shown in Figures 1–4, including a chart of relative risks (Figure 497 
3). Instructions on their use follow.  498 
 499 
 500 
Figure 1: SCORE chart: 10-year risk of fatal CVD in populations of countries at high CV 501 
risk based on the following risk factors: age, sex, smoking, SBP, total cholesterol (copyright 502 
2016). CVD = cardiovascular disease; SCORE = Systematic Coronary Risk Estimation. 503 
 504 
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505 
Figure 2: SCORE chart: 10-year risk of fatal CVD in populations of countries at low CV risk 506 
based on the following risk factors: age, sex, smoking, SBP, total cholesterol (copyright 507 
2016). CVD = cardiovascular disease; SCORE = Systematic Coronary Risk Estimation. 508 
 509 
 510 
 511 
Figure 3 Relative risk chart, derived from SCORE. Conversion of cholesterol: mmol/L 512 
mg/dL: 8 = 310, 7 = 270, 6 = 230, 5 = 190, 4 = 155. 513 
 514 
Please note that Figure 3 shows RELATIVE not absolute risk. Thus a person in the top right 515 
hand box, with multiple CV risk factor, has a risk that is 12 times higher than a person in the 516 
bottom left with normal risk factor levels. This may be helpful when advising a young person 517 
with a low absolute but high relative risk of the need for lifestyle change. 518 
2.3.2 Cardiovascular risk age 519 
The risk age of a person with several CV risk factors is the age of a person of the same gender 520 
with the same level of risk but with ideal levels of risk factors. Thus a 40-year-old with high 521 
levels of some risk factors may have a risk age of a 60-year-old (Figure 4), because the risk 522 
equals that of a 60-year-old with ideal risk factor levels; i.e. non-smoking, total cholesterol of 523 
4 mmol/L and BP of 120 mmHg.67 Risk age is an intuitive and easily understood way of 524 
illustrating the likely reduction in life expectancy that a young person with a low absolute but 525 
high relative risk of CVD will be exposed to if preventive measures are not adopted.67 Table 526 
A showing different risk factor combinations is included in the supplementary material (web 527 
addenda) to provide a more accurate estimation of risk ages. Risk age is also automatically 528 
calculated as part of the latest revision of HeartScore. 529 
Risk age has been shown to be independent of the CV end point used,67 which bypasses the 530 
dilemma of whether to use a risk estimation system based on CV mortality or on total CV 531 
events. Risk age can be used in any population regardless of baseline risk and of secular 532 
changes in mortality, and therefore avoids the need for recalibration.68 At present, risk age is 533 
recommended for helping to communicate about risk, especially to younger people with a low 534 
absolute risk but a high relative risk.  535 
 536 
Figure 4: SCORE chart (for use in high risk European countries) illustrating how the 537 
approximate risk age can be read off the chart. SCORE = Systematic Coronary Risk 538 
Estimation. 539 
2.3.3 Lifetime versus 10-year cardiovascular risk estimation 540 
Conventional CV risk prediction schemes estimate 10-year risk of CV events. Lifetime CV 541 
risk prediction models identify high risk individuals both in the short- and long-term. Such 542 
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models account for predicted risk in the context of competing risks from other diseases over 543 
the remaining expected lifespan of an individual.  544 
Notably, 10-year risk identifies individuals who are most likely to benefit from drug therapy 545 
in the near term. Drug treatment starts to works quite rapidly, and drug treatment can be 546 
largely informed by short-term risk, such as 10-year risk. One problem with short-term risk is 547 
that it is mostly governed by age and consequently few younger individuals, in particular 548 
women reach treatment thresholds. It has therefore been argued that lifetime risk estimation 549 
may enhance risk communication, particularly among younger individuals and women.  550 
Evidence for the role of lifetime risk in treatment decisions is lacking. Sufficient data for 551 
robust lifetime risk estimations, as well as meaningful risk categorization thresholds, are 552 
lacking. Providing lifetime CV risk estimates for some groups at high risk of mortality due to 553 
competing non-CVD causes can be difficult to interpret. Importantly, evidence of the benefits 554 
of lifelong preventive therapy (e.g. BP or lipid lowering drugs) in younger individuals with 555 
low short-term but higher lifetime risks is lacking. For these reasons, we do not recommend 556 
risk stratification for treatment decisions to be based on lifetime risk. However, like risk age 557 
and relative risk, it may be a useful tool in communicating about risk to individuals with high 558 
risk factor levels, but at a low 10-year absolute risk of CV events, such as some younger 559 
people. Whatever approach is used, if absolute risk is low, a high relative risk or risk age 560 
signals the need for active lifestyle advice and awareness that drug treatment may need 561 
consideration as the person ages. Both risk age and lifetime risk are closer to relative than 562 
absolute risk, and none provide an evidence base for drug treatment decisions.  563 
 564 
2.3.4 Low risk, high risk and very high risk countries 565 
The countries considered here are those with national cardiology societies that belong to the 566 
ESC, both European and non-European.  567 
2.3.4.1 What are low risk countries? 568 
The fact that CVD mortality has declined in many European countries means that more now 569 
fall into the low risk category. While any cut-off point is arbitrary and open to debate, in these 570 
guidelines the cut-off points for calling a country “low risk” are based on age-adjusted 2012 571 
CVD mortality rates in those aged 45–74 years (<225/100,000 in men and <175/100,000 in 572 
women).69 This defines the following countries as low risk countries: Andorra, Austria, 573 
Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, 574 
Italy, Luxembourg, Malta, Monaco, The Netherlands, Norway, Portugal, San Marino, 575 
Slovenia, Spain, Sweden, Switzerland and United Kingdom.  576 
2.3.4.2 What are high and very high risk countries? 577 
High risk countries are: Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, 578 
Hungary, Lithuania, Montenegro, Morocco, Poland, Romania, Serbia, Slovakia and 579 
Turkey. 580 
Very high risk European countries present levels of risk which are more than double that of 581 
low risk countries, i.e. CVD mortality > 450/100,000 for men and > 350/100,000 for women. 582 
Additionally, the male: female ratio is smaller than in low risk countries, suggesting a major 583 
problem for women. These countries are: Albania, Algeria, Armenia, Azerbaijan, Belarus, 584 
Bulgaria, Egypt, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Macedonia FYR, Moldova, 585 
Russian Federation, Syrian Arab Republic, Tajikistan, Turkmenistan, Ukraine and 586 
Uzbekistan.  587 
 588 
2.3.5 How to use the risk estimation charts 589 
• The SCORE charts are used in apparently healthy people, not for those with established 590 
CVD or at very high risk or high risk for other reasons (e.g. DM, see section 3a.8, or 591 
chronic kidney disease (CKD), see section 2.4.5.1), who need intensive risk advice 592 
anyway. 593 
• Use of the low risk chart is recommended for the countries listed above. Use of the high 594 
risk chart is recommended for all other European and Mediterranean countries, taking 595 
into account that the high risk charts may underestimate the risk in very high risk 596 
countries (see above). Note that several countries have undertaken national recalibrations 597 
to allow for time trends in mortality and risk factor distributions. Such charts are likely to 598 
better represent risk levels. 599 
• To estimate a person’s 10-year risk of CV death, find the table for their gender, smoking 600 
status and (nearest) age. Within the table find the cell nearest to the person’s BP and total 601 
cholesterol (or total cholesterol: HDL-C ratio). Risk estimates will need to be adjusted 602 
upwards as the person approaches the next age category. 603 
• While no threshold is universally applicable, the intensity of advice should increase with 604 
increasing risk. The effect of interventions on the absolute probability of developing a CV 605 
event increases with an increasing baseline risk; i.e. the number of individuals needed to 606 
treat (NNT) to prevent one event decreases with increasing risk. 607 
 608 
 Low- to moderate-risk persons (calculated SCORE <5%) should be offered 609 
lifestyle advice to maintain their low to moderate risk status.  610 
 High-risk persons (calculated SCORE ≥5% and <10%) qualify for intensive 611 
lifestyle advice, and may be candidates for drug treatment.  612 
 Very-high-risk persons (calculated SCORE ≥10%): drug treatment is more 613 
frequently required. In persons >60 years of age these thresholds should be 614 
interpreted more leniently, because their age-specific risk is normally around these 615 
levels, even when other CV risk factor levels are “normal”. In particular, uncritical 616 
initiation of drug treatments of all elderly with risks greater than the 10% threshold 617 
should be discouraged.  618 
 619 
Use of the risk charts should be qualified by knowledge of the following aspects: 620 
• The charts assist in risk estimation but must be interpreted in the light of the clinician’s 621 
knowledge and experience and in view of the factors that may modify the calculated risk 622 
(see below). 623 
• Relative risks may be high in young persons, even if 10 year absolute risks are low, 624 
because events usually occur later in life. The relative risk chart or estimating risk age 625 
may be helpful in identifying and counselling such persons.  626 
• The lower risk in women is explained by the fact that risk is deferred by 10 years—the 627 
risk of a 60-year-old woman is similar to that of a 50-year-old man. Ultimately more 628 
women than men die of CVD. 629 
• The charts may be used to give some indication of the effects of reducing risk factors, 630 
given that there will be a time lag before risk reduces and that the results of RCTs in 631 
general give better estimates of the benefits of interventions. Those who stop smoking in 632 
general halve their risk. 633 
2.3.6 Modifiers of calculated total cardiovascular risk 634 
Apart from the conventional major CV risk factors included in the risk charts, there are other 635 
risk factors that could be relevant for assessing total CVD risk. The Task Force recommends 636 
additional risk factor assessment if such a risk factor improves risk classification (for 637 
example, by calculation of a net reclassification index (NRI)) and if the assessment is feasible 638 
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in daily practice. In general, reclassification is of most value when the individual’s risk lies 639 
close to a decisional threshold, such as a SCORE risk of 5%. In very high or very low risk 640 
situations, the impact of additional risk factors is unlikely to alter management decisions. 641 
While the presence of risk modifiers may move an individual’s estimated risk upward, 642 
absence of these modifiers should lead to lowering an individual’s estimated risk. 643 
Table 4 lists examples of factors that fulfil the aforementioned criteria. Several other factors 644 
that are frequently discussed in the literature, but may not have the ability to reclassify 645 
subjects, are discussed in subsequent paragraphs. Also discussed further in this section are the 646 
roles of ethnicity and of specific conditions or diseases that may be associated with a higher 647 
than calculated risk, such as CKD, autoimmune diseases, etc. The way modifiers are related to 648 
CV risk may be very different. Social deprivation and being overweight, for example, are 649 
important as “causes of the causes” of CVD, in that they may be associated with higher levels 650 
of conventional risk factors. Family history may reflect a shared environment, genetic factors, 651 
or both. Markers such as computed tomography (CT) calcium scoring are indicators of 652 
disease rather than risk factors for future disease. 653 
 654 
Table 4 Examples of risk modifiers that are likely to have reclassification potential (see 655 
following sections for details) 656 
Socio-economic status, social isolation, or lack of social support  
Family history of premature CVD 
BMI and central obesity 
CT coronary calcium score 
Atherosclerotic plaques determined by carotid artery scanning 
ABI 
ABI = ankle–brachial blood pressure index; BMI = body mass index; CVD = cardiovascular disease; CT = 657 
computed tomography. 658 
2.3.7 Risk categories: priorities 659 
Individuals at highest risk gain most from preventive efforts, and this guides the priorities, 660 
which are detailed in Table 5. 661 
 662 
Table 5 Risk categories 663 
Very high 
risk 
Subjects with any of the following: 
• Documented CVD, clinical or unequivocal on imaging. Documented clinical 
CVD includes previous AMI, ACS, coronary revascularization and other 
arterial revascularization procedures, stroke and TIA, aortic aneurysm and 
PAD. Unequivocally documented CVD on imaging includes significant 
plaque on coronary angiography or carotid ultrasound. It does NOT include 
some increase in continuous imaging parameters such as intima–media 
thickness of the carotid artery.  
• DM with target organ damage such as proteinuria or with a major risk factor 
such as smoking or marked hypercholesterolemia or marked hypertension. 
• Severe CKD (GFR <30 mL/min/1.73 m2). 
• A calculated SCORE ≥10%. 
High risk Subjects with: 
• Markedly elevated single risk factors, in particular cholesterol >8 mmol/L 
(e.g. in familial hypercholesterolemia) or BP ≥180/110 mmHg.  
• Most other people with DM (with the exception of young people with type 1 
DM and without major risk factors that may be at low or moderate risk). 
• Moderate CKD (GFR 30–59 mL/min/1.73 m2) 
• A calculated SCORE ≥5% and <10%.  
Moderate 
risk 
SCORE is ≥1% and <5% at 10 years. Many middle-aged subjects belong to this 
category. 
Low risk SCORE <1%. 
ACS = acute coronary syndrome; AMI = acute myocardial infarction; BP = blood pressure; CKD = chronic 664 
kidney disease; DM = diabetes mellitus; GFR = glomerular filtration rate; PAD = peripheral artery disease; 665 
SCORE = systematic coronary risk estimation; TIA = transient ischaemic attack. 666 
 667 
2.3.8 Risk factor targets 668 
 669 
Table 6 Risk factor goals and target levels for important cardiovascular risk factors  670 
Smoking No exposure to tobacco in any form. 
Diet Low in saturated fat with a focus on wholegrain products, vegetables, fruit 
and fish. 
Physical 
activity 
At least 150 minutes a week of moderate aerobic PA (30 min for 5 
days/week) or 75 minutes a week of vigorous aerobic PA (15 minutes for 5 
days/week) or a combination thereof. 
Body weight BMI 20–25 kg/m2. Waist circumference < 94 cm (men) or < 80 cm 
(women). 
Blood 
pressure 
< 140/90 mmHg a 
  
Lipids b  
LDL c is the 
primary target  
 
 
 
 
HDL-C 
 
 
Triglycerides 
 
Very high risk: <1.8 mmol/L (<70 mg/dL), or a reduction of at least 50% 
if the baseline is between 1.8 and 3.5 mmol/L (70 and 135 mg/dL) d 
High risk: <2.6mmol/L (<100 mg/dL), or a reduction of at least 50% if 
the baseline is between 2.6 and 5.1 mmol/L (100 and 200 mg/dL) 
Low to moderate risk:<3 mmol/L (<115 mg/dL). 
 
No target but >1.0 mmol/L (>40mg/dL) in men and >1.2 mmol/L 
(>48mg/dL) in women indicate lower risk. 
 
No target but <1.7 mmol/L (<150 mg/dL) indicates lower risk and higher 
levels indicate a need to look for other risk factors. 
Diabetes HbA1c <7%. (<53 mmol/mol) 
BMI = body mass index; HbA1c = glycated haemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-671 
C = low density lipoprotein cholesterol.  672 
 673 
a Blood pressure <140/90 mmHg is the general target. The target can be higher in frail elderly, or lower in most 674 
patients with DM (see chapter 3.a.8) and in some (very) high risk patients without DM who can tolerate multiple 675 
blood pressure lowering drugs (see chapter 3.a.9) 676 
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b Non-HDL-C is a reasonable and practical alternative target because it does not require fasting. Non HDL-677 
C secondary targets of <2.6, <3.3 and <3.8 mmol/L (<100, <130 and <145 mg/dL) are recommended for very 678 
high, high and low to moderate risk subjects, respectively. See section 3a.7.10 for more details. 679 
c A view was expressed that primary care physicians might prefer a single general LDL-C goal of 2.6 mmol/L. 680 
While accepting the simplicity of this approach and that it could be useful in some settings, there is better 681 
scientific support for the three targets matched to level of risk. 682 
d This is the general recommendation for those at very high risk. It should be noted that the evidence for patients 683 
with CKD is less strong 684 
 685 
2.3.9 Conclusions 686 
Estimation of total CV risk remains a crucial part of the present guidelines. The priorities 687 
(risk categories) defined in this section are for clinical use and reflect the fact that those at 688 
highest risk of a CVD event gain most from preventive measures. This approach should 689 
complement public actions to reduce community risk factor levels and promote a healthy 690 
lifestyle. The principles of risk estimation and the definition of priorities reflect an attempt to 691 
make complex issues simple and accessible. Their very simplicity makes them vulnerable to 692 
criticism. Above all they must be interpreted in the light of the physician’s detailed 693 
knowledge of his/her patient and in the light of local guidance and conditions. 694 
 695 
Gaps in evidence 696 
• There are no recent RCTs of a total risk approach to (a) risk assessment, or (b) risk 697 
management. 698 
• The young, women, older people and ethnic minorities continue to be under-represented 699 
in clinical trials. 700 
• A systematic comparison of current international guidelines is needed to define areas of 701 
agreement and the reasons for discrepancies. 702 
 703 
2.4 Other risk markers 704 
2.4.1 Family history/(epi)genetics 705 
 706 
 707 
Key messages 708 
• Family history of premature CVD in first degree relatives, before 55 years in men and 65 709 
years in women, increases the risk of CVD.  710 
• Several genetic markers are associated with increased risk of CVD, but their use in 711 
clinical practice is not recommended. 712 
 713 
Recommendations for assessment of family history/(epi) genetics 714 
Recommendations Classa Levelb Refc 
Assessment of family history of premature CVD (defined as a 
fatal or non-fatal CVD event or/and established diagnosis of CVD 
in first degree male relatives before 55 years or female relatives 
before 65 years) is recommended as part of cardiovascular risk 
assessment. 
I C 70 
The generalized use of DNA-based tests for CVD risk assessment 
is not recommended. 
III B 71, 72 
CVD = cardiovascular disease. 715 
aClass of recommendation. 716 
bLevel of evidence. 717 
cReference(s) supporting recommendations. 718 
 719 
2.4.1.1 Family history 720 
Familial history of premature CVD is a crude but simple indicator of the risk of developing 721 
CVD, reflecting both the genetic trait and the environment shared among household 722 
members.70 A positive family history of premature CV death is associated with an increased 723 
risk of early and lifetime CVD.73 In the few studies that simultaneously assessed and reported 724 
the effects of family history and genetic scores, family history remained significantly 725 
associated with incidence of CVD after adjusting for the genetic scores.74, 75 Limited data 726 
exist regarding the ability of family history to improve prediction of CVD beyond 727 
conventional CV risk factors.76-78 One possible explanation is the varying definitions of 728 
family history applied79 and that conventional CV risk factors can partly explain the impact of 729 
family history.  730 
Family history of premature CVD is simple, inexpensive information that should be part of 731 
CV risk assessment in all subjects. Family history can be a risk modifier to optimal 732 
management after the calculated risk using SCORE lies around a decisional threshold: a 733 
positive family history would favour more intensive interventions while a negative family 734 
history would translate into less intensive treatment.80 735 
2.4.1.2 Genetic markers 736 
Genetic screening and counselling is effective in some conditions such as familial 737 
hypercholesterolaemia (FH) (see section 3a.7.9). This paragraph will focus on genetic 738 
screening for high CV risk in the general population. 739 
Several recent genome-wide association studies have identified candidate genes associated 740 
with CVD. As the effect of each genetic polymorphism is small, most studies used genetic 741 
scores to summarize the genetic component. There is a lack of consensus regarding which 742 
genes and their corresponding single nucleotide polymorphisms (SNPs) should be included in 743 
a genetic risk score, and which method should be used to calculate the genetic score. 744 
The association of genetic scores with incident CVD has been prospectively studied, adjusting 745 
for the main CV risk factors, and most studies found a significant association, with the 746 
relative risks varying between 1.02 and 1.49 per increase in one score unit.81 The ability of 747 
genetic scores to predict CV events beyond traditional CV risk factors (i.e. defined by the Net 748 
Reclassification Index or NRI) was found in about half of the studies. The NRI is a statistical 749 
measure quantifying the usefulness of adding new variables to a risk prediction equation 82. 750 
The biggest improvements in the NRI were observed in participants at intermediate risk, 751 
while little or no improvement was observed in participants at high risk.74, 83 One study 752 
estimated that one additional CAD event for every 318 people screened at intermediate risk 753 
could be prevented by measuring the CAD-specific genetic score in addition to established 754 
risk factors.83 Importantly, as the frequency of polymorphisms might differ, the results may 755 
vary between populations.75, 84, 85 Recently, a genetic risk score based on 27 genetic variants 756 
enabled the identification of subjects at increased risk of CAD and who would benefit the 757 
most from statin therapy, even after adjustment on family history 86 Still, it is likely that some 758 
reported associations might be due to chance87 and replication studies are needed to confirm 759 
positive findings. 760 
Currently, many commercial tests are available, allowing an almost complete assessment of 761 
an individual’s genome, and strong pressure is applied to use this information to predict 762 
genetic risk and to make genetic testing a routine measure.88 Given the lack of agreement 763 
regarding which genetic markers should be included, how genetic risk scores should be 764 
calculated, and uncertainties about improvement in CV risk prediction, the use of genetic 765 
markers for prediction of CVD is therefore not recommended. 766 
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2.4.1.3 Epigenetics 767 
Epigenetics studies the chemical changes in DNA that affect gene expression. Methylation of 768 
genes related to CV risk factors is associated with variation in CV risk factor levels,89, 90 and 769 
lower DNA methylation levels are associated with increased risk of CAD or stroke91. No 770 
information exists, however, regarding the effect of epigenetic markers in improving CVD 771 
risk prediction beyond conventional risk factors. Thus, epigenetic screening of CVD is not 772 
recommended. 773 
 774 
Gaps in evidence 775 
• The impact of adding family history to the current SCORE risk equation should be 776 
assessed. 777 
• Future studies should assess the power of different genetic risk scores to improve CVD 778 
risk prediction in several different populations, the number of events prevented, and the 779 
cost-effectiveness of including genetic data in risk assessment. 780 
 781 
2.4.2 Psychosocial risk factors 782 
Key messages 783 
• Low socio-economic status, lack of social support, stress at work and in family life, 784 
hostility, depression, anxiety, and other mental disorders contribute both to the risk of 785 
developing CVD and a worse prognosis of CVD, with the absence of these items being 786 
associated with a lower risk of developing CVD and a better prognosis of CVD.  787 
• Psychosocial risk factors act as barriers to treatment adherence and efforts to improve 788 
lifestyle, as well as to promoting health in patients and populations. 789 
 790 
Recommendations for assessment of psychosocial risk factors 791 
Recommendations Classa Levelb Refc 
Psychosocial risk factor assessment, using clinical interview or 
standardized questionnaires, should be considered to identify 
possible barriers to lifestyle change or adherence to medication in 
individuals at high CVD risk or with established CVD. 
IIa B 92-94 
aClass of recommendation. 792 
bLevel of evidence. 793 
cReference(s) supporting recommendations. 794 
 795 
Low socio-economic status, defined as low educational level, low income, holding a low-796 
status job, or living in a poor residential area, confer an increased risk of CAD; the relative 797 
risk (RR) of CAD mortality risk is 1.3 to 2.0.95, 96 Compared to the Framingham risk score, 798 
adding social deprivation to CV risk assessment was able to reduce unattributed risk 799 
substantially.45 800 
People who are isolated or disconnected from others are at increased risk of developing and 801 
dying prematurely from CAD. Similarly, lack of social support increases CAD risk and 802 
worsens the prognosis of CAD.97 803 
Acute mental stressors may act as triggers of acute coronary syndromes (ACS). These 804 
stressors include exposure to natural catastrophe as well as personal stressors, e.g. defeat or 805 
other serious life events, resulting in acute strong negative emotions, e.g. outbursts of anger or 806 
grief.98 After death of a significant person, the incidence rate of acute myocardial infarction 807 
(AMI) is elevated 21-fold during the first 24 hours, declining steadily during the subsequent 808 
days.99 809 
Chronic stress at work (e.g. long working hours, extensive overtime work, high psychological 810 
demands, unfairness, and job strain) predicts premature incident CAD in men (RR ~ 1.2 to 811 
1.5).100 In addition, long-term stressful conditions in family life increase CAD risk (RR ~ 2.7–812 
4.0).101 102 813 
Clinical depression and depressive symptoms predict incident CAD (RR 1.6 and 1.9)103 and 814 
worsen its prognosis (RR 1.6 and 2.4).94, 98, 103, 104 Vital exhaustion, most likely representing 815 
somatic symptoms of depression, significantly contributed to incident CAD (population 816 
attributable risk 21.1% in women, and 27.7% in men). The net reclassification index 817 
improved significantly.105 Panic attacks also increase the risk of incident CAD (RR 4.2). 106 818 
Anxiety is an independent risk factor for incident CAD (RR 1.3)94, for cardiac mortality 819 
following AMI (OR 1.2) 107 and cardiac events (OR 1.7) 108.  820 
Meta-analyses reported a 1.5-fold risk of CVD incidence, a 1.2-fold risk of CAD, and 1.7-fold 821 
risk for stroke in patients with schizophrenia,109 and a 1.3-fold risk for incident CAD, even 822 
after adjustment for depression, in patients with post-traumatic stress disorder.110  823 
Hostility is a personality trait, characterized by extensive experience of mistrust, rage, and 824 
anger, and the tendency to engage in aggressive, maladaptive social relationships. A meta-825 
analysis confirmed that anger and hostility are associated with a small but significant 826 
increased risk for CV events in both healthy and CVD populations (RR 1.2).111 The type D 827 
(“distressed”) personality involves an enduring tendency to experience a broad spectrum of 828 
negative emotions (negative affectivity) and to inhibit self-expression in relation to others 829 
(social inhibition). The type D personality has been shown to predict poor prognosis in 830 
patients with CAD (RR 2.2).112 831 
In most situations, psychosocial risk factors cluster in individuals and groups. For example, 832 
both women and men of lower socio-economic status and/or with chronic stress are more 833 
likely to be depressed, hostile, and socially isolated.113 The INTERHEART study has shown 834 
that a cluster of psychosocial risk factors (i.e. social deprivation, stress at work or in family 835 
life, and depression) is associated with increased risk for myocardial infarction (MI) (RR 3.5 836 
for women and 2.3 for men). The population attributable risk was 40% in women and 25% in 837 
men.114  838 
Mechanisms that link psychosocial factors to increased CV risk include unhealthy lifestyle 839 
(more frequent smoking, unhealthy food choice, and less physical activity (PA)) and low 840 
adherence to behaviour-change recommendations or CV medication.95, 115 In addition, 841 
depression and/or chronic stress are associated with alterations in autonomic function, in the 842 
hypothalamic–pituitary axis and in other endocrine markers, which affect haemostatic and 843 
inflammatory processes, endothelial function, and myocardial perfusion.113 Enhanced risk in 844 
patients with depression may also be due in part to adverse effects of tricyclic 845 
antidepressants.93 846 
Assessment of psychosocial factors in patients and persons with CV risk factors should be 847 
considered for use as risk modifiers in CV risk prediction, especially in individuals with 848 
SCORE risks around decisional thresholds. In addition, psychosocial factors can help identify 849 
possible barriers to lifestyle change and adherence to medication. Standardized methods are 850 
available to assess psychosocial factors in many languages and countries.92 Alternatively, a 851 
preliminary assessment of psychosocial factors can be made within the physicians’ clinical 852 
interview, as shown in Table 7. 853 
 854 
Table 7 Core questions for the assessment of psychosocial risk factors in clinical practice  855 
Low socio-economic 
status 
What is your highest educational degree? 
Are you a manual worker? 
Work and family 
stress 
Do you lack control over how to meet the demands at work? 
Is your reward inappropriate for your effort? 
Do you have serious problems with your spouse? 
Social isolation Are you living alone?  
Do you lack a close confidant? 
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Have you lost an important relative or friend over the last year? 
Depression Do you feel down, depressed and hopeless?  
Have you lost interest and pleasure in life? 
Anxiety Do you suddenly feel fear or panic?  
Are you frequently unable to stop or control worrying? 
Hostility Do you frequently feel angry over little things?  
Do you often feel annoyed about other people’s habits? 
Type D personality In general, do you often feel anxious, irritable, or depressed?  
Do you avoid sharing your thoughts and feelings with other people? 
Post-traumatic stress 
disorder 
Have you been exposed to a traumatic event? Do you suffer from 
nightmares or intrusive thoughts? 
Other mental 
disorders 
Do you suffer from any other mental disorder? 
 856 
No more than minimum education according to the requirement of the country and/or a “yes” 857 
for one or more items indicate an increased CV risk and could be applied as a modifier of CV 858 
risk (see chapter 2.3.6). The management of psychosocial risk factors should be addressed 859 
according to chapter 3a.2. 860 
 861 
Gaps in evidence 862 
• It remains unknown whether routine screening for psychosocial risk factors contributes to 863 
fewer future cardiac events.  864 
2.4.3 Circulating and urinary biomarkers 865 
Key messages 866 
• CV circulating and urinary biomarkers have either no or only limited value when added to 867 
CVD risk assessment with the SCORE system. 868 
• There is evidence of publication bias in the field of novel biomarkers of CV risk, leading 869 
to inflated estimates of strength of association and potential added value.  870 
 871 
 872 
 873 
 874 
Recommendations for assessment of circulating and urinary biomarkers 875 
Recommendations Classa Levelb Refc 
Routine assessment of circulating or urinary 
biomarkers is not recommended for refinement of 
CVD risk stratification. 
III B 116, 117 
aClass of recommendation. 876 
bLevel of evidence. 877 
cReference(s) supporting recommendations. 878 
 879 
In general, biomarkers can be classified into inflammatory (e.g. high-sensitivity C-reactive 880 
protein (hsCRP, fibrinogen), thrombotic (e.g. homocysteine, lipoprotein-associated 881 
phospholipase A2), glucose- and lipid-related markers (e.g. apolipoproteins), and organ-882 
specific markers (e.g. renal, cardiac). However, for the purpose of overall CV risk estimation, 883 
these distinctions are generally not relevant. Also, from the perspective of risk stratification 884 
(i.e. prediction of future CV events), the question of whether a biomarker is causally related to 885 
CVD or may be a marker of preclinical disease is equally irrelevant. 886 
Among the most extensively studied and discussed biomarkers is hsCRP. This biomarker has 887 
shown consistency across large prospective studies as a risk factor integrating multiple 888 
metabolic and low-grade inflammatory factors, with RRs approaching those of classical CV 889 
risk factors. However, its contribution to the existing methods of CV risk assessment is 890 
probably small.118  891 
Meta-analyses and systematic reviews suggest that the vast majority of other circulating and 892 
urinary biomarkers also have no or limited proven ability to improve risk classification. 893 
However, the extent to which they have been tested for their ability to add value to risk 894 
stratification varies considerably,116, 117 with strong evidence of reporting bias.119 Organ-895 
specific biomarkers may be useful to guide therapy in specific circumstances (e.g. 896 
albuminuria in hypertension or DM may predict kidney dysfunction and warrant renal-897 
protective interventions), for which we refer to section 3a. 898 
If, despite these recommendations, biomarkers are used as risk modifiers, it is important to 899 
note that having an unfavourable biomarker profile may be associated with a somewhat higher 900 
risk, but also that a favourable profile is associated with a lower risk than calculated. The 901 
degree to which the calculated risk is affected by biomarkers is generally unknown, but 902 
almost universally smaller than the (adjusted) relative risks reported for these biomarkers in 903 
the literature.120 Hence, in these patients particularly with a moderate risk profile, only 904 
relatively small adjustments in calculated risk are justifiable, and patients who are clearly at 905 
high or low risk should not be reclassified based on biomarkers.121 906 
 907 
Gaps in evidence 908 
• Not all potentially useful circulatory and urinary biomarkers have undergone state-of-the-909 
art assessment of their added value in CV risk prediction on top of conventional risk 910 
factors.  911 
• Biomarkers may be useful in specific subgroups, but this has been addressed in only a 912 
limited number of studies.  913 
• The role of metabolomics as risk factors for CVD and to improve CV risk prediction 914 
beyond conventional risk factors should be further assessed. 915 
 916 
2.4.4 Measurement of preclinical vascular damage 917 
Key messages 918 
• Routine screening with imaging modalities to predict future CV events is generally not 919 
recommended in clinical practice.  920 
• Imaging methods may be considered as risk modifiers in CV risk assessment, i.e. in 921 
individuals with calculated CV risks based on the major conventional risk factors around 922 
the decisional thresholds.  923 
 924 
Recommendations for imaging methods 925 
Recommendations Classa Levelb Refc 
Coronary artery calcium scoring may be considered as 
a risk modifier in CV risk assessment. 
IIb B 122-127 
Atherosclerotic plaque detection by carotid artery 
scanning may be considered as a risk modifier in CV 
risk assessment.  
IIb B 128-130 
ABI may be considered as a risk modifier in CV risk 
assessment. 
IIb B 131-134 
Carotid ultrasound IMT screening for CV risk 
assessment is not recommended. 
III A 130, 135 
ABI = ankle–brachial index; CV = cardiovascular; IMT = intima–media thickness. 926 
aClass of recommendation. 927 
bLevel of evidence. 928 
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cReference(s) supporting recommendations. 929 
 930 
Although most of the CVD may be explained by traditional risk factors, there is substantial 931 
variation in the amount of atherosclerosis. This has maintained interest in non-invasive 932 
imaging techniques to improve CV risk assessment. In individuals with calculated CV risks 933 
based on the major conventional risk factors around the decisional thresholds, some imaging 934 
techniques may be considered as risk modifiers to improve risk prediction and decision 935 
making. 936 
2.4.4.1 Coronary artery calcium  937 
Coronary artery calcium (CAC) is examined through electron beam or multislice CT. 938 
Calcifications indicate late stage subclinical coronary atherosclerosis.136 Atherosclerotic 939 
coronary arteries do not necessarily always show calcifications. The extent of the calcification 940 
correlates with the extent of total coronary plaque burden.136 CAC is not an indicator of the 941 
(in)stability of an atherosclerotic plaque.137 In patients with ACS, the extent of CAC is more 942 
pronounced than in those without CAD.138 943 
The quantification of CAC scoring is fairly consistent across studies. Most studies use the 944 
Agatston score.139 The value of the score can be further increased if the age and sex 945 
distribution within percentiles are taken into account. A CAC score ≥300Agatston units or 946 
≥75th percentile for age, sex, and ethnicity is considered to indicate increased CV risk.  947 
CAC has shown a very high negative predictive value, since the Agatston score of 0 has a 948 
negative predictive value of nearly 100% for ruling out significant coronary narrowing.122 949 
However, studies have questioned the negative predictive value of CAC because significant 950 
stenosis in the absence of CAC is possible.123 Many prospective studies have shown the 951 
association of CAC with CAD, and the Agatston score is an independent predictor of CAD.124 952 
Importantly, some studies showed that including CAC may improve CV risk prediction in 953 
addition to conventional risk factors, and also in terms of the reclassification of individuals in 954 
risk categories.125 Thus, CAC scoring may be considered in individuals with calculated 955 
SCORE charts risks around the 5% or 10% thresholds.126, 127  956 
Although recent studies also showed the presence of CAC in low-risk population, the added 957 
predictive value on CV events remains to be demonstrated. 140-142 958 
There are concerns regarding costs and radiation exposure. For CAC scoring the radiation 959 
exposure with the properly selected techniques is ±1mSv. 960 
2.4.4.2 Carotid ultrasound 961 
Population-based studies have shown correlations between the severity of atherosclerosis in 962 
one arterial territory and the involvement of other arteries.128 Therefore, early detection of 963 
arterial disease in apparently healthy individuals has focused on peripheral arteries and in 964 
particular on the carotid arteries. Risk assessment using carotid ultrasound focuses on the 965 
measurement of the intima–media thickness (IMT) and the presence and characteristics of 966 
plaques.  967 
The IMT is not only a measure of early atherosclerosis but also of smooth muscle 968 
hypertrophy/hyperplasia. There is a graded increase in CV risk with rising IMT,128 and a 969 
value >0.9 mm is considered abnormal. The risk of stroke associated with IMT is non-linear, 970 
with hazards increasing more rapidly at lower IMTs than at higher IMTs. The IMT-associated 971 
risk of cardiac events is also non-linear.129 The extent of carotid IMT is an independent 972 
predictor of CVD, but seems to be more predictive in women than in men.  973 
The lack of standardization regarding the definition and measurement of IMT, its high 974 
variability and low intra-individual reproducibility have raised concerns. A recent meta-975 
analysis failed to demonstrate any added value of IMT compared to the Framingham Risk 976 
Score in predicting future CVD, even in the intermediate risk group.130 Thus, the systematic 977 
use of carotid ultrasound IMT to improve risk assessment is not recommended.  978 
Plaque is usually defined as the presence of a focal wall thickening that it is at least 50% 979 
greater from the surrounding vessel wall or as a focal region with IMT measurement ≥1.5 mm 980 
that protrudes into the lumen.143 Plaques may be characterized by their number, size, 981 
irregularity, and echodensity (echolucent vs. calcified). Plaques are related to both coronary 982 
and cerebrovascular events, and echolucent (as opposed to calcified) plaques increase 983 
ischaemic cerebrovascular events.129 Many studies emphasize the greater value of measures 984 
that include plaque area and thickness, rather than IMT alone, in predicting CVD. Therefore, 985 
even though formal reclassification analyses have not been undertaken, carotid artery plaque 986 
assessment using ultrasonography may be considered to be a risk modifier in CV risk 987 
prediction in some cases. 988 
 2.4.4.3 Arterial stiffness 989 
Arterial stiffness is commonly measured using either aortic pulse wave velocity (PWV) or 990 
arterial augmentation index. An increase in arterial stiffness is usually related to damage in 991 
the arterial wall, as has been shown in hypertensive patients.144 Although the relationship 992 
between aortic stiffness and CVD is continuous, a PWV threshold of 12 m/s has been 993 
suggested as a conservative estimate of significant alterations of aortic function in middle-994 
aged hypertensive patients. A meta-analysis showed that arterial stiffness predicts future CVD 995 
and improves risk classification.144 However, the validity of this conclusion is offset by 996 
evidence of substantial publication bias.119 The Task Force concludes that arterial stiffness 997 
may serve as a useful biomarker to improve CV risk prediction for patients close to decisional 998 
thresholds, but its systematic use in the general population to improve risk assessment is not 999 
recommended. 1000 
2.4.4.4 Ankle–brachial index 1001 
The ankle–brachial (BP) index (ABI) is an easy-to-perform and reproducible test to detect 1002 
asymptomatic atherosclerotic disease. An ABI <0.9 indicates ≥50% stenosis between the 1003 
aorta and the distal leg arteries. Because of its acceptable sensitivity (79%) and specificity 1004 
(90%),133 an ABI <0.90 is considered to be a reliable marker of peripheral artery disease 1005 
(PAD).131 An ABI value indicating significant PAD adds value to medical history, because 1006 
50–89% of patients with an ABI <0.9 do not have typical claudication132 and it is present in 1007 
12–27% of asymptomatic individuals over 55 years of age.  1008 
The ABI is inversely related to CV risk.134 but there is controversy regarding its potential to 1009 
reclassify patients into different risk categories.133, 145 1010 
2.4.4.5. Echocardiography 1011 
Echocardiography is more sensitive than electrocardiography in diagnosing left ventricular 1012 
hypertrophy (LVH) and it precisely quantifies left ventricular (LV) mass and geometric LVH 1013 
patterns. Cardiac abnormalities detected by echocardiography have an additional predictive 1014 
power.146, 147 In view of the lack of convincing evidence that echocardiography improves CV 1015 
risk reclassification and because of the logistical challenges in performing it, this imaging tool 1016 
is not recommended to improve CV risk prediction. 1017 
 1018 
Gaps in evidence 1019 
• Currently, most imaging techniques have not been rigorously tested as screening tools in 1020 
CV risk assessment; more evidence on calibration, reclassification, and cost-effectiveness 1021 
is still needed. 1022 
• The reduction of CVD risk in patients treated with lipid or BP lowering drugs because of 1023 
reclassification with, for example, CAC or ABI remains to be demonstrated. 1024 
 1025 
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2.4.5 Clinical conditions affecting cardiovascular disease risk 1026 
2.4.5.1 Chronic kidney disease 1027 
Key message 1028 
• CKD is associated with an increased risk of CVD, independent of conventional CVD risk 1029 
factors.  1030 
 1031 
Hypertension, dyslipidaemia, and DM are common among patients with CKD. In addition, 1032 
inflammatory mediators and promoters of calcification cause vascular injury, and may explain 1033 
why CKD is associated with CVD even after adjustment for conventional risk factors.148 A 1034 
decreasing estimated glomerular filtration rate (eGFR) is an important sign of a gradually 1035 
increasing risk for CVD-related mortality, starting below 75 mL/min/1.73 m2 and gradually 1036 
increasing to a ~ 3-fold risk in patients with values of 15 mL/min/1.73 m2. End-stage renal 1037 
disease is associated with a very high CV risk. Independent of eGFR, increased albumin 1038 
excretion is also associated with CV mortality risk; the RR is ~ 2.5 in overt proteinuria.149 1039 
Studies assessing whether the accuracy of CV risk stratification improves with the addition of 1040 
eGFR levels are emerging 150, but there is no consensus on which measure of renal function 1041 
(i.e. which formula, and creatinine- or cystatine-C-based) best predicts CVD.151, 152 Based on 1042 
the evidence, the Task Force decided to classify patients with severe CKD (GFR <30 1043 
mL/min/1.73 m2) as 'very high risk' and those with moderate CKD (GFR 30–59 mL/min/1.73 1044 
m2) as 'high risk' (see Table 5, chapter 2). 1045 
  1046 
Gaps in evidence  1047 
• The contribution of various CKD markers to CVD risk stratification remains unclear. 1048 
2.4.5.2 Influenza 1049 
Key message 1050 
• There is an association between acute respiratory infections, especially those occurring at 1051 
times of peak influenza virus circulation, and AMI. 1052 
 1053 
 1054 
Recommendation for influenza vaccination 1055 
Recommendation Classa Levelb Refc 
Annual influenza vaccination may be considered in patients 
with established CVD. 
 
IIb C 153-156 
aClass of recommendation. 1056 
bLevel of evidence. 1057 
cReference(s) supporting recommendations. 1058 
 1059 
Influenza can trigger a CV event. Studies show an increase in rates of MI during the annual 1060 
influenza season. The risk of MI or stroke was more than four times higher after a respiratory 1061 
tract infection, with the highest risk in the first 3 days.153 A recent meta-analysis suggests that 1062 
preventing influenza, particularly by means of vaccination, can prevent influenza triggered 1063 
AMI,156 but there is concern that some studies are biased.153-155, 157 1064 
 1065 
Gaps in evidence  1066 
• Large-scale RCTs are needed to assess the efficacy of influenza vaccination in preventing 1067 
influenza triggered AMI.  1068 
2.4.5.3 Periodontitis 1069 
Studies have linked periodontal disease to both atherosclerosis and CVD,158, 159 and 1070 
serological studies have linked elevated periodontal bacteria antibody titres to atherosclerotic 1071 
disease.160 A longitudinal study has suggested that an improvement in clinical and microbial 1072 
periodontal status is related to a decreased rate of carotid artery IMT progression during a 3-1073 
year follow-up period,161, but IMT progression does not seem to be associated with CV 1074 
events.135 Thus, if active treatment or prevention of periodontitis improved, clinical prognosis 1075 
is still unclear.  1076 
2.4.5.4 Patients treated for cancer 1077 
Key messages 1078 
• Patients surviving cancer after treatment with chemotherapy or radiotherapy are at 1079 
increased risk for CVD. 1080 
• The increased incidence of CVD is correlated with the (combination of) treatments given 1081 
and the administered dose. 1082 
• The presence of traditional CV risk factors in cancer patients further increases CV risk.  1083 
 1084 
Recommendations for patients treated for cancer  1085 
Recommendations 
Classa Levelb Refc 
Cardio-protection in high-risk patients* receiving type I 
chemotherapy should be considered for LV dysfunction 
prevention 
IIa B 162, 163 
Optimization of the CV risk profile should be considered in 
cancer treated patients. IIa C  
aClass of recommendation. 1086 
bLevel of evidence. 1087 
cReference(s) supporting recommendations. 1088 
* High-risk patients are mainly those individuals receiving high cumulative doses of type I chemotherapy and/or 1089 
combined treatment with other chemotherapic agents and radiotherapy, and/or with CV uncontrolled risk factors. 1090 
 1091 
 1092 
Survivors of cancer represent an increasingly large population, most of whom have received 1093 
chemotherapy and/or radiotherapy. Cardio-toxicity due to chemotherapy is related to a direct 1094 
effect on the cell (anthracycline-like) through the generation of reactive oxygen species 1095 
(ROS). It can be mediated by topoisomerase-IIβ in cardiomyocytes through the formation of 1096 
ternary complexes (TopIIβ- anthracycline-DNA) inducing DNA double-strand breaks and 1097 
transcriptome changes responsible for defective mitochondrial biogenesis and ROS formation. 1098 
Some agents (fluorouracil, bevacizumab, sorafenib, and sunitinib can induce a direct ischemic 1099 
effect not related to the premature developement of atherosclerotic lesions. Moreover, they 1100 
can increase risk factors such as hypertension and accelerate atherosclerosis, especially in 1101 
older patients. These effects can be irreversible (type I agents) or partially reversible (type II 1102 
agents) and can develop many years after treatment exposure. Typically, anthracyclines are 1103 
the prototype of type I agents and trastuzumab of type II agents.164 1104 
Cardio-toxicity due to chest radiotherapy can induce micro- and macrovascular injury. It can 1105 
accelerate atherosclerosis and this may occur many years after the initial exposure.165-171 1106 
Latency and severity of radiotherapy cardiotoxicity is related to multiple factors including the 1107 
dose (total/per fraction), the volume of the heart irradiated, concomitant administration of 1108 
other cardiotoxic drugs, and patient factors (younger age, traditional risk factors,172 history of 1109 
heart disease).  1110 
 1111 
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The first step, in identification of higher risk for cardio-toxicity, consists of a careful baseline 1112 
assessment of CV risk factors. Primary care, cardiology and oncology should work together to 1113 
deliver optimal survivorship care that addresses CVD risk factors, as well as prevalent 1114 
disease. Positive health-promoting behaviour, including lifestyle factors (healthy diet, 1115 
smoking cessation, regular exercise, weight control) should be strongly advised. In particular, 1116 
aerobic exercise is considered as a promising non-pharmacological strategy to prevent and/or 1117 
treat chemotherapy-induced cardio-toxicity.173  1118 
Signs or symptoms of cardiac dysfunction should be monitored before and periodically during 1119 
treatment for early detection of even asymptomatic abnormalities in patients receiving 1120 
potentially cardio-toxic chemotherapy and heart failure (HF) guideline recommendation 1121 
should be followed if indicated.174 Thus, pre-treatment evaluation of LV function is 1122 
required.175 A targeted approach to treat patients with early LV dysfunction in combination 1123 
with global longitudinal strain abnormalities and biomarker (notably troponin) elevation has 1124 
been proposed.175, 176 1125 
In the case of a decrease in LV function during or after chemotherapy, cardio-toxic agents 1126 
should be whenever possible avoided or delayed until after discussion with the oncology 1127 
team. This calls for adequate communication between oncology and cardiology.  1128 
To reduce chemotherapy type I cardiotoxicity, a variety of prophylactic treatments (including 1129 
beta-blockers, ACE-inhibitors, dexrazozane and statins) has been tested and compiled in a 1130 
recent meta-analysis.163 It has been stressed that early preventive treatment is mandatory to 1131 
exert a maximum effect.177, 178.175, 176  1132 
 1133 
Gaps in evidence 1134 
• Evidence on the effect of early preventive measures to reduce type I cardio-toxicity is 1135 
inconclusive. 1136 
• The most appropriate strategy to improve risk stratification and prevent CVD in patients 1137 
treated for cancer needs to be tested prospectively. 1138 
2.4.5.5 Autoimmune disease 1139 
Key messages 1140 
• Rheumatoid arthritis (RA) enhances CV risk independently of traditional risk factors, with 1141 
an RR of 1.4 to 1.5 in men and women, respectively.  1142 
• There is mounting evidence that other immune diseases, such as ankylosing spondylitis or 1143 
early severe psoriasis, also increase CV risk, with RRs approaching those in RA.  1144 
• Post hoc analysis of two statin trials suggests that the relative reduction in CVD incidence 1145 
in autoimmune diseases is comparable to that seen in the other conditions.  1146 
 1147 
Recommendations for autoimmune disease 1148 
Recommendations Classa Levelb Refc 
The use of a 1.5 factor risk multiplier for CV risk in rheumatoid 
arthritis should be considered, particularly if disease activity is 
high. 
IIa B 179 
The use of a 1.5 risk multiplier for CV risk in immune 
inflammatory diseases other than rheumatoid arthritis may be 
considered on a patient-by-patient basis, depending on disease 
activity/severity. 
IIb C 179 
aClass of recommendation. 1149 
bLevel of evidence. 1150 
cReference(s) supporting recommendations. 1151 
 1152 
There is now clear evidence implicating high-grade inflammation as a pathway for 1153 
accelerated vascular disease.180 Systemic inflammation appears to enhance CV risk directly 1154 
and indirectly via accentuation of existing risk pathways.180 While early small studies 1155 
suggested RA increases CV risk beyond other risk markers, the recent analysis of the national 1156 
QRESEARCH database in 2.3 million people provides the best available evidence for this.47 1157 
Such evidence has now been implemented in some national risk scores58 and European 1158 
guidelines.179  1159 
Evidence in psoriasis is less rigorous but a recent paper demonstrates broadly comparable CV 1160 
risks in RA and in early severe psoriasis.181 Robust data for independently elevated CV risks 1161 
in other autoimmune conditions are generally lacking. Hence, clinical judgment should be 1162 
applied on a case-by-case basis. There is evidence from post hoc analysis of randomized trials 1163 
to support a statin-associated reduction in CV risk in autoimmune conditions.182 Finally, in all 1164 
autoimmune diseases, drug interactions with anti-inflammatory and immunosuppressive drugs 1165 
with, for example, statins, antiplatelet agents, and anti-hypertensives deserve attention. 1166 
 1167 
Gaps in evidence 1168 
• The association between non-RA immune inflammatory disease and CVD is less clear 1169 
than for RA. 1170 
• The relationship between anti-rheumatic drugs and CV risk is unknown.  1171 
 1172 
2.4.5.6 Obstructive sleep apnoea syndrome  1173 
Key message 1174 
• There is evidence of a positive relationship between obstructive sleep apnoea syndrome 1175 
(OSAS) and hypertension, CAD, atrial fibrillation (AF), stroke, and HF. 1176 
 1177 
OSAS is characterized by recurrent partial or complete collapse of the upper airway during 1178 
sleep. It affects an estimated 9% of adult women and 24% of adult men and has been 1179 
associated with an RR of 1.7 for CV morbidity and mortality.183 Repetitive bursts of 1180 
sympathetic activity, surges of BP, and oxidative stress brought on by pain and episodic 1181 
hypoxaemia associated with increased levels of mediators of inflammation are thought to 1182 
promote endothelial dysfunction and atherosclerosis.183 Screening for OSAS can be 1183 
performed using the Berlin Questionnaire, daytime sleepiness assessed by the Epworth 1184 
Sleepiness Scale and overnight oxyimetry.184 Definitive diagnosis often requires 1185 
polysomnography, usually during a night in a sleep laboratory during which multiple 1186 
physiological variables are continuously recorded. Treatment options first include behavioural 1187 
changes, such as avoiding alcohol, caffeine or other stimulants of wakefulness before sleep, 1188 
increased physical activity, discontinuation of sedating drugs and obesity control. Continuous 1189 
positive airway pressure is the gold-standard therapy and reduces CV mortality and events.185  1190 
  1191 
Gaps in evidence 1192 
• More studies are needed to determine whether routine screening reduces (non)fatal CVD.  1193 
 1194 
2.4.5.7 Erectile dysfunction 1195 
Key message 1196 
• Erectile dysfunction (ED) is associated with future CV events in men without and with 1197 
established CVD. 1198 
 1199 
Recommendation for erectile dysfunction 1200 
Recommendation Classa Levelb 
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Assessment of CV risk factors and CVD signs or symptoms in 
men with ED should be considered IIa C 
CVD = cardiovascular disease; ED = erectile dysfunction. 1201 
aClass of recommendation. 1202 
bLevel of evidence. 1203 
 1204 
ED, defined as the consistent inability to reach and maintain an erection satisfactory for 1205 
sexual activity, is common, affecting almost 40% of men over 40 years of age (with varying 1206 
degrees of severity), and increases in frequency with age. ED and CVD share common risk 1207 
factors including age, hypercholesterolaemia, hypertension, insulin resistance and DM, 1208 
smoking, obesity, metabolic syndrome, sedentary lifestyle, and depression. CVD and ED also 1209 
share a common pathophysiological basis of aetiology and progression.186 Numerous studies 1210 
have established that ED is associated with asymptomatic CAD.187, 188 ED precedes CAD, 1211 
stroke, and PAD by a period that usually ranges from 2–5 years (average 3 years). A meta-1212 
analysis showed that patients with ED compared with subjects without ED have a 44% higher 1213 
risk for total CV events, 62% for AMI, 39% for stroke, and 25% for all-cause mortality.188 1214 
The predictive ability of ED is higher in younger ED patients despite the fact that probability 1215 
of ED increases with age, and it most likely identifies a group of patients with early and 1216 
aggressive CVD. Thorough history taking, including CV symptoms, presence of risk factors 1217 
and comorbid conditions, assessment of ED severity, and physical examination are mandatory 1218 
first-line elements of investigation. Lifestyle changes are effective in improving sexual 1219 
function in men: these include physical exercise, improved nutrition, weight control, and 1220 
smoking cessation. 186 1221 
 1222 
Gaps in evidence 1223 
• The benefit of ED routine screening and the most effective tool to assess it are still 1224 
unclear. 1225 
 1226 
2.5 Relevant groups 1227 
 1228 
2.5.1 Individuals under 50 years of age 1229 
Key messages 1230 
• Some people under 50 have high relative or lifetime CV risk and should be offered 1231 
lifestyle advice as a minimum. 1232 
• Some younger people will have high single CV risk factors that, of themselves, warrant 1233 
intervention, such as cholesterol levels >8 mmol/L or a BP of 180/110 mmHg or higher. 1234 
• The most important group of people under 50 to identify are those with a family history of 1235 
premature CVD who should be tested for familial hypercholesterolemia (FH) and treated 1236 
accordingly. 1237 
 1238 
Recommendation for individuals < 50 years of age 1239 
Recommendation Classa Levelb Refc 
It is recommended to screen all individuals under 50 year of 
age with a family history of premature CVD in a first degree 
relative (under 55 year of age in males, under 65 year of age 
in females) for familial hypercholesterolemia using a 
validated clinical score.  
I B 189-191 
aClass of recommendation. 1240 
bLevel of evidence. 1241 
cReference(s) supporting recommendations. 1242 
 1243 
The most powerful driver of risk in all short-term (5- or 10-year) CV risk algorithms is age. 1244 
As a consequence, all standard CV risk calculators show people under 50 as low CVD risk 1245 
regardless of underlying risk factors. However, some younger individuals are at very high 1246 
relative risk compared to individuals at a similar age and may have high lifetime risk: they are 1247 
more likely to develop CVD early and may prematurely suffer fatal or non-fatal CV events. 1248 
So trying to identify who may be at such risk is an important challenge. 1249 
2.5.1.1 Assessing cardiovascular disease risk in people under 50 1250 
Information on CV risk factors should be routinely collected in all adults under 50 years of 1251 
age with a first degree family history of premature (i.e. under 55 for male and 65 for female 1252 
relatives) CVD. There are no data on the right age to begin collecting such information in the 1253 
general population, but some guidelines advocate starting from age 40.192 Repeating such 1254 
assessments occasionally, such as every 5 years, is recommended, but there are no data to 1255 
guide this interval.  1256 
People under 50 should be assessed using the standard algorithm in terms of treatment 1257 
decisions. However, in the absence of a very high individual risk factor level or diagnosis of 1258 
FH, their 10 year risk will never be high enough to warrant BP or lipid lowering therapy. 1259 
Physicians may want to further differentiate CV risk in younger people by using a relative 1260 
risk chart (see Figure 3, section 2.3.1); this might be useful in assisting people under 50 to 1261 
judge their risk in relation to someone of the same age with low levels of risk factors.  1262 
Alternatively, physicians should consider using a risk age calculator (Figure 4, section 2.3.2) 1263 
or a lifetime risk calculator, such as the JBS3 web-based tool (see Figure C in web 1264 
addenda),58 which might act as an educational tool in terms of how changing risk factors 1265 
might change the lifetime risk score as well as illustrate long-term CVD risk. 1266 
People under 50 with a positive family history of premature CVD should be screened for FH 1267 
(see section 2.4.1) by clinical criteria (or occasionally genetic testing), such as those defined 1268 
by the Dutch Lipid Clinic Network criteria.189 Alternatives are the Simon Broome Registry 1269 
criteria 190 or the US MedPed Program.191  1270 
 1271 
2.5.1.2 Management of cardiovascular disease risk in people under 50 1272 
All people under 50 with elevated CVD risk factors should be counselled on lifestyle (with 1273 
emphasis on avoiding smoking, overweight and sedentary behaviour) and the relationship 1274 
between risk factors and subsequent disease. There are no data on what are the most effective 1275 
methods of changing health behaviours in younger people. However, smoking cessation, 1276 
healthy weight maintenance, and regular aerobic activity are all important behaviours to 1277 
provide advice and support with.  1278 
Younger people with very high BP levels warranting treatment should be managed the same 1279 
as hypertension in older people. In younger people who are judged eligible for a statin, on the 1280 
grounds of either FH or very high lipid levels, the management offered is the same as for 1281 
older people. Very importantly, for all patients deemed to suffer with FH, the physician 1282 
making the management decisions should arrange for FH screening for family members (see 1283 
section 3a.7.9). 1284 
 1285 
Gaps in knowledge  1286 
• Age to commence formal CV risk estimation. 1287 
• Whether and how to screen populations for FH. 1288 
 1289 
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2.5.2 Elderly 1290 
Age is the dominant driver of cardiovascular risk, and most indivuduals are already at (very) 1291 
high risk at the age of 65 years (see section 2.3.1). Especially in the oldest old, cardiovascular 1292 
prevention is controversial. Opponents argue that risk should not be treated when it is 1293 
essentially age-driven. Proponents, on the other hand, point out that many preventive 1294 
treatments are still effective at high age in terms of postponing morbidity and mortality.  1295 
The Task Force has taken the position that epidemiological evidence of absolute risk 1296 
reduction in clinical trials is the main driver for recommendations in this guideline. Still, we 1297 
encourage a discussion with patients regarding quality of life and life potentially gained, as 1298 
well as regarding the ethical dilemmas of treating risk inherent to ageing, the total burden of 1299 
drug treatment, and the inevitable uncertainties of benefit. 1300 
In this guideline, sections on treatment of the main risk factors contain recommendations or 1301 
considerations specific to elderly when evidence is available.  1302 
Hypertension: Most of the elderly-specific evidence is available for BP (section 3a.9). In 1303 
general, more lenient treatment targets are advocated in elderly. The hypertension literature 1304 
also contains increasing evidence that biological rather than calender age is important 193.  1305 
DM: evidence supporting more lenient glycemic control targets in elderly is also available in 1306 
DM (section 3a.8). The role of biological age/frailty is less well established than for BP, but 1307 
nonetheless a Class IIa recommendation is given to relax glycemic targets in elderly or frail 1308 
patients. 1309 
Hyperlipidemia: Few areas in CVD prevention are more controversial than the mass use of 1310 
statins in elderly. As the lipid chapter points out, there is no evidence of decreasing 1311 
effectiveness of statins in patients over 75 years (section 3a.7). On the other hand, cost-1312 
effectiveness of statins in these patients is offset by even small geriatric-specific adverse 1313 
effects.194 Also, evidence supporting effectiveness in the oldest old (i.e. older than 80 years is 1314 
very limited. A recent trial suggested no harm of stopping statins in elderly with a limited life 1315 
expectancy.195 Taken together, the recommendations of cholesterol lowering treatment in 1316 
elderly should be followed with caution and common sense, adverse effects should be 1317 
monitored closely, and treatment should be reconsidered periodically. 1318 
2.5.3 Female-specific conditions 1319 
Key messages 1320 
• Several obstetric complications, in particular pre-eclampsia and pregnancy-related 1321 
hypertension, are associated with higher risk of CVD later in life. This higher risk is 1322 
explained, at least partly, by hypertension and DM. 1323 
• Polycystic ovary syndrome (PCOS) confers a significant risk for future development of 1324 
DM. 1325 
 1326 
Recommendations for female-specific conditions 1327 
Recommendations Classa Levelb Refc 
In women with a history of pre-eclampsia and/or pregnancy-
induced hypertension, periodic screening for hypertension 
and DM should be considered. 
IIa B 196-199 
In women with a history of polycystic ovary syndrome or 
gestational DM, periodic screening for DM should be 
considered. 
IIa B 200, 201 202, 
203 
In women with a history of giving premature birth, periodic 
screening for hypertension and DM may be considered. 
IIb B 204, 205 
aClass of recommendation. 1328 
bLevel of evidence. 1329 
cReference(s) supporting recommendations. 1330 
 1331 
Specific conditions that may occur in females only and may have an impact on CVD risk can 1332 
be separated into obstetric and non-obstetric conditions. 1333 
2.5.2.1 Obstetric conditions 1334 
Pre-eclampsia (defined as pregnancy-related hypertension accompanied by proteinuria) 1335 
occurs in 1–2% of all pregnancies. Studies suggest that pre-eclampsia is associated with an 1336 
increase in CV risk by a factor 1.5 to 2.5,196, 197 while the RR of developing hypertension is 1337 
around 3,198 and DM approximately 2.196, 199 Because most studies did not adjust the elevated 1338 
risk of future CVD for the development of conventional risk factors, it cannot be established 1339 
whether the increased CV risk after pre-eclampsia occurs independent of CV risk factors. The 1340 
rationale for screening these women for occurrence of hypertension and DM is, however, 1341 
quite strong. 1342 
Pregnancy-related hypertension affects 10–15% of all pregnancies. The associated risk of 1343 
later CVD is lower than for pre-eclampsia, but is still elevated (RR 1.9 to 2.5).204 Also the risk 1344 
for sustained or future hypertension is elevated (RR vary widely, from 2.0 to 7.2 or even 1345 
higher).198, 206. Again, however, there was incomplete adjustment for conventional risk factors. 1346 
The risk of developing DM is probably elevated also in these women, but exact estimates are 1347 
not available.  1348 
There are no data to suggest that recurrent pregnancy loss is associated with an increased CV 1349 
risk. A history of premature birth is possibly associated with increased risk of CVD in 1350 
offspring (RR 1.5 to 2.0),204, 205 which may partially be explained by an increased incidence of 1351 
hypertension and DM.  1352 
Finally, gestational diabetes confers a sharply elevated risk of future DM, with up to 50% 1353 
developing DM within 5 years after pregnancy.202 Previously, oral glucose tolerance testing 1354 
was advocated to screen for DM in such patients, but screening by fasting glucose or glycated 1355 
hemoglobin may be preferable.203  1356 
2.5.2.2 Non-obstetric conditions 1357 
PCOS affects approximately 5% of all women in their fertile years. PCOS has been 1358 
associated with an increased risk for future development of CVD, but larger studies produced 1359 
conflicting results.200, 207 The risk of developing hypertension is probably somewhat 1360 
increased, but again the data are conflicting.207 PCOS does seem to be associated with a 1361 
higher risk of developing DM (RR 2 to 4),200, 201 suggesting that periodic screening for DM is 1362 
appropriate. 1363 
Premature menopause, better defined as primary ovarian insufficiency, occurs in roughly 1364 
1% in women aged ≤ 40 years. It has been reported to be associated with an increased risk of 1365 
CVD (RR approximately 1.5),208 but studies are sparse. There are insufficient data to draw 1366 
conclusions on a possible increased risk of hypertension or DM. 1367 
 1368 
Gaps in evidence 1369 
• The degree to which increased CVD risk associated with several of the female-specific 1370 
conditions occurs independent of conventional CVD risk factors is unknown. 1371 
• Information on whether female-specific conditions improve risk classification in women 1372 
is unknown. 1373 
 1374 
2.5.4 Ethnic minorities 1375 
Key messages 1376 
• CVD risk varies considerably between immigrant groups. South Asians and sub-Saharian 1377 
Africans have a higher risk while Chinese and South Americans have a lower risk. 1378 
• South Asians are characterized by a high prevalence and an inadequate management of 1379 
DM. 1380 
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• Current risk estimation equations do not provide adequate estimations of CVD risk in 1381 
ethnic minorities. 1382 
 1383 
Recommendation for ethnic minorities 1384 
Recommendation Classa Levelb Refc 
Ethnicity should be considered in CVD risk assessment. IIa A 209, 210 
aClass of recommendation. 1385 
bLevel of evidence. 1386 
cReference(s) supporting recommendations. 1387 
 1388 
Europe welcomes a large number of non-EU immigrants per year, mainly from India, China, 1389 
North Africa and Pakistan. One out of 25 Europeans comes from outside Europe, but data 1390 
regarding CVD risk or CVD risk factors among immigrants are scarce and of differing 1391 
quality.211  1392 
First generation migrants usually display lower CVD mortality rates than natives of the host 1393 
country,212 but with time, migrants tend to approach the CVD risk in their host country.212, 213 1394 
Relative to natives of the host country, CVD mortality risk, as well as the prevalence and 1395 
management of CVD risk factors among migrants, varies according to country of origin and 1396 
host country.213-215 Given the considerable variety in CVD risk factors between immigrant 1397 
groups, no single CVD risk score performs adequately in all groups and the use of ethnic-1398 
specific scores might be necessary.209  1399 
Immigrants from South Asia (notably India and Pakistan) present high CVD rates216-218 and 1400 
have a much higher prevalence of DM,219, 220 while the prevalence of other CV risk factors is 1401 
slightly lower than or comparable to natives of the host country.219, 221 Interestingly, the 1402 
increased prevalence of DM raises the CVD risk in South Asians in some studies216 but not in 1403 
others. Management of DM is also significantly worse, while management of high BP and 1404 
hypercholesterolaemia is better among South Asians than host country natives.222 The higher 1405 
CVD risk among South Asians makes screening more cost-effective than in other immigrant 1406 
groups, but risk prediction using SCORE might not be optimal.223 1407 
Immigrants from China and Vietnam present lower CVD risk than natives of the host 1408 
country,216, although this finding has been challenged.217 This lower risk seems attributable to 1409 
lower levels of CV risk factors219 and higher HDL-C levels.224 1410 
Immigrants from Turkey have higher estimated CVD risk and higher CVD mortality rates214 1411 
than host country natives. This seems mainly due to the higher prevalence of smoking, DM, 1412 
dyslipidaemia, hypertension and obesity rates.224-226 Management of CVD risk factors also 1413 
varies according to host country: there are no differences in hypertension control compared to 1414 
natives in the Netherlands,226 but worse control in Denmark.227 1415 
Immigrants from Morocco present lower CVD rates than natives from the host country.214 1416 
Possible explanations include lower BP and cholesterol levels and smoking rates,225, 226 1417 
although a higher prevalence of DM and obesity has also been found.226 No differences 1418 
between Moroccan immigrants and Dutch natives were found regarding hypertension 1419 
control.225 1420 
Immigrants from sub-Saharan Africa and the Caribbean present higher CVD rates than 1421 
natives from the host country in some studies,215, 216, 228 but not all.216 African immigrants 1422 
have higher DM rates220 but smoke less221 than natives from the host country. Management of 1423 
CVD risk factors was worse than among natives in one study,222 but not in another.229 1424 
Immigrants from South America have lower CVD mortality rates than natives in Spain,230 1425 
while no difference was found in Denmark.231 South American immigrants in Spain have a 1426 
lower prevalence of CV risk factors and CVD rates than natives in Spain, but these 1427 
differences decrease with increasing length of stay.232 1428 
Based on available mortality and prospective data,210 the following correction factors could be 1429 
applied when assessing CVD risk using SCORE among first generation immigrants only.  1430 
• Southern Asia: multiply the risk by 1.4 1431 
• Sub-Saharan Africa and the Caribbean: multiply the risk by 1.3 1432 
• Western Asia: multiply the risk by 1.2 1433 
• Northern Africa: multiply the risk by 0.9 1434 
• Eastern Asia or South America: multiply the risk by 0.7 1435 
These values reflect the best estimations from available data and should be interpreted with 1436 
caution, but can be used to guide CV risk management.  1437 
 1438 
Gaps in evidence 1439 
• Studies focusing on CVD risk and prevalence of CVD risk factors among minorities in 1440 
Europe are needed. 1441 
• Validation of the SCORE risk estimation among ethnic minorities is needed. 1442 
• Ethnicity-specific thresholds to define high risk (based on SCORE evaluation) should be 1443 
identified. Alternatively, ethnicity-specific CVD risk equations should be obtained. 1444 
 1445 
1446 
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3a. How to intervene at the individual level: risk factor intervention 1447 
 1448 
3a.1 Behaviour change  1449 
Key message 1450 
• Cognitive-behavioural methods are effective in supporting persons in adopting a healthy 1451 
lifestyle. 1452 
 1453 
Recommendations for facilitating changes in behaviour 1454 
Recommendations Classa Levelb Refc 
Established cognitive-behavioural strategies (eg. 
motivational interviewing) to facilitate lifestyle change are 
recommended.  
I A 233 
Involvement of multidisciplinary healthcare professionals 
(e.g. nurses, dieticians, psychologists) to promote healthy 
behaviours is recommended. 
I A 234, 235 
In individuals at very high CVD risk, multimodal 
interventions integrating education on healthy lifestyle and 
medical resources, physical activity, stress management and 
counselling on psychosocial risk factors, are recommended 
to promote healthy behaviour. 
I A 235, 236 
CVD = cardiovascular disease. 1455 
aClass of recommendation. 1456 
bLevel of evidence. 1457 
cReference(s) supporting recommendations. 1458 
 1459 
 “Lifestyle” is usually based on longstanding behavioural patterns that are maintained by 1460 
social environment. Individual and environmental factors impede the ability to adopt a healthy 1461 
lifestyle, as does complex or confusing advice from caregivers. Friendly and positive 1462 
interaction enhances an individual’s ability to cope with illness and adhere to recommended 1463 
lifestyle changes (“empowerment”). It is important to explore each patient’s experiences, 1464 
thoughts and worries, previous knowledge, and circumstances of everyday life. Individualized 1465 
counselling is the basis for motivation and commitment. Decision-making should be shared 1466 
between caregiver and patient (including also the individual’s spouse and family).234, 237 Use 1467 
of the principles of effective communication 238 listed in Table 8 will facilitate treatment and 1468 
prevention of CVD. 1469 
 1470 
Table 8 Principles of effective communication to facilitate behavioural change 1471 
• Spend enough time with the individual to create a therapeutic relationship – even a few 
more minutes can make a difference. 
• Acknowledge the individual's personal view of his/her disease and contributing factors. 
• Encourage expression of worries and anxieties, concerns and self-evaluation of 
motivation for behaviour change and chances of success. 
• Speak to the individual in his/her own language and be supportive of every improvement 
in lifestyle. 
• Ask questions to check that the individual has understood the advice and has any support 
he or she requires to follow it. 
• Acknowledge that changing life-long habits can be difficult and that sustained gradual 
change is often more permanent than a rapid change. 
• Accept that individuals may need support for a long time and that repeated efforts to 
encourage and maintain lifestyle change may be necessary in many individuals. 
• Make sure that all health professionals involved provide consistent information. 
 1472 
In addition, caregivers can build on cognitive-behavioural strategies to assess the individual’s 1473 
thoughts, attitudes, and beliefs concerning the perceived ability to change behaviour, as well 1474 
as the environmental context. Behavioural interventions such as “motivational interviewing” 1475 
increase motivation and self-efficacy.233 1476 
Previous unsuccessful attempts often affect self-efficacy for future change. A crucial step is to 1477 
help set realistic goals combined with self monitoring of the chosen behaviour.234 Moving 1478 
forward in small, consecutive steps is key to changing long-term behaviour.234 1479 
Communication training is important for health professionals. The following “Ten strategic 1480 
steps” enhance counselling on behavioural change effectively (Table 9)239.  1481 
 1482 
Table 9: Ten strategic steps to facilitate behaviour change  1483 
1. Develop a therapeutic alliance. 
2. Counsel all individuals at risk of or with manifest CVD 
3. Assist individuals to understand the relationship between their behaviour and health 
4. Help individuals assess the barriers to behaviour change 
5. Gain commitments from individuals to own their behaviour change 
6. Involve individuals in identifying and selecting the risk factors to change 
7. Use a combination of strategies including reinforcement of the individual’s capacity for 
change 
8. Design a lifestyle-modification plan  
9. Involve other healthcare staff whenever possible 
10. Monitor progress through follow-up contact 
 1484 
Combining the knowledge and skills of caregivers (such as physicians, nurses, psychologists, 1485 
experts in nutrition, cardiac rehabilitation, and sports medicine) into multimodal, behavioural 1486 
interventions can optimize preventive efforts.234-236 Multimodal behavioural interventions are 1487 
especially recommended for individuals at very high risk.234-236 These interventions include 1488 
promoting a healthy lifestyle through behaviour change including nutrition, PA, relaxation 1489 
training, weight management, and smoking cessation programmes for resistant smokers.235, 236 1490 
They enhance coping with illness, and improve adherence and CV outcome.240 241 1491 
Psychosocial risk factors (stress, social isolation, and negative emotions) that may act as 1492 
barriers against behaviour change should be addressed in tailored individual or group 1493 
counselling sessions.235, 236 1494 
There is evidence that more extensive/longer interventions lead to better long-term results 1495 
with respect to behaviour change and prognosis.234 Individuals of low socio-economic status, 1496 
older age, or female sex may need tailored programmes in order to meet their specific needs 1497 
regarding information and emotional support. 234, 242, 243 1498 
 1499 
Gaps in evidence 1500 
• There is limited evidence to determine which interventions are the most effective in 1501 
specific groups (e.g. young–old, male–female, high vs. low socio-economic status). 1502 
 1503 
 1504 
 1505 
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3a.2 Psychosocial factors 1506 
Key messages 1507 
• Treatment of psychosocial risk factors can counteract psychosocial stress, depression and 1508 
anxiety, thus facilitating behaviour change, quality of life, and prognosis. 1509 
• The caregiver–patient interaction should follow the principles of patient-centred 1510 
communication. Age- and sex-specific psychosocial aspects should be considered. 1511 
Recommendations for psychosocial factors 1512 
Recommendations Classa Levelb Refc 
Multimodal behavioural interventions, integrating health 
education, physical exercise and psychological therapy, for 
psychosocial risk factors and coping with illness are 
recommended in patients with established CVD and 
psychosocial symptoms in order to improve psychosocial health. 
I A 244 
Referral for psychotherapy, medication or collaborative care 
should be considered in the case of clinically significant 
symptoms of depression, anxiety or hostility.  
IIa A 245, 246  
Treatment of psychosocial risk factors with the aim of preventing 
CAD should be considered when the risk factor itself is a 
diagnosable disorder (e.g. depression) or when the factor 
worsens classical risk factors. 
IIa B 247, 248 
CAD = coronary artery disease; CVD = cardiovascular disease. 1513 
aClass of recommendation. 1514 
bLevel of evidence. 1515 
cReference(s) supporting recommendations. 1516 
 1517 
Caregivers in clinical practice are in a unique position to directly support their patients 1518 
regarding psychosocial risk factors in individuals with high CV risk or with established 1519 
disease. Empathic, patient-centred communication helps to establish and maintain a trustful 1520 
relationship and is a powerful source of emotional support and professional guidance in 1521 
coping with psychosocial stressors, depression, anxiety, CV risk factors, and CVD.249, 250 The 1522 
principles of a supportive caregiver–patient interaction are249, 250: 1523 
• Spend enough time with the patient, listen carefully, repeat essential keywords; 1524 
• Consider age- and sex-specific psychosocial aspects; 1525 
• Encourage expression of emotions, do not trivialize psychosocial burdens and worries;  1526 
• Explain essential medical facts in his/her own language, convey hope, relief from feelings 1527 
of guilt, and reinforce adaptive thoughts and actions; 1528 
• In the case of severe mental symptoms, obtain treatment preferences and perform shared-1529 
decision making regarding further diagnostic and therapeutic steps;  1530 
• Summarize important aspects of the consultation in order to signal that the patient has 1531 
been understood; 1532 
• Offer regular follow-up contacts. 1533 
Specialised psychological interventions have additional beneficial effects on distress, 1534 
depressiveness and anxiousness, even when added to standard rehabilitation.244 These 1535 
interventions include individual or group counselling on psychosocial risk factors and coping 1536 
with illness, stress management programmes, meditation, autogenic training, biofeedback, 1537 
breathing, yoga, and/or muscular relaxation. 1538 
Large and consistent effects on depression have been shown in “collaborative care”, which 1539 
may involve a systematic assessment of depression, a (non-physician) care manager to 1540 
perform longitudinal symptom monitoring, treatment interventions and care coordination, and 1541 
specialist-provided stepped care recommendations and treatment.246 Collaborative care for 1542 
depression resulted in a 48% lower risk for developing first CAD events 8 years after 1543 
treatment compared to usual care (RR 0.52, 95% CI 0.31–0.86).247 Internet-delivered 1544 
cognitive behavioural therapy in depressed patients with high CVD risk produced small, but 1545 
robust, improvement of depressive symptoms, adherence and some health behaviours.248.  1546 
In patients with established CAD, mental health treatments for depression (psychotherapy 1547 
and/or medication) have moderate efficacy for reducing cardiac events (NNT 34), but do not 1548 
reduce total mortality.245 Especially collaborative care is effective on depressive symptoms 1549 
and partially also on cardiac prognosis.251, 252 Furthermore, there is evidence that physical 1550 
activity can effectively improve depression in patients with CAD.253  1551 
In addition to the treatment of mood symptoms, there are several other approaches to 1552 
psychosocial intervention that have proved useful. Two RCTs254, 255 have shown the 1553 
favourable impact of stress management and social support groups on the prognosis of 1554 
clinical CAD. Nurse-led interventions reveal beneficial effects on anxiety, depression and 1555 
general well-being in CAD patients.256, 257  1556 
In hostile CAD patients, a group-based hostility-control intervention may lead not only to 1557 
decreases in behaviourally assessed hostility levels, but also to decreased levels of depression, 1558 
resting heart rate (HR), and CV reactivity to mental stress, as well as to increased social 1559 
support and satisfaction with life.258 Work reorganizations aimed at improving autonomy and 1560 
increasing control at work may result in improved social support and reduction in 1561 
physiological stress responses. Hence, reduction of work stress in managers and supervisors 1562 
may have beneficial health effects on the target individuals and may also improve perceived 1563 
social support in their subordinates.259 1564 
 1565 
Gaps in evidence 1566 
• Evidence that treatment of clinically significant depression and anxiety alone will prevent 1567 
CVD and improve outcomes is inconclusive. 1568 
3a.3 Sedentary behaviour and physical activity  1569 
Key messages 1570 
• Regular PA is a mainstay of CV prevention; participation decreases all-cause and CV 1571 
mortality. 1572 
• PA increases fitness and improves mental health. 1573 
• Sedentary subjects should be encouraged to start light-intensity aerobic PA. 1574 
 1575 
 1576 
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CV = cardiovascular; PA = physical activity. 1577 
aClass of recommendation. 1578 
bLevel of evidence. 1579 
cReference(s) supporting recommendations. 1580 
dVolume is the total weekly dose of PA 1581 
 1582 
3a.3.1 Introduction 1583 
Regular PA is related to a reduced risk of many adverse health outcomes over a wide age 1584 
range: all cause and CVD mortality in healthy individuals, 260, 269, 271 in subjects with coronary 1585 
risk factors271 and in cardiac patients272. PA has a positive effect on many risk factors, 1586 
including hypertension, low-density lipoprotein cholesterol (LDL-C) and non-HDL-C, body 1587 
weight and type 2 DM.269 In healthy subjects, PA and cardiorespiratory fitness are associated 1588 
with a significant reduction (20–30%) in risk of all-cause and CV mortality, in a dose–1589 
response fashion.261, 262 This applies for both men and women and across a broad range of 1590 
ages from childhood to the very elderly. A sedentary lifestyle is one of the major risk factors 1591 
for CVD independently of participation in PA.273 1592 
3a.3.2 Physical activity prescription  1593 
Health providers should assess the PA level in any subject (how many days and minutes per 1594 
day are spent on average doing PA at moderate or vigorous intensity. They should warn 1595 
against inactivity, and help add PA to daily life. Subjects should be advised on appropriate 1596 
types of activities, ways of progressing, and should be helped to set personal goals to achieve 1597 
and maintain the benefits. To this end, individuals should be encouraged to find some activity 1598 
they either enjoy and/or that they could include in their daily routines, as such activities are 1599 
more likely to be sustainable. For a more effective behaviour change, clinicians should 1600 
explore practical ways to overcome barriers to exercise. For this reason the link between 1601 
primary care and local community-based structures for activity, recreation and sport is 1602 
crucial.264 The amount of time spent being sedentary should be minimized by active travelling 1603 
Recommendations Classa Levelb Refc 
It is recommended for healthy adults of all ages to perform at least 150 
minutes a week of moderate intensity or 75 minutes a week of vigorous 
intensity aerobic PA or an equivalent combination thereof.  I A 
260-
263  
For additional benefits in healthy adults, a gradual increase in aerobic 
PA to 300 minutes a week of moderate intensity, or 150 minutes a 
week of vigorous intensity aerobic PA, or an equivalent combination 
thereof is recommended. 
I A 261, 
262 
Regular assessment and counselling on PA is recommended to promote 
the engagement and, if necessary, to support anincrease in PA volume 
over time.d 
I B 
264-
266 
PA is recommended in low risk individuals without further assessment. 
I C 
267, 
268 
Multiple sessions of PA should be considered, each lasting ≥ 10 
minutes and evenly spread throughout the week, i.e. on 4–5 days a 
week and preferably every day of the week. IIa B 
269, 
270 
Clinical evaluation, including exercise testing, should be considered for 
sedentary people with CV risk factors who intend to engage in vigorous 
PAs or sports.  
IIa C 267 
(cycling or walking), taking breaks from extended periods of sitting, and reducing screen 1604 
time.274 Brief exercise advices are more cost-effective than supervised gym–based exercise 1605 
classes or instructor-led walking program 266. 1606 
3a.3.2.1 Aerobic physical activity 1607 
Aerobic PA, the most studied and recommended modality, with a beneficial dose–response 1608 
effect on prognosis,261, 262, 270 consists of movements of large muscle mass, involved in a 1609 
rhythmic manner for a sustained period. It includes every day activity, such as active travel 1610 
(cycling or walking), heavy household work, gardening, occupational activity, and leisure 1611 
time activity or exercise such as brisk walking, nordic-walking, hiking, jogging or running, 1612 
cycling, cross-country skiing, aerobic dancing, skating, rowing or swimming.  1613 
Similar to all other interventions, its prescription can be adjusted in terms of frequency, 1614 
duration and intensity. However, practising PA below the lowest recommended levels should 1615 
be encouraged in individuals unable to meet the minimum or in those sedentary individuals 1616 
who have just started and recommended to gradually increase the level. 1617 
Intensity: moderate or vigorous aerobic exercise should be recommended. It can be expressed 1618 
either in absolute or relative terms.  1619 
Absolute intensity is the amount of energy expended per minute of activity, assessed by 1620 
oxygen uptake per unit of time (mL.min-1or L.min-1) or by metabolic equivalent (MET, which 1621 
is estimated as the rate of energy expenditure while sitting at rest, by convention this 1622 
corresponds to 3.5 mL O2 kg-1 min-1). 275 A list of PA intensities in MET values is 1623 
available.276 An absolute measure does not take into account individual factors such as body 1624 
weight, sex, and fitness level: older persons exercising at a vigorous intensity of 6 METs, may 1625 
be exercising at their maximal intensity, while a younger person working at the same absolute 1626 
intensity will be exercising moderately.  1627 
Relative intensity is the level of effort required to perform an activity. Less fit individuals 1628 
generally require a higher level of effort than fitter people to perform the same activity. It is 1629 
determined relative to an individual’s level of cardiorespiratory fitness (V̇O2max) or as a 1630 
percentage of a person’s measured or estimated maximum heart rate (HR), which is 220 – 1631 
age, (%HRmax). It also can be expressed as an index of individual rate of effort (how hard the 1632 
person feels he/she is exercising), i.e. the rating of perceived exertion (RPE) or by frequency 1633 
of breathing (the so-called “Talk Test”). For individuals on medication it is important to 1634 
consider possible modification of HR response and to refer to other relative intensity 1635 
parameters. Especially for older and deconditioned individuals, a relative measure of intensity 1636 
is more appropriate. Classification for both absolute and relative intensity and examples are 1637 
presented in Table 10. 1638 
 1639 
Table 10 Classification of physical activity intensity and examples of absolute and relative 1640 
intensity levels 1641 
Absolute intensity Relative intensity 
Intensity MET Examples %HRmax RPE (Borg 
scale score) 
Talk Test 
Light 
 
1.1–2.9 Walking < 4.7 km/h, light 
household work 
50–63 10–11  
Moderate 3–5.9 Walking briskly (4.8–6.5 
km/h), slow cycling (15 km/h), 
painting/decorating, 
vacuuming, gardening 
(mowing lawn), golf (pulling 
clubs in trolley), tennis 
(doubles), ballroom dancing, 
64–76 12–13 Breathing is faster 
but compatible with 
speaking full 
sentences 
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water aerobics 
Vigorous ≥ 6 Race-walking, jogging or 
running, bicycling > 15 km/h, 
heavy gardening (continuous 
digging or hoeing), swimming 
laps, tennis (single) 
77–93 14–16 Breathing very 
hard, incompatible 
with carrying on a 
conversation 
comfortably 
MET (metabolic equivalent) is estimated as the energy cost of a given activity divided by resting energy 1642 
expenditure: 1 MET = 3.5 mL O2 kg-1 min-1oxygen consumption (V̇O2). 1643 
RPE, rating of perceived exertion (20 value Borg score). 1644 
%HRmax, percentage of measured or estimated maximum heart rate (220 − age). 1645 
Modified from Howley.277 1646 
 1647 
Frequency: At least 3–5 sessions per week, but preferably every day.  1648 
Duration. It is recommended to accumulate at least 30 minutes per day, 5 days/week of 1649 
moderate intensity (i.e. 150 min/week), or 15 minutes per day, 5 days/week of vigorous 1650 
intensity (75 min/week), or a combination of both, performed in sessions of at least 10 1651 
minutes’ duration. Shorter exercise bouts (i.e. < 10 minutes) may also be appropriate 1652 
especially in very deconditioned individuals.269, 278, 279 For lipid control or body weight 1653 
management, longer durations of exercise, 40 and 60–90 minutes per day respectively, have 1654 
been proposed.280  1655 
Aerobic interval training and high intensity interval training cannot yet be broadly 1656 
recommended, until further data on safety and efficacy are available.268  1657 
3a.3.2.2 Muscle strength/resistance physical activity 1658 
Isotonic PA stimulates bone formation and reduces bone loss, preserves and enhances muscle 1659 
mass, strength, power and functional ability, with some evidence of benefit in lipid and BP 1660 
control, insulin sensitivity, especially in combination with aerobic exercise.269, 281 It should 1661 
target the major muscle groups (agonist and antagonist) and include multi-joint or compound 1662 
movements through the full range of motion of the joints, such as working with resistance-1663 
bands, calisthenic exercise using body weight for resistance, carrying heavy loads, and heavy 1664 
gardening. For each exercise session, the suggested prescription is 2–3 sets of 8–12 1665 
repetitions at the intensity of 60–80% of the individual’s one repetition maximum (1-RM; the 1666 
maximum load that can be lifted one time) at the frequency of least 2 days a week. For older 1667 
adults or very deconditioned individuals it is suggested to start with 1 set of 10-15 repetitions 1668 
at 60-70% of 1RM.282  1669 
3a.3.2.3 Neuromotor physical activity 1670 
For older adults at risk of falls, neuromotor exercise helps to maintain and improve balance, 1671 
and motor skills (balance, agility, coordination and gait). This includes multifaceted activities 1672 
such as tai chi and yoga, and recreational activities using paddles or sport balls to challenge 1673 
hand eye coordination. The optimal volume is not known.278 1674 
3a.3.2.4 Phases and progression of physical activity 1675 
PA sessions should include the following phases: warm-up, conditioning phase (aerobic, 1676 
muscle strength/resistance, and neuromotor exercise), cool-down, and stretching/flexibility. 1677 
Progressive warm-up before and cool-down after exercise may prevent injuries and adverse 1678 
cardiac events. Inactive adult should start gradually, at light or moderate intensity for short 1679 
periods of time (even less than 10 minute), with sessions spread throughout the week. With 1680 
the improvement in exercise tolerance, each subject progresses in the level of PA, but the 1681 
increases in any components (i.e frequency, duration and intensity) should be gradual, to 1682 
minimize risks of muscle soreness, injury, fatigue and the long-term risk of overtraining.278 1683 
Following any adjustments, the individual should check for adverse effects (e.g. excessive 1684 
shortness of breath) and if there are any such effects, downward adjustments should be 1685 
made.278 1686 
 1687 
3a.3.3 Risk assessment 1688 
The risk of an adverse CV response during PA is extremely low for apparently healthy adults 1689 
(5 to 17 sudden deaths per million population per year).283 The risk of participation is 1690 
outweighed by substantial health benefits conferred by PA.269 Risk during light or moderate 1691 
intensity exercise is lower than during vigorous activity269: thus in healthy individuals who 1692 
wish to undertake moderate PA, such as a walking programme, a preliminary medical 1693 
evaluation is not needed.268  1694 
Before starting more intensive leisure-time activities (i.e. structured or competitive activity, 1695 
amateur sport, exercise and fitness training), risk assessment should be tailored to the 1696 
individual’s clinical (i.e. metabolic, musculoskeletal condition/disease) and cardiac risk 1697 
profile, the current level of habitual PA, and the intended level of PA.267 Individuals who 1698 
exercise only occasionally seem to have an increased risk of acute coronary events and 1699 
sudden cardiac death during or after exercise.284 Sedentary subjects and those with CV risk 1700 
factors should start aerobic PA at low-intensity activity and progress gradually. Clinical 1701 
evaluation, including exercise testing, may be considered for sedentary people with CV risk 1702 
factors who intend to engage in vigorous PA and sports. The information gathered from 1703 
exercise tests may be useful in establishing a safe and effective exercise prescription. 1704 
Validated self-assessment questionnaires have been proposed for sedentary individuals 1705 
entering low-intensity leisure-time sport activity or starting moderate intensity activities267 1706 
(see Table B in web addenda). 1707 
 1708 
Gaps in evidence 1709 
• The lower and upper limit of aerobic PA intensity, duration and frequency to exert a 1710 
beneficial effect is unknown. 1711 
• The effectiveness of PA monitoring, versus simple counselling, to optimize the motivation 1712 
of patients to adhere to active lifestyle, versus simple counselling is not known  1713 
• The role and sustainability of modern technology (such as comprises wearable 1714 
technology, “exergaming” and smartphone’s apps) motivating people to undertake more 1715 
PA has not been established 1716 
3a.4 Smoking intervention 1717 
Key messages  1718 
• Stopping smoking is the most cost-effective strategy for CVD prevention. 1719 
• There is a strong evidence base for:  1720 
o brief interventions with advice to stop smoking, 1721 
o all types of nicotine replacement therapy (NRT), 1722 
o bupropion, 1723 
o varenicline, 1724 
o more effectiveness of drugs in combination, except for except for NRT plus 1725 
varenicline  1726 
o most effective are brief interventions plus assistance with stopping using drug 1727 
therapy and follow-up support.  1728 
• Electronic cigarettes (e-cigarettes) may help in smoking cessation but should be covered 1729 
by the same marketing restriction as cigarettes 1730 
• Passive secondary smoking carries significant risk, with the need to protect non-smokers. 1731 
 1732 
 1733 
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 1734 
 1735 
Recommendations for smoking intervention strategies 1736 
Recommendations  Classa Levelb Refc 
It is recommended to identify smokers and provide repeated 
advice on stopping with offers to help, by the use of follow up 
support, nicotine replacement therapies, varenicline, and 
bupropion individually or in combination. 
I A 285-288 
It is recommended to stop all smoking of tobacco or herbal 
products, as this is strongly and independently causal of CVD. 
I B 289-293 
It is recommended to avoid passive smoking I  B 294, 295 
aClass of recommendation. 1737 
bLevel of evidence. 1738 
cReference(s) supporting recommendations. 1739 
 1740 
3a.4.1 Introduction 1741 
Smoking is a lethal addictive disorder. A lifetime smoker has a 50% probability of dying due 1742 
to smoking, and on average will lose 10 years of life,289 contrasting with under 3 years in 1743 
severe hypertension and < 1 year with mild hypertension.290 Smoking is an established cause 1744 
of a plethora of diseases and is responsible for 50% of all avoidable deaths in smokers, half of 1745 
these due to CVD. Ten-year fatal CVD risk is approximately doubled in smokers. The relative 1746 
risk in smokers < 50 years is even five-fold higher than in non-smokers.291 1747 
Slightly less than half of lifetime smokers will carry on smoking until death. Around 70% of 1748 
UK smokers want to stop smoking at some time in the future,292 with around 43% trying to 1749 
stop in the past year, but only 2–3% of the population succeed in stopping.293 Even modest 1750 
and low levels of smoking confer vascular risk296 1751 
Although the rate of smoking is declining in Europe, it remains very common and is 1752 
increasing in women, adolescents, and the socially disadvantaged.297 Widening education-1753 
related inequalities in smoking-cessation rates have been observed in many European 1754 
countries. In the EUROASPIRE IV survey among CAD patients, 16% smoked after a mean 1755 
follow-up time of 16 months, and nearly half of the participants who smoked at the time of 1756 
their coronary event were persistent smokers. The survey also found that evidence-based 1757 
treatment for smoking cessation was underused.6 1758 
3a.4.2 Dosage and type  1759 
The risks associated with smoking show a dose–response relationship with no lower limit for 1760 
deleterious effects.298 Duration also plays a role, and while cigarette smoking is the most 1761 
common, all types of smoked tobacco, including low-tar (“mild” or “light”) cigarettes, filter 1762 
cigarettes, cigars and pipes, are harmful.294 Smoking is deleterious regardless of how it is 1763 
done, including by waterpipe. Tobacco smoke is more harmful when inhaled but smokers 1764 
who claim not to inhale the smoke (e.g. pipe smokers) are also at increased risk of CVD. 1765 
Smokeless tobacco is also associated with a small but statistically significant increased risk of 1766 
MI and stroke. 1767 
3a.4.3 Passive smoking  1768 
Passive smoking increases the risk of CAD.295, 299 A smoking spouse or workplace exposure 1769 
increases CVD risk by an estimated 30% Major health benefits result from reduced 1770 
environmental tobacco smoke, with public smoking bans in various different geographical 1771 
locations leading to significant decreases in MI rates (see section 3c.4). 1772 
3a.4.4 Mechanisms by which tobacco smoking increases risk 1773 
Smoking enhances the development of both atherosclerosis and superimposed thrombotic 1774 
phenomena. Smoking affects endothelial function, oxidative processes, platelet function, 1775 
fibrinolysis, inflammation, lipid oxidation, and vasomotor function. In experimental studies, 1776 
several of these effects are fully or partly reversible within a very short time. Plaque 1777 
formation is not thought to be fully reversible and thus smokers would never be expected to 1778 
reach the risk level of never-smokers concerning CVD. Nicotine replacement shows no 1779 
adverse effect on outcomes in patients with cardiac disease,300, 301  1780 
3a.4.5 Smoking cessation 1781 
The benefits of smoking cessation have a major evidence base. Some advantages are almost 1782 
immediate; others take more time. CVD risk in former smokers is in between that of current 1783 
and never-smokers.  1784 
Stopping smoking after a MI is potentially the most effective of all preventive measures: a 1785 
systematic review and meta-analysis showed reductions in MIs and in the composite 1786 
endpoints of death/MI (RRs 0.57 and 0.74, respectively) compared with continued 1787 
smoking.302 The benefit is consistent over gender, duration of follow-up, study site, and time 1788 
period. Significant morbidity reductions occur within the first 6 months.303 Randomized trials 1789 
also support smoking cessation, with risk of CVD approaching (but never equalling) the risk 1790 
of never-smokers within 10–15 years. 1791 
Smoking reduction has not been shown to increase probability of future smoking cessation, 1792 
but some advocate nicotine-assisted smoking reduction in smokers unable or unwilling to 1793 
quit. Quitting must be encouraged in all smokers (Table 11). There is no age limit to the 1794 
benefits of smoking cessation. Passive smoking should also be avoided. 1795 
 1796 
Table 11 The “Five As” for a smoking cessation strategy for routine practice 1797 
A-ASK: Systematically inquire about smoking status at every opportunity. 
A-ADVISE: Unequivocally urge all smokers to quit. 
A-ASSESS: Determine the person’s degree of addiction and readiness to quit. 
A-ASSIST: Agree on a smoking-cessation strategy, including setting a quit date, 
behavioural counselling and pharmacological support. 
A-ARRANGE: Arrange a schedule of follow-up. 
 1798 
Professional support can increase the odds of stopping (RR 1.66, 95% CI 1.42–1.94).304 An 1799 
impetus for smoking cessation occurs at the time of diagnosing or (invasive) treatment of 1800 
CVD. Prompting a person to try to quit, brief reiteration of CV and other health hazards, and 1801 
agreeing on a specific plan with a follow-up arrangement are evidence-based interventions 1802 
(see Figure D in web addenda).  1803 
Smoking cessation programmes initiated during hospital admission should continue for a 1804 
prolonged period after discharge. A smoking history including daily tobacco consumption and 1805 
degree of addiction (most commonly assessed by the Fagerström test304) may guide the degree 1806 
of support and pharmacological aid. Smokers should be advised about expected weight gain 1807 
of on average 5 kg and that the health benefits of tobacco cessation far outweigh the risks 1808 
from weight gain. 1809 
3a.4.6 Evidence-based drug interventions 1810 
Following the failure of advice, encouragement and motivational interventions, and in 1811 
addition to them, NRT, varenicline or bupropion should be offered to assist cessation.288 All 1812 
forms of NRT (chewing gum, transdermal nicotine patches, nasal spray, inhaler, sublingual 1813 
tablets) are effective: in a systematic review, the RR for abstinence with NRT versus control 1814 
was 1.60: NRTs increase the rate of quitting by 50 to 70%, regardless of setting.305  1815 
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The antidepressant bupropion aids long-term smoking cessation with a similar efficacy to 1816 
NRT.306 A meta-analysis of 44 trials comparing long-term cessation rates using bupropion 1817 
versus control yielded a relative success rate of 1.62 285 Bupropion carries a known risk of 1818 
seizures (reported as about 1 per 1000 users), 306 without increased risks of neuropsychiatric 1819 
or heart and circulatory problems. Overall, NRT and bupropion help about 80% more people 1820 
to quit than placebo; this means that for every 10 people who quit with placebo about 18 1821 
could be expected to quit with NRT or with bupropion.288  1822 
The partial nicotine receptor agonist varenicline at standard dose increases the chances of 1823 
quitting more than two-fold compared with placebo (14 trials, 6166 people).285 The number of 1824 
people stopping smoking with varenicline is higher than with bupropion (three trials, 1622 1825 
people). Varenicline more than doubles the chances of quitting compared with placebo, so 1826 
that for every 10 who quit with placebo about 28 could be expected to quit with varenicline. 1827 
Varenicline helps about 50% more people to quit than nicotine patch and “other” NRT 1828 
(tablets, sprays, lozenges and inhalers), and about 70% more people than nicotine gum. So for 1829 
every 10 people who quit with NRT patch or with “other” NRT, about 15 could be expected 1830 
to quit with varenicline, and for every 10 who quit with NRT gum about 17 could be expected 1831 
to quit with varenicline.288  1832 
Low-dose varenicline (four trials, 1272 people) roughly doubles the chances of quitting, and 1833 
reduces the number and severity of side effects. The main side effect of varenicline is nausea, 1834 
but this is mostly at mild or moderate levels and usually subsides over time.288 Though 1835 
concerns have been raised, retrospective cohort studies and an RCT,307 indicate no severe 1836 
adverse events with varenicline in the setting of ACS patients, with the large EVITA trial in 1837 
ACS ongoing. 1838 
Clonidine helped people to quit, but causes side effects and is therefore a second line agent. It 1839 
is not clear whether mecamylamine used with NRT helps people to quit. Other treatments did 1840 
not seem to help. So far, nicotine vaccines are not licensed for use anywhere in the world.288 1841 
Combining two types of NRT is as effective as using varenicline, and helps more people to 1842 
quit than single types of NRT.288 1843 
3a.4.7 Electronic cigarettes 1844 
E-cigarettes are battery-operated devices that simulate combustible cigarettes by heating 1845 
nicotine and other chemicals into a vapour that is inhaled. Electronic cigarettes deliver the 1846 
addictive nicotine without the vast majority of tobacco chemicals, and the EMA has 1847 
concluded that electronic cigarettes are less harmful than tobacco. 1848 
Evidence on the effectiveness of electronic cigarettes is limited due to the small number of 1849 
trials, low event rates and wide confidence intervals.308 However data from observational 1850 
studies and randomized trial suggest that efficacy of first generation electronic cigarettes is 1851 
similar to that of transdermal NRT patches309 or the NRT inhalators.310 Benefit may come 1852 
from low nicotine delivery or just the non-nicotine behavioural components of electronic 1853 
cigarette use. About 6% of former smokers who used electronic cigarettes daily relapsed to 1854 
smoking after 1 month, and 6% after one year, and nearly a half of dual users of both tobacco 1855 
and e-cigarettes stopped smoking after one year, indicating that electronic cigarette use might 1856 
be effective in relapse prevention and smoking cessation.311 These studies and “real world” 1857 
data indicate that electronic cigarettes are moderately effective as smoking cessation and harm 1858 
reduction aids, but that a significant component of that effect is due to changes in behaviour 1859 
rather than in nicotine delivery. Although the long-term safety of electronic cigarettes is 1860 
unknown, no safety issues have been observed in the short term (2 years). Thus, there is a 1861 
debate whether e-cigarettes should be formally regulated and subject to licensing restrictions 1862 
since the potential for addiction is high. 1863 
3a.4.8 Other smoking-cessation interventions 1864 
Both individual and group behavioural interventions are effective in helping smokers quit. 1865 
Support from the partner and family is important. There are no reliable data that acupuncture, 1866 
acupressure, laser therapy, hypnotherapy, or electrostimulation are effective for smoking 1867 
cessation. 1868 
 1869 
Gaps in evidence 1870 
• More efficient, safe, and cost-effective smoking cessation aids are required. 1871 
 1872 
3a.5 Nutrition  1873 
Key messages 1874 
• Dietary habits influence the risk of CVD and other chronic diseases such as cancer. 1875 
• Energy intake should be limited to the amount of energy needed to maintain (or obtain) a 1876 
healthy weight; that is, a BMI >20.0 and < 25.0 kg/m². 1877 
• In general, when following the rules for a healthy diet, no dietary supplements are needed. 1878 
 1879 
Recommendation on nutrition 1880 
Recommendation Classa Levelb Refc 
A healthy diet is recommended as a cornerstone of CVD prevention 
in all individuals I B  
312 
aClass of recommendation. 1881 
bLevel of evidence. 1882 
cReference(s) supporting recommendations. 1883 
 1884 
3a.5.1 Introduction 1885 
Dietary habits influence CV risk, either through an effect on risk factors such as cholesterol, 1886 
BP, body weight and DM, or through other effects.312 Table 12 summarises the characteristics 1887 
of a healthy diet. 1888 
 1889 
Table 12 Healthy diet characteristics 1890 
• Saturated fatty acids to account for < 10% of total energy intake, through 
replacement by polyunsaturated fatty acids. 
• Trans unsaturated fatty acids: as little as possible, preferably no intake from 
processed food, and < 1% of total energy intake from natural origin. 
• < 5 g of salt per day. 
• 30–45 g of fibre per day, preferably from wholegrain products. 
• ≥200 g of fruit per day (2–3 servings). 
• ≥200 g of vegetables per day (2–3 servings). 
• Fish 1-2 times per week, one of which to be oily fish. 
• 30 grams unsalted nuts per day 
• Consumption of alcoholic beverages should be limited to 2 glasses per day (20 g/d of 
alcohol) for men and 1 glass per day (10 g/d of alcohol) for women. 
• Sugar-sweetened soft drinks and alcoholic beverages consumption must be 
discouraged 
 1891 
Most evidence on the relation between nutrition and CVD is based on observational studies; 1892 
randomized clinical trials estimating the impact of diet on endpoints are scarce. The impact of 1893 
diet is studied on three levels: specific nutrients, specific foods/food groups, or specific 1894 
dietary patterns, of which the Mediterranean diet is the most studied.  1895 
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The nutrients of interest with respect to CVD are fatty acids (which mainly affect lipoprotein 1896 
levels), minerals (which mainly affect BP), vitamins, and fibre. 1897 
 1898 
3a.5.2 Fatty acids 1899 
For prevention of CVD, the types of fatty acids consumed are more important than the total 1900 
fat content.  1901 
The risk of CAD is reduced by 2–3% when 1% of energy intake from saturated fatty acids is 1902 
replaced by polyunsaturated fatty acids. The same has not been clearly shown for the 1903 
replacement with carbohydrates and monounsaturated fatty acids (MUFAs). Saturated fatty 1904 
acid intake should be reduced to a maximum of 10% of energy intake by replacing it with 1905 
polyunsaturated fatty acids.313  1906 
MUFAs have a favourable effect on HDL-C levels when they replace saturated fatty acids or 1907 
carbohydrates,314 but there is little evidence that MUFAs lower CAD risk. 1908 
Polyunsaturated fatty acids lower LDL-C levels, and to a lesser extent HDL-C levels, when 1909 
they replace saturated fatty acids. The polyunsaturated fatty acids can be divided into two 1910 
subgroups: n-6 fatty acids, mainly from plant foods; and n-3 fatty acids, mainly from fish oils 1911 
and fats. Within the subclass of n-3 fatty acids, eicosapentaenoic acid and docosahexaenoic 1912 
acid (EPA/DHA) are especially important. They do not change serum cholesterol levels, and, 1913 
with currently available cardio-protective therapies, it is debateable whether they exert a 1914 
favourable effect on all cause, CAD mortality, and stroke mortality.315, 316 1915 
The trans fatty acids, a subclass of unsaturated fatty acids, have been shown to be especially 1916 
harmful, due to their unfavourable impact on both total cholesterol (increase) and HDL-C 1917 
(decrease). These fatty acids are formed during industrial processing (hardening) of fats, and 1918 
are present in margarine and bakery products, for example. A meta-analysis of prospective 1919 
cohort studies has shown that, on average, a 2% increase in energy intake from trans fatty acid 1920 
increases CAD risk by 23%.317 It is recommended to derive < 1% of total energy intake from 1921 
trans fatty acids – the less the better. 1922 
The impact of dietary cholesterol on serum cholesterol levels is weak compared with that of 1923 
the fatty acid composition of the diet. When guidelines are followed to lower saturated fat 1924 
intake, this usually also leads to a reduction in dietary cholesterol intake. Some guidelines 1925 
(including this one) on healthy diet do not therefore give specific guidelines on intake of 1926 
dietary cholesterol; others recommend a limited intake of < 300 mg/day. 1927 
3a.5.3 Minerals 1928 
A meta-analysis estimated that even a modest reduction in sodium intake of 1 g/day reduces 1929 
SBP by 3.1 mmHg in hypertensive patients and 1.6 mmHg in normotensive patients.318 The 1930 
Dietary Approaches to Stop Hypertension (DASH) trial showed a dose–response relation 1931 
between sodium reduction and BP reduction.319 In most western countries salt intake is high 1932 
(around 9–10 g/day), whereas the recommended maximum intake is 5 g/day. Optimal intake 1933 
levels might be as low as around 3 g/day. Although the relation between salt intake and BP 1934 
remains controversial, the totality of evidence warrants salt reduction as an important way to 1935 
prevent CAD and stroke. On average 80% of salt intake comes from processed foods, while 1936 
only 20% is added later on. Salt reduction can be achieved by making different dietary 1937 
choices (fewer processed foods, more basic foods) as well as reformulation of foods (lowering 1938 
salt content) (see chapter 3c.2) 1939 
Potassium has favourable effects on BP. Main sources of potassium are fruits and vegetables. 1940 
An inverse statistically significant association exists between potassium intake and risk of 1941 
incident stroke (risk ratio 0.76, 95% CI 0.66 to 0.89).320 Apart from reducing sodium intake, 1942 
increasing potassium intake contributes to BP lowering.  1943 
3a.5.4 Vitamins 1944 
Many case–control and prospective observational studies have observed inverse associations 1945 
between levels of vitamin A and E and risk of CVD. However, intervention trials have failed 1946 
to confirm these observational studies. Also for the B-vitamins (B6, folic acid and B12) and 1947 
vitamin C, trials have shown no beneficial effects. 1948 
In the bottom tertile of serum levels of vitamin D, CV and total mortality is 35% higher (RR 1949 
1.35, 95% CI 1.13–1.61) than in the highest tertile.321 A 41% higher risk of CV mortality (RR 1950 
1.41, 95% CI 1.18–1.68) and 57% higher risk of all-cause mortality (RR 1.57, 95% CI 1.36–1951 
1.81) has been reported in the lowest versus highest quintile.322 A much smaller effect was 1952 
observed in RCTs: an 11% risk reduction in all-cause mortality was observed for vitamin D3 1953 
supplementation (RR 0.89, 95% CI 0.80–0.99), but not for vitamin D2 supplementation.321 1954 
Due to lack of power it was not possible to look at CV mortality specifically. Therefore, 1955 
conclusions about vitamin D supplementation (type of supplement (D2 or D3), dosage and 1956 
duration) for CV prevention cannot yet be drawn.  1957 
3a.5.5. Fibre 1958 
Recent meta-analyses of prospective cohort studies show that a 7 g/day higher intake of total 1959 
fibre is associated with a 9% lower risk of CAD (RR 0.91, 95% CI 0.87–0.94),323 and a 10 1960 
g/day higher fibre intake is associated with a 16% lower risk of stroke (RR 0.84, 95% CI 1961 
0.75–0.94)324 and a 6% lower risk of type 2 DM (RR 0.94, 95% CI 0.91–0.97).325 There is no 1962 
evidence yet for a similar association with fibre from fruits and vegetables. Although the 1963 
mechanism has not been elucidated completely, it is known that a high fibre intake reduces 1964 
postprandial glucose responses after carbohydrate-rich meals, and lowers total cholesterol and 1965 
LDL-C levels.  1966 
3a.5.6 Foods and food groups 1967 
3a.5.6.1 Fruits and vegetables 1968 
Prospective cohort studies have shown a protective effect of consumption of fruits and 1969 
vegetables on CVD, but RCTs are scarce. A meta-analysis reported a decrease of 4% (RR 1970 
0.96, 95% CI 0.92–0.99) in CV mortality for each additional serving of fruits (equivalent to 1971 
77 g) and vegetables (equivalent to 80 g) per day, while all-cause mortality did not reduce 1972 
further with intakes above 5 servings.326 A meta-analysis reported a risk reduction for stroke 1973 
of 11% (RR 0.89, 95% CI 0.83–0.97) for 3–5 daily fruit and vegetables servings and of 26% 1974 
(RR 0.74, 95% CI 0.69–0.79) for > 5 servings, compared with < 3 servings.327 A meta-1975 
analysis on CAD reported a 4% decrease in CAD risk (RR 0.96, 95% CI 0.93–0.99) for each 1976 
additional serving of fruits and vegetables per day.328 1977 
3a.5.6.2 Nuts 1978 
A meta-analysis of prospective cohort studies has shown that daily consumption of 30 grams 1979 
of nuts reduces the risk of CVD by about 30% (RR 0.71, 95% CI 0.59-0.85).329 It must be 1980 
noted that the energy density of nuts is high.  1981 
3a.5.6.3 Fish 1982 
The protective effect of fish on CVD is attributed to the n-3 fatty acid content. Pooled risk 1983 
estimates from prospective cohort studies show that eating fish at least once a week results in 1984 
a 16% reduction in risk of CAD (RR 0.85, 95% CI 0.75–0.95) compared to eating less fish.330 1985 
A recent meta-analysis showed that eating fish 2–4 times a week reduces the risk of stroke by 1986 
6% (RR 0.94, 95% CI 0.90–0.98) compared with eating fish less than once a week.331 The 1987 
relation between fish intake and CV risk is not linear. Especially in the range of no or very 1988 
low intake, risk is increased. The public health impact of a small increase in fish consumption 1989 
in the general population is therefore potentially large.  1990 
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For fish oil, three randomized controlled prevention trials have been published. All three 1991 
trials, in post-AMI or CAD patients who received an extra amount of 400–1000 g EPA/DHA 1992 
daily, did not observe a reduction in CV events in the intervention group. A recent meta-1993 
analysis of 20 trials, mostly prevention of recurrent CV events and mostly using fish oil 1994 
supplements, showed no benefit of fish oil supplementation on CV outcomes.316  1995 
3a.5.6.4 Alcoholic beverages 1996 
Drinking ≥ 3 alcoholic beverages per day is associated with elevated CVD risk. Results from 1997 
epidemiological studies suggest a lower risk of CVD occurring with moderate (1–2 units per 1998 
day) alcohol consumption compared to non-drinkers. This association appears not to be 1999 
explained by special characteristics of abstainers,332 though the potential for residual 2000 
confounding and reverse causality cannot be fully excluded. Moreover, a recent Mendelian 2001 
randomization study including analyses from 59 epidemiological studies has shed doubt on 2002 
any beneficial effect of moderate alcohol consumption,333 suggesting that lowest risks for CV 2003 
outcomes were in abstainers, and that any amount of alcohol was associated with elevated BP 2004 
and BMI.  2005 
3a.5.6.5 Soft drinks and sugar 2006 
Sugar-sweetened soft drinks are the largest single food source of calories in the US diet and 2007 
are important in Europe. In children and adolescents beverages may now even account for 10–2008 
15% of the calories consumed. Regular consumption of soft drinks has been associated with 2009 
overweight, metabolic syndrome, and type 2 DM. Substitution of sugar-sweetened soft drinks 2010 
with artificially sweetened drinks resulted in less weight gain in children over an 18 month 2011 
period.334 Sugar-sweetened beverages also cause weight gain in adults. Regular consumption 2012 
of sugar-sweetened beverages (i.e. 2 servings per day compared with 1 serving per month) 2013 
was associated with a 35% higher risk of CAD in women, even after other unhealthy lifestyle 2014 
and dietary factors were accounted for, whereas artificially sweetened beverages were not 2015 
associated with CAD. The WHO guideline recommends a maximum intake of 10% of energy 2016 
from sugar (mono- and disaccharides); that includes added sugars as well as sugars present in 2017 
fruits and fruit juices.335  2018 
3a.5.7 Functional foods 2019 
Functional foods containing phytosterols (plant sterols and stanols) are effective in lowering 2020 
LDL-C levels by on average 10%, when consumed in amounts of 2 g/day. The cholesterol-2021 
lowering effect is additional to that obtained with a low-fat diet or use of statins. Further 2022 
cholesterol reduction can be obtained with higher doses of phytosterols336. No studies with 2023 
clinical endpoints have been performed yet. 2024 
3a.5.8 Dietary patterns 2025 
Studying the impact of a total dietary pattern theoretically shows the full preventive potential 2026 
of diet, because it yields a combined estimate of the impact of several favourable dietary 2027 
habits. The Mediterranean diet comprises many of the nutrients and foods that have been 2028 
discussed previously: high intake of fruits, vegetables, legumes, wholegrain products, fish and 2029 
unsaturated fatty acids (especially olive oil), moderate consumption of alcohol (mostly wine, 2030 
preferably consumed with meals), and a low consumption of (red) meat, dairy products and 2031 
saturated fatty acids. A meta-analysis of prospective cohort studies has demonstrated that 2032 
greater adherence to the Mediterranean diet is associated with a 10% reduction in CV 2033 
incidence or mortality (pooled RR 0.90, 95% CI 0.87–0.93) and an 8% reduction in all-cause 2034 
mortality (pooled RR 0.92, 95% CI 0.90–0.94).337 An RCT in high risk individuals suggested 2035 
that following a Mediterranean diet over a 5-year period, compared to a control diet, is related 2036 
to a 29% lower risk of CVD (RR 0.71, 95% CI 0.56–0.90).338  2037 
 2038 
Gaps in evidence 2039 
• The biggest challenge in dietary prevention of CVDs is to develop more effective 2040 
strategies to make people change their diet (both quantitatively and qualitatively) and to 2041 
maintain that healthy diet and a normal weight.  2042 
• Research into the substances in foods that underlie the protective effects is ongoing.  2043 
 2044 
3a.6 Body weight 2045 
Key messages 2046 
• Both overweight and obesity are associated with an increased risk of CVD death and all-2047 
cause mortality. All-cause mortality is lowest with a BMI of 20–25 kg/m2 (in those <60 2048 
years); further weight reduction cannot be considered protective against CVD.  2049 
• Healthy weight in the elderly is higher than in the young and middle-aged  2050 
• Achieving and maintaining a healthy weight have a favourable effect on metabolic risk 2051 
factors (BP, blood lipids, glucose tolerance) and lower CV risk. 2052 
 2053 
Recommendation for body weight 2054 
Recommendation Classa Levelb  Refc 
It is recommended that subjects with healthy weight*  
maintain their weight. It is recommended that overweight 
and obese people achieve a healthy weight (or aim for a 
reduction in weight) in order to reduce BP, dyslipidaemia 
and risk of developing type 2 DM, and thus improve the CV 
risk profile. 
I A 339, 340 
* BMI 20-25 kg/m2. There is evidence that optimal weight in elderly is higher than in the young and middle-2055 
aged340  2056 
BP = blood pressure; CVD = cardiovascular disease; DM = diabetes mellitus. 2057 
aClass of recommendation. 2058 
bLevel of evidence. 2059 
cReference(s) supporting recommendations. 2060 
 2061 
3a.6.1 Introduction  2062 
In many countries favourable trends in major risk factors such as blood cholesterol, BP and 2063 
smoking prevalence have been observed, translating into reduced CV mortality. However, 2064 
BMI has strongly increased in all countries over the past decades resulting in a concomitant 2065 
increase in prevalence of type 2 DM. In the USA it has been projected that if obesity trends 2066 
from 2005 to 2020 continue, obesity will increasingly offset the positive effects of declining 2067 
smoking rates.341 The main clinical complications of increasing body weight are: (1) increases 2068 
in BP, dyslipidaemia, insulin resistance, systemic inflammation and prothrombotic state, and 2069 
albuminuria; and (2) development of DM, CV events (HF, CAD, AF, stroke). 2070 
3a.6.2 Which index of obesity is the best predictor of cardiovascular risk? 2071 
BMI (weight (kg)/height(m2)) can be measured easily and is used extensively to define 2072 
categories of body weight (see Table C in the web addenda).342 In addition to the amount of 2073 
body fat, its distribution is important. Body fat stored in the abdomen (intra-abdominal fat) 2074 
carries a higher risk than subcutaneous fat.  2075 
Several measures of body fatness are available (see Table D in the web addenda). Most data 2076 
are available for BMI, waist:hip circumference ratio, and simple waist circumference. The 2077 
optimal level for measurement of waist circumference is midway from the lower rib margin to 2078 
the anterior superior iliac crest, in the standing position. The WHO thresholds for waist 2079 
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circumference are the most widely accepted in Europe. Based on these thresholds, two action 2080 
levels are recommended:  2081 
(1) Waist circumference ≥ 94 cm in men and ≥ 80 cm in women represents the threshold at 2082 
which no further weight should be gained.  2083 
(2) Waist circumference ≥ 102 cm in men and ≥ 88 cm in women represents the threshold at 2084 
which weight reduction should be advised.  2085 
These thresholds have been calculated based on Caucasians and it is apparent that different 2086 
cut-points for anthropometric measurements are required in different races and ethnicities. A 2087 
meta-analysis concluded that both BMI and waist circumference are similarly strong and 2088 
continuously associated with CVD and type 2 DM.343 Therefore, BMI generally suffices in 2089 
routine practice. 2090 
3a.6.3 Does “metabolically healthy obesity” exist? 2091 
The phenotype of “metabolically healthy obesity” (MHO), defined by the presence of obesity 2092 
in the absence of metabolic risk factors, has gained a lot of interest. Some studies argue that a 2093 
specific subgroup of obese individuals is resistant to metabolic complications such as 2094 
hypertension and insulin resistance and at increased risk. However, MHO individuals present 2095 
a higher all-cause mortality compared to normal weight metabolically healthy individuals.344, 2096 
345 Long-term results from the Whitehall study support the notion that MHO is a transient 2097 
phase346 moving towards gluco-metabolic abnormalities, rather than a specific “state”. 2098 
3a.6.4 The obesity paradox in established heart disease 2099 
At the population level, obesity is associated with CVD risk. However, among those with 2100 
established CAD, the evidence is contradictory. Systematic reviews of patients with CAD or 2101 
undergoing percutaneous coronary intervention have suggested an “obesity paradox” whereby 2102 
obesity appears protective.339, 347 This is also the case for HF patients. However, this evidence 2103 
should not be misinterpreted to recommend higher target BMIs for those with established 2104 
CVD since reverse causality may be operating. Cardiorespiratory fitness might influence 2105 
relationships between adiposity and clinical prognosis in the obesity paradox. Normal weight 2106 
unfit individuals have a higher risk of mortality than fit individuals regardless of their BMI. 2107 
Overweight and obese fit individuals have mortality risks similar to normal weight fit 2108 
individuals.348 Furthermore, the results of the EPIC study suggest that the influence of 2109 
physical inactivity on mortality appears to be greater than that of high BMI.349 2110 
3a.6.5 Treatment goals and modalities 2111 
CVD risk has a continuous positive relationship with BMI and other measures of body fat. 2112 
Because all-cause mortality appears to increase at BMI levels below 20,340 we do not 2113 
recommend such low BMI levels as treatment goals. 2114 
Although diet, exercise and behaviour modifications are the mainstay therapies for 2115 
overweight and obesity, they are often unsuccessful for long-term treatment. Medical therapy 2116 
with orlistat and/or bariatric surgery are additional options. A recent meta-analysis indicates 2117 
that patients undergoing bariatric surgery have a reduced risk of MI, stroke, CV events and 2118 
mortality compared to non-surgical controls.350  2119 
 2120 
Gaps in evidence 2121 
• Knowledge and implementation of effective strategies to achieve weight loss and maintain 2122 
a long-term healthy weight. 2123 
• Identification of the relative roles of diet, exercise, and behaviour modification in the 2124 
management of overweight and obese people. 2125 
• Optimal level of BMI over the lifecourse (at higher ages and after a CV event) 2126 
 2127 
3a.7 Lipid control 2128 
 2129 
Key messages: 2130 
• Elevated levels of plasma LDL-C are causal to atherosclerosis. 2131 
• Reduction of LDL-C decreases CV events. 2132 
• Low HDL-C is associated with increased CV risk, but manoeuvres to increase HDL-C 2133 
have not been associated with a decreased CV risk. 2134 
• Lifestyle and dietary changes are recommended for all. 2135 
• Total CV risk should guide the intensity of the intervention. 2136 
• Total cholesterol and HDL-C are adequately measured on non-fasting samples so allowing 2137 
non-HDL-C to be derived 2138 
 2139 
Recommendations for lipid control 2140 
Recommendationsd e  Classa Levelb Refc 
In patients at VERY HIGH CV risk, an LDL-C goal <1.8 mmol/L 
(<70 mg/dL), or a reduction of at least 50% if the baseline is 
between 1.8 and 3.5 mmol/L (70 and 135 mg/dL) is recommended.f 
I 
 
B 351-354 
In patients at HIGH CV risk, an LDL-C goal <2.6 mmol/L (<100 
mg/dL), or a reduction of at least 50% if the baseline is between 2.6 
and 5.1 mmol/L (100 and 200 mg/dL) is recommended. 
I B 351-354 
In the remaining patients on LDL-C lowering treatment, an LDL-C 
goal <3.0 mmol/L (<115 mg/dL) should be considered. 
IIa C 351-354 
CV = cardiovascular; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein 2141 
cholesterol. 2142 
aClass of recommendation. 2143 
bLevel of evidence. 2144 
cReference(s) supporting recommendations. 2145 
d Non-HDL-C is a reasonable and practical alternative target because it does not require fasting. Non HDL-C 2146 
secondary targets of <2.6, <3.3 and <3.8 mmol/L (<100, <130 and <145 mg/dL) are recommended for very high, 2147 
high and low to moderate risk subjects, respectively See section 3a.7.10 for more details  2148 
e A view was expressed that primary care physicians might prefer a single LDL-C goal of 2.6 mmol/L (100 2149 
mg/dL). While accepting the simplicity of this approach and that it could be useful in some settings, there is 2150 
better scientific support for the three targets matched to level of risk 2151 
f This is the general recommendation for those at very high risk. It should be noted that the evidence for patients 2152 
with CKD is less strong. 2153 
 2154 
3a.7.1 Introduction  2155 
The crucial role of dyslipidaemia, especially hypercholesterolaemia, in the development of 2156 
CVD is documented beyond any doubt by genetic, pathology, observational, and intervention 2157 
studies.  2158 
In blood plasma, lipids such as cholesterol and triglycerides circulate as lipoproteins in 2159 
association with various proteins (apolipoproteins). The main carrier of cholesterol in plasma 2160 
(LDL-C) is atherogenic. The role of triglyceride-rich lipoproteins is currently under active 2161 
investigation: chylomicrons and large very low-density lipoproteins (VLDLs) appear not to be 2162 
atherogenic, but very high concentrations of these triglyceride-rich lipoproteins can cause 2163 
pancreatitis. Remnant lipoproteins (total cholesterol - (LDL+HDL Cholesterol)) have recently 2164 
been identified in Mendelian randomization studies as pro-atherogenic lipoproteins. 2165 
3a.7.2 Total and low-density lipoprotein cholesterol 2166 
Most cholesterol is normally carried in LDL-C. Over a wide range of plasma cholesterol 2167 
concentrations, there is a strong and graded positive association between total as well as LDL-2168 
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C and risk of CVD.355 This association applies to men and women, and to those without CVD 2169 
as well as with established CVD. 2170 
The evidence that reducing plasma LDL-C reduces CVD risk is unequivocal; the results of 2171 
epidemiological studies and trials with and without statins using angiographic or clinical 2172 
endpoints confirm that the reduction of LDL-C is of prime concern in the prevention of 2173 
CVD.38  2174 
Meta-analyses of many statin trials show a dose-dependent relative reduction in CVD with 2175 
LDL-C lowering. Every 1.0 mmol/L reduction in LDL-C is associated with a corresponding 2176 
20–25% reduction in CVD mortality and non-fatal MI.351  2177 
3a.7.3 Apolipoprotein B 2178 
Apolipoprotein B (apoB, the main apoprotein of atherogenic lipoproteins) levels have also 2179 
been measured in outcome studies in parallel with LDL-C.356 Based on the available evidence, 2180 
it appears that apoB is a similar risk marker to LDL-C.357 Also, there appears to be less 2181 
laboratory error in the determination of apoB than LDL-C, particularly in patients with 2182 
marked hypertriglyceridaemia (>3.4 mmol/L or >300 mg/dL), but there is no evidence that 2183 
apoB is a better predictor of CVD than LDL-C.358 2184 
3a.7.4 Triglycerides 2185 
Hypertriglyceridaemia is a significant independent CVD risk factor, but the association is far 2186 
weaker than for hypercholesterolaemia.359 The risk is associated more strongly with moderate 2187 
than with very severe hypertriglyceridaemia (>10 mmol/L or >~900 mg/dL), which is, on the 2188 
other hand, a risk factor for pancreatitis. There are, however, no randomized trials to provide 2189 
sufficient evidence to derive target levels for triglycerides. Meta-analyses suggest that 2190 
targeting triglycerides may reduce CVD in specific subgroups with high triglycerides and low 2191 
HDL-C. At present, fasting triglycerides >1.7 mmol/L (>~150 mg/dL) continue to be 2192 
considered as a marker of increased risk, but concentrations ≤1.7 mmol/L are not evidence-2193 
based target levels for therapy.  2194 
3a.7.5 High-density lipoprotein cholesterol 2195 
Low HDL-C is independently associated with higher CVD risk.360 Low HDL-C may even 2196 
rival hypercholesterolaemia (due to high concentrations of LDL-C) as a risk factor for 2197 
CAD.361 The combination of moderately elevated triglycerides and low concentrations of 2198 
HDL-C is very common in patients with type 2 DM, abdominal obesity, insulin resistance, 2199 
and those who are physically inactive. This lipid pattern is also characterized by the presence 2200 
of small, dense, atherogenic LDL particles. An HDL-C level <1.0 mmol/L (<40 mg/dL) in 2201 
men and <1.2 mmol/L (<45 mg/dL) in women may be regarded as a marker of increased risk. 2202 
Recent Mendelian randomization studies, however, cast doubt on the causal role of HDL-C in 2203 
CVD.362 Physical activity and other lifestyle factors, rather than drug treatment, remain 2204 
important means of increasing HDL-C levels. 2205 
3a.7.6 Lipoprotein(a) 2206 
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein to which an additional protein called 2207 
apolipoprotein(a) is attached. High concentrations of Lp(a) are associated with increased risk 2208 
of CAD and ischaemic stroke, and Mendelian randomization studies support a causal role in 2209 
CVD for Lp(a). There is no randomized intervention study showing that reducing Lp(a) 2210 
decreases CVD risk.363 At present there is no justification for screening the general population 2211 
for Lp(a), but it may be considered in patients at moderate risk to refine risk evaluation or in 2212 
subjects with a family history of early CVD. 2213 
3a.7.7 Apolipoprotein B/apolipoprotein A1 ratio 2214 
Apolipoprotein A1 (apoA1) is the major apoprotein of high-density lipoprotein. It is beyond 2215 
doubt that the apoB:apoA1 ratio is one of the strongest risk markers.114, 356 However, there is 2216 
insufficient evidence to support this variable as a treatment goal. As the measurement of 2217 
apolipoproteins is not available to all physicians in Europe, is more costly than currently used 2218 
lipid variables, and only adds moderately to the information derived from currently applied 2219 
lipid parameters, its use is not recommended. 2220 
3a.7.8 Calculated lipoprotein variables 2221 
3a.7.8.1 Low-density lipoprotein cholesterol 2222 
LDL-C can be measured directly, but in most studies and in many laboratories LDL-C is 2223 
calculated using the Friedewald formula 364:  2224 
• In mmol/L: LDL-C = total cholesterol – HDL-C – (0.45 × triglycerides) 2225 
• In mg/dL: LDL-C = total cholesterol – HDL-C – (0.2 × triglycerides) 2226 
The calculation is valid only when the concentration of triglycerides is < 4.5 mmol/L (<~400 2227 
mg/dL). Similar problems may be faced when LDL-C is low (<~1.3 mmol/L or <50 mg/dL). 2228 
Direct methods may be less sensitive to plasma triglyceride levels. However, recent data show 2229 
that the direct methods may also be biased when triglyceride levels are high. Also, the values 2230 
obtained with the different direct methods are not necessarily identical, especially for low and 2231 
high LDL-C values. 2232 
3a.7.8.2 Non-high-density lipoprotein cholesterol (accurate in non-fasting samples) 2233 
Non-HDL-C comprises the cholesterol in low-density lipoprotein, intermediate-density 2234 
lipoprotein, remnant and VLDL, capturing therefore all the information regarding pro-2235 
atherogenic lipoproteins. Non-HDL-C predicts CVD risk even better than LDL-C.352 LDL-C 2236 
limits may be transferred to non-HDL-C limits by adding 0.8 mmol/L (30 mg/dL). Calculated 2237 
by simply subtracting HDL-C from total cholesterol, non-HDL-C, unlike LDL-C, does not 2238 
require the triglyceride concentration to be < 4.5 mmol/L (< 400 mg/dL). Therefore, it is 2239 
certainly a better measure than calculated LDL-C for patients with increased plasma 2240 
triglyceride concentrations, but also has an additional advantage of not requiring patients to 2241 
fast before blood sampling. There is evidence for a role of non-HDL-C as a treatment 2242 
target.365 As non-HDL-C is capturing the information regarding all the atherogenic apoB 2243 
containing lipoproteins, we suggest that it is a reasonable alternative treatment goal while 2244 
acknowledging that is has not been an endpoint in therapeutic trials. 2245 
3a.7.8.3 Remnant cholesterol 2246 
Recently the remnant cholesterol (total cholesterol minus HDL-C + LDL-C) has been shown 2247 
to be causally related to atherosclerosis in Mendelian randomization studies. This parameter, 2248 
however, is not suggested as a predictor or main target for therapy as further population data 2249 
and clinical studies are awaited.  2250 
3a.7.9 Exclusion of secondary and familial dyslipidaemia 2251 
The presence of dyslipidaemias secondary to other conditions must be excluded before 2252 
beginning treatment, as treatment of underlying disease improves hyperlipidaemia without 2253 
requiring antilipidaemic therapy. This is particularly true for hypothyroidism. Secondary 2254 
dyslipidaemias can also be caused by alcohol abuse, DM, Cushing's syndrome, diseases of the 2255 
liver and kidneys, and several drugs (e.g. corticosteroids). Patients who could have genetic 2256 
dyslipidaemias, such as FH, can be identified by extreme lipid abnormalities and/or family 2257 
history. These patients should, if possible, be referred for specialist evaluation. The treatment 2258 
recommendations in this guideline may not apply to these specific patients, who are dealt with 2259 
in detail in the ESC/European Atherosclerosis Society guidelines on dyslipidaemias.38, 353 An 2260 
LDL-C >5.1 mmol/L (>200 mg/dL) in therapy naïve patients requires careful evaluation for 2261 
possible FH. However in the presence of premature CVD or family history, possible FH 2262 
should be considered also at lower LDL-C levels. 2263 
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3a.7.10 Who should be treated and what are the goals? 2264 
In general, RCTs are the ideal evidence base for decisional thresholds and treatment goals. 2265 
For treatment goals, this requires RCTs randomly allocating subjects to different lipid goals 2266 
levels. However, most evidence in terms of treatment goals is derived from observational 2267 
studies and from post-hoc analyses of RCTs (and meta-regression analyses thereof) randomly 2268 
allocating different treatment strategies (and not treatment goals). Hence, recommendations 2269 
reflect consensus based on large-scale epidemiological data and RCTs comparing treatment 2270 
regimens, not on RCTs comparing different lipid goal levels. 2271 
In the past an LDL-C of 2.6 mmol/L (100 mg/dL) has been considered a treatment threshold 2272 
and goal. This goal remains reasonable for most patients who have an indication for LDL-C-2273 
lowering therapy based on calculation of the CV risk (see section 2). 2274 
Evidence from trials has suggested that lowering LDL-C to ≤1.8 mmol/L (<70 mg/dL) is 2275 
associated with lower risk of recurrent CVD events.366 Therefore, an LDL-C level of 1.8 2276 
mmol/L (70 mg/dL) appears to be a reasonable goal for prevention of recurrent CV events, 2277 
and in other very-high-risk subjects. A treatment goal of a LDL-C reduction of at least 50% is 2278 
also recommended if the baseline LDL-C level is between 1.8 and 3.5 mmol/L (70 and 135 2279 
mg/dL). 2280 
Non-HDL-C target values may be an alternate target if non-fasting samples are obtained and 2281 
goals should be <2.6, <3.3 and <3.8 mmol/L, (<100, <130 and <145 mg/dL) in very high, 2282 
high and low CV risk, respectively. In addition this is a secondary goal in people with 2283 
elevated triglycerides. In the same subjects, although not generally recommended, apoB levels 2284 
at <80 and <100 mg/dL can be reasonable goals for subjects with very high or high CV risk, 2285 
respectively. 2286 
 2287 
The benefit of cholesterol-lowering therapy depends on initial levels of risk: the higher the 2288 
risk, the greater the benefit in absolute risk reduction (Table 13). There are no differences in 2289 
relative reduction between men and women and between younger and older age or between 2290 
those with and without DM.367 2291 
 2292 
Table 13 Possible intervention strategies as a function of total cardiovascular risk and low-2293 
density lipoprotein cholesterol level  2294 
 2295 
 2296 
 2297 
CV = cardiovascular;; LDL-C = low-density lipoprotein cholesterol; SCORE = Systematic Coronary Risk 2298 
Estimation.  2299 
Guidance on the use of drug treatment must be interpreted in the light of the physician’s judgement and 2300 
knowledge with regards to his or her individual patient. Note that risk stratification is not applicable in FH, 2301 
where drug treatment is recommended, and that, in this table, drug treatment may be considered at risks lower 2302 
than the generic treatment thresholds indicated in section 2. Thus treatment may occasionally be considered in 2303 
moderate risk (1–5%) individuals, provided that patients are well-informed of the limited absolute risk reduction, 2304 
and high numbers needed to treat. In higher risk (5–10%), drug therapy is associated with somewhat larger 2305 
absolute benefits, and should at least be considered. Drug therapy is strongly advised in those at very high risk (≥ 2306 
10%). If baseline LDL-C in this category is already below the target level of 1.8 mmol/L, benefit of statin 2307 
therapy initiation is less certain, but may still be present.  2308 
3a.7.11 Patients with kidney disease 2309 
CKD can be characterized by mixed dyslipidaemia (high triglycerides, high LDL-C, and low 2310 
HDL-C).368 Statin therapy has a beneficial effect on CVD outcomes in CKD369 and in some 2311 
studies slows the rate of kidney function loss.370, 371 Similar data have been observed for 2312 
combination therapy of a statin with ezetimibe, but not for ezetimibe alone.369. For patients 2313 
with end stage renal disease we recommend hypolipidaemic therapy should not be initiated. If 2314 
patients with CKD already on a hypolipidaemic therapy enter end stage renal disease, the 2315 
therapy may be maintained.369 2316 
3a.7.12 Drugs 2317 
The currently available lipid-lowering drugs include inhibitors of 3-hydroxy-3-2318 
methylglutaryl-coenzyme A reductase (statins), fibrates, bile acid sequestrants (anion 2319 
exchange resins), niacin (nicotinic acid), selective cholesterol absorption inhibitors (e.g. 2320 
ezetimibe), and, more recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) 2321 
inhibitors. Response to all therapy varies quite largely among individuals and therefore 2322 
monitoring the effect on LDL-C levels is recommended. 2323 
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Statins, by decreasing LDL-C, reduce CV morbidity and mortality as well as the need for 2324 
coronary artery interventions.372, 373 Statins at doses that effectively reduce LDL-C by at least 2325 
50% also seem to halt progression or even contribute to regression of coronary 2326 
atherosclerosis.374 Statins also lower triglycerides and meta-analysis evidence shows statins 2327 
may also lower pancreatitis risk.375 Therefore, they should be used as the drugs of first choice 2328 
in patients with hypercholesterolaemia or combined hyperlipidaemia.  2329 
Data indicate that combination therapy with ezetimibe also brings a benefit that is in line with 2330 
the Cholesterol Treatment Trialists’ Collaboration (CTT) meta-analysis supporting the notion 2331 
that LDL-C reduction is key to the achieved benefit independent of the approach used.354, 376  2332 
Increased levels of liver enzymes in plasma occur occasionally during statin therapy, and in 2333 
most cases are reversible. Routine monitoring of liver enzyme values is not indicated. In 2334 
addition, 5–10% of patients receiving statins complain of myalgia, but rhabdomyolysis is 2335 
extremely rare. The risk of myopathy (severe muscular symptoms) can be minimized by 2336 
identifying vulnerable patients and/or by avoiding statin interactions with specific drugs377 2337 
(see Table E in web addenda). Because statins are prescribed on a long-term basis, possible 2338 
interactions with other drugs deserve particular and continuous attention, as many patients 2339 
will receive pharmacological therapy for concomitant conditions.378 In practice, the 2340 
management of a patient with myalgia but without a major creatinine kinase rise is based on 2341 
trial and error and usually involves trial of a different statin, or the use of a very low dosage 2342 
several days a week with a gradual increase.377  2343 
In general, the safety profile of statins is acceptable, and earlier observations that lipid-2344 
lowering treatment may contribute to an increase in non-CV mortality (e.g. cancers, suicides, 2345 
depression) or mental disorders are not confirmed in a large meta-analysis.379 Increased blood 2346 
sugar and glycated haemoglobin (HbA1c) levels, i.e. increased risk of type 2 DM, occur after 2347 
statin treatment and are dose dependent, in part linked to very slight weight gain, but the 2348 
benefits of statins outweigh the risks for the vast majority of patients.378-380 Patients should be 2349 
reminded that adhering to lifestyle changes when prescribed a statin should lessen any modest 2350 
DM risk.380-383 2351 
Non-statin treatment  2352 
Selective cholesterol absorption inhibitors (e.g. ezetimibe) are not usually used as 2353 
monotherapy to decrease LDL-C concentrations, unless patients are intolerant to statins. They 2354 
are recommended as combination therapy with statins in selected patients when a specific 2355 
goal is not reached with the maximal tolerated dose of a statin. 2356 
Bile acid sequestrants also decrease total cholesterol and LDL-C but are poorly tolerated and 2357 
tend to increase plasma triglyceride concentrations. They are therefore not recommended for 2358 
routine use in CVD prevention. 2359 
Fibrates and niacin are used primarily for triglyceride lowering and increasing HDL-C, while 2360 
fish oils (omega-3 fatty acids) in doses of 2–4 g/day are used for triglyceride lowering.361, 384 2361 
The evidence supporting use of these drugs for CVD event reduction is limited and, given the 2362 
strong evidence favouring statins, routine use of these drugs in CVD prevention is not 2363 
recommended. When triglycerides exceed 10 mmol/L (900 mg/dL), in order to prevent 2364 
pancreatitis, triglycerides must be reduced not only by drugs but also by restriction of alcohol, 2365 
treatment of DM, withdrawal of oestrogen therapy, etc. In those rare patients with severe 2366 
primary hypertriglyceridaemia, specialist referral must be considered. 2367 
Regarding new therapies, recent data from phase I–III trials show that PCSK9 inhibitors 2368 
sharply decrease LDL-C up to 60%, either as monotherapy or in addition to maximal statin 2369 
dose. Whether this approach results in the predicted reduction in CV events is being addressed 2370 
in large outcome trials: preliminary evidence suggest that this is the case.385-387 2371 
 2372 
3a.7.13 Drug combinations 2373 
Patients with dyslipidaemia, particularly those with established CVD, DM, or asymptomatic 2374 
high-risk individuals, may not always reach treatment goals, even with the highest tolerated 2375 
statin dose. Therefore, combination treatment may be needed. It must be stressed, however, 2376 
that the only combination that has evidence for clinical benefit (one large RCT) is that of a 2377 
statin combined with ezetimibe.354 Based on the relatively limited body of evidence, clinicians 2378 
may restrict the use of this combination to patients at high or very-high risk of CVD. 2379 
Combinations of niacin and a statin increase HDL-C and decrease triglycerides better than 2380 
either of these drugs alone, but flushing is the main adverse effect of niacin, which may affect 2381 
compliance. Furthermore, there is no evidence of clinical benefit for this combination 388. 2382 
Fibrates, particularly fenofibrate, may be useful, not only for decreasing high triglyceride 2383 
concentrations and increasing low HDL-C, but for lowering LDL-C further when applied 2384 
together with a statin. There is limited evidence for this combination in terms of reduction in 2385 
CVD events. In selected cases, however, this approach may be considered such as when, 2386 
during statin treatment, triglycerides remain high and/or HDL-C is very low. Other drugs 2387 
metabolized through cytochrome P450 should be avoided when this combination is 2388 
prescribed. Fibrates should preferably be taken in the morning and statins in the evening to 2389 
minimize peak dose concentrations and decrease the risk of myopathy. Patients have to be 2390 
instructed about warning symptoms (myalgia), even though such adverse effects are very rare. 2391 
Gemfibrozil should not be added to a statin treatment due to the high potential for 2392 
interactions. 2393 
If target levels cannot be reached even on maximal doses of lipid-lowering therapy or drug 2394 
combinations, patients will still benefit from treatment to the extent by which the 2395 
dyslipidaemia has been improved. In these patients, increased attention to other risk factors 2396 
may help to reduce total risk. 2397 
 2398 
Gaps in evidence 2399 
• Triglyceride or HDL-C values as a target for therapy 2400 
• Whether Lp(a) lowering against background statin therapy can reduce the risk of CVD 2401 
• How to increase adoption of non-HDL-C and non-fasting samples in clinical practice 2402 
• Whether functional foods and food supplements with a lipid-lowering effect can safely 2403 
reduce the risk of CVD 2404 
 2405 
 2406 
3a.8 Diabetes Mellitus (Type 2 and Type 1) 2407 
 2408 
Key messages 2409 
• The importance of multifactorial approach is very important in patients with type 2 DM 2410 
• Lifestyle management to aid weight control by sustainable dietary changes and increased 2411 
PA levels should be central in the management of patients with type 2 DM.  2412 
• Intensive management of hyperglycaemia reduces the risk of microvascular complications 2413 
and, to a lesser extent, risk of CVD. However, targets should be relaxed in the elderly, 2414 
frail, those with long duration of DM, or those with existing CVD.  2415 
• Intensive treatment of BP in DM, with a target of 140 mmHg systolic for the majority, 2416 
reduces the risk of macrovascular and microvascular outcomes. A lower SBP target of 130 2417 
mmHg further lessens risks for stroke, retinopathy and albuminuria and should be applied 2418 
to selected patients.  2419 
• Lipid lowering is a key mechanism to lower CVD risk in both type 2 and type 1 DM. All 2420 
patients above 40 years of age and selected younger patients at elevated risk are 2421 
recommended for statin therapy as first line.  2422 
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• In DM patients with existing CVD, the use of an Sodium-glucose co-transporter-2 2423 
(SGLT2) inhibitor substantially lessened CVD and total mortality and HF hospitalisation 2424 
without major adverse effects. SGLT2 inhibitors should be considered early in the course 2425 
of DM management in such patients. 2426 
• Recent evidence points to sizeable reductions in CVD mortality in DM patients via 2427 
improvement in risk factor management, though rising worldwide DM prevalence will 2428 
create increasing major challenges. More should be done to prevent DM.  2429 
 2430 
Recommendations for management of diabetes 2431 
Recommendations Classa Levelb Refc 
Lifestyle changes including smoking cessation, low fat diet, high 
fibre diet, aerobic physical activity, and strength training are 
recommended. 
I A 389 
Reduction in energy intake is recommended to patients to help 
achieve lower weight or prevent weight gain. 
I B 389 
A target HbA1c for the reduction in risk of CVD and 
microvascular complications in DM of <7.0% (<53 mmol/mol) is 
recommended for the majority of non-pregnant adults with either 
type 1 or type 2 DM. 
I A 390, 391 
For patients with a long duration of DM, the elderly, frail, or those 
with existing CVD, HbA1c targets should be relaxed (i.e. less 
stringent).  
IIa B 391 
A target HbA1c of ≤ 6.5% (≤ 48 mmol/mol) should be considered 
at diagnosis or early in the course of type 2 DM in patients, who 
are not frail and do not have CVD.   
IIa B 391 
When screening for DM in individuals with or without CVD, 
HbA1c (which can be done non-fasting) or fasting blood glucose 
should be used. An oral glucose tolerance test can be offered when 
there is still doubt. 
IIa A 392 
Metformin is recommended as first-line therapy, if tolerated and 
not contra-indicated, following evaluation of renal function. 
I B 393 
Avoidance of hypoglycaemia and excessive weight gain should be 
considered and individual approaches (with respect to both 
treatment targets and drug choices) should be considered in 
patients with advanced disease. 
IIa B 391, 394, 395 
In patients with type 2 DM and CVD, the use of an SGLT2 
inhibitors should be considered early in the course of the disease 
to reduce CV and total mortality. 
IIa B 396 
Lipid lowering agents (principally statins) are recommended to 
reduce CV risk in all patients with type 2 or type 1 DM above the 
age of 40 years.  
I A 372, 373 
Lipid lowering agents (principally statins) may be considered also 
in individuals below 40 years of age if at significantly elevated 
risk based on the presence of micro-vascular complications or of 
multiple CV risk factors.  
IIb A 372, 373 
In DM patients at very high risk (see table 5), a LDL-C target <1.8 
mmol/L (<70 mg/dL), or a reduction of at least 50% if the baseline 
LDL-C is between 1.8 and 3.5 mmol/L (70 and 135 mg/dL), is 
recommended.d 
In DM patients with high risk (see table 5), LDL-C target <2.6 
mmol/L (<100mg/dL) or a reduction of at least 50% if the baseline 
I B 397 
LDL-C is between 2.6 and 5.1 mmol/L (100 and 200 mg/dL) is 
recommended.d 
BP targets in type 2 DM are generally recommended to be 
<140/85 mmHg, but a lower target of <130/80 mmHg is 
recommended in selected patients (e.g. younger patients at 
elevated risk for specific complications) for additional gains on 
stroke, retinopathy and albuminuria risk. Renin-angiotensin-
aldosterone system blocker is recommended in the treatment of 
hypertension in DM, particularly in the presence of proteinuria or 
micro- albuminuria. Recommended BP target in patients with type 
1 DM is <130/80 mmHg. 
I B 398, 399 
The use of drugs that increase HDL-C to prevent CVD in type 2 
DM is not recommended. 
III A 388 
Antiplatelet therapy (e.g. with aspirin) is not recommended for 
people with DM who do not have CVD 
III A 400 
    
BP = blood pressure; CV = cardiovascular; DM = diabetes mellitus; HbA1c = glycated haemoglobin; HDL-C = 2432 
high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; SGLT2 = Sodium-glucose 2433 
co-transporter-2.  2434 
aClass of recommendation. 2435 
bLevel of evidence. 2436 
cReference(s) supporting recommendations. 2437 
d Non-HDL-C is a reasonable and practical alternative target because it does not require fasting. Non HDL-C 2438 
secondary targets of <2.6 and <3.3 mmol/L (<100 and <130 mg/dL) are recommended for very high, and high 2439 
risk subjects, respectively See section 3a.7.10 for more details  2440 
 2441 
 2442 
People with DM are on average at double the risk of CVD.401 A simple DM risk questionnaire 2443 
can guide which patients without CVD should be tested for DM.402  2444 
Keeping close to the recommended targets for BP, lipid control, glycaemia, and HbA1c is 2445 
important for the prevention of CVD. Clear reductions have occurred in CVD death rates in 2446 
DM consistent with better management of risk factors, though rising prevalence of DM 2447 
continues to create pressures on all healthcare systems. 2448 
The targets, especially the glycaemic and in some cases lipid targets, should be less 2449 
stringently implemented in older people with DM, those with longer duration of DM, those 2450 
with evidence of CVD, and the frail.403  2451 
There is mounting evidence for a very high relative risk in younger individuals with type 2 2452 
DM (age < 40 years)404 and additional guidance on care is needed.  2453 
Excepting for glucose management, prevention of CVD follows the same general principles 2454 
as for people without DM. Achieving low BP levels and low LDL-C and total cholesterol 2455 
concentrations is particularly important. Many treatment targets are more stringent for 2456 
patients with DM. Typically, patients with type 2 DM have multiple CVD risk factors, each 2457 
requiring treatment according to existing guidelines.  2458 
3a.8.1 Lifestyle intervention  2459 
ESC and European Association for the Study of Diabetes scientific statements advocate 2460 
lifestyle management as a first measure for the prevention and management of DM.389 Most 2461 
patients with DM are obese and weight control is a central component. Several dietary 2462 
patterns can be adopted where the predominance of fruits, vegetables, wholegrain cereals and 2463 
low-fat protein sources is more important than the precise proportions of total energy 2464 
provided by the major macronutrients. Salt intake should be restricted. Specific dietary 2465 
recommendations include limiting saturated and trans fats and alcohol intake, monitoring 2466 
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carbohydrate consumption, and increasing dietary fibre. A Mediterranean-type diet is 2467 
acceptable, where fat sources are derived primarily from monounsaturated oils.  2468 
A combination of aerobic and resistance exercise training is effective in the prevention of the 2469 
progression of DM and for the control of glycaemia. Little is known about how to promote 2470 
and sustain PA; however, reinforcement by healthcare providers to patients to find sustainable 2471 
ways to increase PA is crucial. Smoking increases the risk of DM, CVD and premature death, 2472 
and should be strongly discouraged (see section 3a.4.5).389, 405 Lifestyle intervention can also 2473 
prevent DM development in those at elevated risk and, in turn, lowers future microvascular 2474 
and macrovascular risks.406  2475 
3a.8.2 Cardiovascular risk 2476 
DM is not a CAD risk equivalent state at diagnosis or in those with short duration of 2477 
disease.407, 408 In general, risk levels approach CAD risk equivalence after about a decade or in 2478 
those with proteinuria or low eGFR.408-410 Emerging data suggest that patients who develop 2479 
DM at a younger age have a high complication burden.404 People with DM with existing CAD 2480 
have a vascular risk well in excess of those with CAD but without DM and a substantially 2481 
lower life expectancy.411 2482 
Statins are recommended for all those newly diagnosed with type 2 DM beyond a certain age 2483 
(> 40 years is currently recommended). This recommendation reflects greater lifetime 2484 
vascular risk trajectories in these individuals. However, a proportion of DM patients at 40–50 2485 
years of age may have low 10 year risk of CVD due to normal BP and lipid levels and being 2486 
non-smokers, and in such cases there remains a role for physician judgement. Equally, in 2487 
some patients with type 2 DM < 40 years of age with evidence of end-organ damage or 2488 
significant risk factors, statins may be indicated.  2489 
3a.8.3 Glucose control 2490 
The UK Prospective Diabetes Study (UKPDS) established the importance of intensive 2491 
glucose lowering with respect to CVD risk reduction, in newly diagnosed patients with DM 2492 
but not treated with modern BP and lipid lowering therapies, with best evidence to support 2493 
metformin, leading to its position as first line therapy. Three trials were conducted to see if 2494 
CV events could be reduced further with more intensive glycaemia treatment and lower target 2495 
HbA1c levels.391, 395, 412 However, the results were surprising with unexpected increases in 2496 
total and CVD deaths in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 2497 
trial and a trend towards an increase in CVD death in the Veterans Affairs Diabetes Trial 2498 
(VADT). The results prompted concerns about the safety of intensive glucose lowering and 2499 
the appropriateness of pursuing tight glucose control, particularly in older people with DM 2500 
and in those with existing CVD. Subsequent meta-analyses of intensive glucose control 2501 
including data from UKPDS, Prospective Pioglitazone Clinical Trial in Macrovascular Events 2502 
(PROactive), ACCORD, Action in Diabetes and Vascular disease: PreterAx and Diamicron 2503 
MR Controlled Evaluation (ADVANCE), and VADT413 showed significant reductions in non-2504 
fatal AMI and CAD events, but no effect on stroke or total mortality.414, 415 The additional 2505 
analyses of these trials suggested that CVD benefits for an average HbA1c reduction of 2506 
around 0.9% over 5 years were far less than via usual reductions in cholesterol and BP seen 2507 
with statins and available BP lowering agents. Four recent trials of newer DM therapies 2508 
(DPP-4 and GLP-1)416-419 in patients with DM and existing CVD or at high risk demonstrated 2509 
non-inferiority (i.e. safety) but not superiority with respect to CVD risk. There was, however, 2510 
an increase in the rate of hospitalization for HF with saxagliptin in SAVOR-TIMI 53.418 2511 
Very recently, the SGLT2 inhibitor, empaglaflozin demonstrated substantial reduction in 2512 
CVD death (by 38%) and all-cause mortality (by 32%) as well as in hospitalisation for HF (by 2513 
35%), as compared to standard care, suggesting use of an SLGT2 inhibitor should come very 2514 
early in the course of management of patients with DM and CVD. 396 The pattern of trial 2515 
results whereby non-fatal MI and stroke were not reduced by active treatment as well as the 2516 
rapid separation of mortality curves suggest that the mechanism of benefit was likely to relate 2517 
more to cardio-renal haemodynamic effects than to atherothrombotic actions or effects of 2518 
glucose-lowering per se. More research on understanding the trial results is needed.  2519 
 2520 
3a.8.4 Blood pressure 2521 
In people with type 2 DM, apart from lifestyle interventions, the reduction of BP (along with 2522 
cholesterol) should be targeted as strictly as targeting glucose/HbA1c levels. BP targets 2523 
should be considered regardless of overall CV risk score in patients with type 2 DM.  2524 
Hypertension is more common in patients with type 2 DM compared with the general 2525 
population. A recent systematic review and meta-analysis of randomized trials of BP lowering 2526 
agents in over 100,000 patients with type 2 DM confirmed that lowering BP reduces risk of 2527 
all-cause mortality, CV events, CAD events, stroke, HF, retinopathy, new or worsening 2528 
albuminuria, and renal failure.420 The results were similar when trials with low risk of bias 2529 
were selected. Furthermore, a systolic target < 140 mmHg lessens risk of total mortality and 2530 
most separate outcomes. Further reductions in risk for albuminuria, retinopathy and stroke, 2531 
but not in overall survival or aggregate clinical endpoints, were achieved with a systolic target 2532 
< 130 mmHg. In people over 80 years of age, targets should be set higher, aiming for < 2533 
150/90 mmHg, unless renal impairment is present.  2534 
Combination treatment is commonly needed to lower BP effectively in DM. An angiotensin-2535 
converting enzyme inhibitor (ACE-I) or an angiotensin receptor blocker (ARB), where 2536 
tolerated, should always be included as first line therapy because of the evidence of superior 2537 
protective effects against initiation or progression of nephropathy. 2538 
3a.8.5 Lipid-lowering therapy 2539 
The Heart Protection Study (HPS) demonstrated that treatment with simvastatin 40 mg 2540 
reduced the risk of CAD and stroke in people with DM and individuals without DM who had 2541 
no prior AMI or angina pectoris.373 Further robust support for statin benefit came from the 2542 
Collaborative Atorvastatin Diabetes Study (CARDS) study, which compared 10 mg 2543 
atorvastatin with placebo,372 and from the CTT meta-analysis in DM patients.421 There is also 2544 
trial evidence to show greater CVD risk reduction with more intense statin therapy in DM 2545 
patients.397 More recent trial evidence shows clear CVD benefit of lowering LDL-C with 2546 
ezetimibe on top of statin in patients with type 2 DM.354 Emerging evidence also shows that 2547 
PCSK9 inhibitors are equally efficacious in lowering LDL-cholesterol in type 2 DM patients, 2548 
though results of CV outcome trials are awaited.422 Lower treatment targets should be pursued 2549 
in patients with type 2 DM who have overt CVD or CKD. 2550 
While the most common lipid abnormality in type 2 DM is raised triglyceride and low HDL-2551 
C, trials examining possible CVD benefits of lipid (mainly triglyceride) lowering with fibrates 2552 
in DM have not been positive. The FDA states that the current evidence base is insufficient to 2553 
support fibrates for CVD protection and that more trial evidence is needed.423 2554 
Prescribing of lipid lowering agents in older people with DM (> 85 years) requires special 2555 
consideration because exposure to higher doses (or higher potency) may not increase life 2556 
expectancy, but may increase the risk of adverse effects.  2557 
3a.8.6 Antithrombotic therapy 2558 
Patients with type 1 or type 2 DM have an increased tendency to develop thrombotic 2559 
phenomena. The Antiplatelet Trialists’ Collaboration meta-analysis demonstrated benefits of 2560 
antithrombotic therapy (mainly aspirin) in patients with diabetes with clinically established 2561 
CAD, cerebrovascular disease, or other forms of thrombotic disease, with a 25% reduction in 2562 
risk of CV events.424  2563 
The role of aspirin in patients without CVD remains unproven. A meta-analysis of six RCTs 2564 
found no statistically significant reduction in the risk of major CV events or all-cause 2565 
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mortality when aspirin was compared with placebo or no aspirin in people with DM and no 2566 
pre-existing CVD.400 Further trials are ongoing.  2567 
3a.8.7 Microalbuminuria  2568 
Microalbuminuria (urinary albumin excretion from 30 to 300 mg/24 h) predicts the 2569 
development of overt nephropathy in patients with type 1 or type 2 DM, while the presence of 2570 
overt proteinuria (300 mg/24 h) generally indicates established renal parenchymal damage. In 2571 
patients with diabetes and hypertension, microalbuminuria – even below the current threshold 2572 
values – predicts CV events, and a continuous relationship between CV as well as non-CV 2573 
mortality and urinary protein/creatinine ratios has been reported. Microalbuminuria can be 2574 
measured from spot urine samples (due to inaccuracy in sampling, 24 h or night-time urine 2575 
collection is discouraged) by indexing the urinary albumin concentration to the urinary 2576 
creatinine concentration (2.5/3.5 to 25/35 mg/mmol). Patients with DM and microalbuminuria 2577 
or proteinuria should be treated with an ACE-I or ARB regardless of baseline BP. 2578 
 2579 
Gaps in evidence 2580 
• There is a need examine whether a type 2 DM CV risk score based on either 10-year or 2581 
lifetime risk help improve targeting of preventative therapies, and lead to a reduction in 2582 
CV risk or gain of lifetime years free from disease. 2583 
• Further trial data are needed to establish if the empaglaflozin outcome findings hold for 2584 
other classes of SGLT2 inhibitors, and to better understand mechanisms of benefit. It 2585 
would also be useful to know if SGLT2 inhibitors lessen CV mortality and HF risks in 2586 
patients with DM but without CVD.  2587 
• More research on the benefits of glucagon-like peptide 1 (GLP-1) receptor agonists on 2588 
CVD risk is needed and trials are due to be reported in subsequent years. Early evidence 2589 
suggests no CVD benefit with short term use of DPP4 inhibitors in people at high risk for 2590 
CVD, as reviewed.425  2591 
 2592 
3a.8.8 Type 1 diabetes 2593 
Key messages  2594 
• CVD and mortality risks have come down in type 1 DM patients but remain unacceptably 2595 
elevated in those with very poor glycaemic control or any evidence of kidney disease. 2596 
• Intensive management of hyperglycaemia in DM reduces the risk of macrovascular 2597 
complications and premature mortality; a target of 6.6% - 7.5% (48–58 mmol/mol) 2598 
HbA1c is recommended.  2599 
• Recommended BP target in the majority of patients with type 1 DM is 130/80 mmHg. 2600 
• Lipid lowering agents targeting LDL-C reduction should be recommended to the majority 2601 
of patients above 40 years of age and to those younger than this with evidence of 2602 
nephropathy or with multiple risk factors. 2603 
 2604 
Type 1 DM is due to a lack of insulin production in the pancreas, confirmed by absent or 2605 
virtually absent C-peptide levels. The average age of onset is around 14, though persons of 2606 
any age can develop Type 1 DM. Type 1 DM should be suspected on any patient who 2607 
progresses to insulin within first year of diagnosis. A contemporary large study in Scotland 2608 
observed a relative risk for CVD events of 2.3 in men and 3 in women with type 1 DM 2609 
compared to the general population,426 suggesting CVD risks may have declined over time, 2610 
commensurate with improvements in life expectancy.427 Another report from Sweden 2611 
demonstrated CVD mortality rates in type 1 DM to be twice the rates of the general 2612 
population in those with HbA1c levels below 6.9% (52 mmol/mol), whereas risk was 2613 
especially high (around 10-fold) in those with very poor control (≥9.7%, ≥83 mmol/mol).428 2614 
In the majority of studies, the risk of CVD events or mortality was highest among those with 2615 
diabetic nephropathy, macroalbuminuria or CKD. Presence of proliferative retinopathy and 2616 
autonomic neuropathy also signalled elevated CVD risk. 2617 
The Diabetes Control and Complications Trial (DCCT) established the importance of tight 2618 
glucose control to lessen risks of both microvascular and macrovascular disease. A 27-year 2619 
follow-up of this trial showed that 6.5 years of initial intensive DM therapy in type 1 DM was 2620 
associated with a modestly lower all-cause mortality rate when compared with conventional 2621 
therapy.429 A glycaemic target for HbA1c of 6.5% to 7.5% (48–58 mmol/L) appears a 2622 
balanced approach for long-term care of patients with type 1 DM. The use of insulin 2623 
analogues, insulin pumps and continuous glucose monitoring to improve glycaemic control 2624 
while minimizing hypoglycaemia, is the subject of intense research, as is the use of agents 2625 
(e.g. metformin, GLP-1 agonists) commonly used in type 2 DM.  2626 
The CTT suggested lipid lowering with statins is as equally effective in type 1 patients as in 2627 
type 2.430 All patients above 40 years of age with type 1 DM should be recommended for 2628 
statins unless they have a short duration of DM and no other risk factors. Younger patients 2629 
with multiple risk factors or evidence of end organ damage (albuminuria, low eGFR, or 2630 
proliferative retinopathy, neuropathy) should be considered for statin therapy.  2631 
A target BP of 130/80 mmHg is accepted practice in type 1 DM, with evidence of specific 2632 
benefits of ACE-I or ARB on the early development and later progression of microvascular 2633 
disease in younger type 1 DM. A lower target BP of 120/75–80 mmHg may be helpful in 2634 
younger type 1 DM (aged < 40 years) with persistent microalbuminuria. Studies supporting 2635 
improved CVD outcome in type 1 DM through BP reduction are lacking. As more patients 2636 
with type 1 DM are living to older age, SBP targets may need to be relaxed (140 mmHg) in 2637 
some to avoid side effects.  2638 
Current evidence suggests many patients with type 1 DM > 40 years of age continue to 2639 
smoke, are still not receiving statins, and, perhaps most importantly, have very poor glucose 2640 
control.426 Further efforts to target these established risk factors are needed.  2641 
 2642 
 2643 
Gaps in evidence 2644 
• Further studies are needed on metformin and GLP-1 receptor agonists in (subgroups of) 2645 
patients with type 1 DM to determine whether they improve glycaemic control, aid weight 2646 
changes and improve clinical outcomes.  2647 
• There is a need for a CVD risk score in type 1 DM to better guide initiation of 2648 
preventative therapies in younger patients.  2649 
 2650 
3a.9 Hypertension 2651 
 2652 
Key messages 2653 
• Elevated BP is a major risk factor for CAD, HF, cerebrovascular disease, PAD, CKD, and 2654 
AF. 2655 
• The decision to start BP lowering treatment depends on BP level and total CV risk. 2656 
• Benefits of treatment are mainly driven by BP reduction per se, not by drug type. 2657 
• Combination treatment is needed to control BP in most patients. 2658 
 2659 
Recommendations for management of hypertension 2660 
Recommendations  Classa Levelb Refc 
Lifestyle measures (weight control, increased physical activity, 
alcohol moderation, sodium restriction, and 
increased consumption of fruits, vegetables, and low-fat dairy 
I A 338, 431-433 
6JTF_Mastercopy 20160125 CONFIDENTIAL DOCUMENT 71 
 
products) are recommended in all patients with hypertension 
and in individuals with high normal BP. 
All major BP lowering drug classes (i.e. diuretics, ACE-I, 
calcium antagonists, ARBs, and beta-blockers) do not differ 
significantly in their BP-lowering efficacy and thus are 
recommended as BP lowering treatment. 
I A 434, 435 
In asymptomatic subjects with hypertension but free of CVD, 
CKD, and DM, total CV risk stratification using the SCORE 
model is recommended. 
I B 30 
Drug treatment is recommended in patients with grade 3 
hypertension irrespective of CV risk, as well as in patients 
with grade 1 or 2 hypertension who are at very high CV risk. 
I B 436 
Drug treatment should be considered in patients with grade 1 
or 2 hypertension who are at high CV risk.  
IIa B 436 
In patients at low to moderate total CV risk and with grade 1 
or 2 hypertension, lifestyle measures are recommended.  
I B 436 
In patients at low to moderate total CV risk and with grade 1 
or 2 hypertension, if lifestyle measures fail to reduce BP, 
drug treatment may be considered. 
IIb B 436 
SBP <140 mmHg and DBP <90 mmHg are recommended in 
all treated hypertensive patients < 60 years old. 
I B 436 
In patients >60 years old with SBP ≥160 mmHg, it is 
recommended to reduce SBP to between 150 and 140 
mmHg. 
I B 437 
In fit patients <80 years old, a target SBP < 140 mmHg may 
be considered if treatment is well tolerated. In some of these 
patients a target SBP <120 mmHg may be considered if at 
(very) high risk and tolerate multiple BP lowering drugs. 
IIb B 437, 438 
In individuals >80 years and with initial SBP ≥160 mmHg, it 
is recommended to reduce SBP to between 150 and 140 
mmHg, provided they are in good physical and mental 
conditions. 
I B 437 
In frail elderly patients, a careful treatment intensity (e.g. 
number of BP lowering drugs) and BP targets should be 
considered, and clinical effects of treatment should be 
carefully monitored. 
IIa B 439 
Initiation of BP lowering therapy with a two-drug 
combination may be considered in patients with markedly 
elevated baseline BP or at high CV risk. Combination of two 
drugs at fixed doses in a single pill may be considered 
because of improved adherence. 
IIb C 440 
Beta-blockers and thiazide diuretics are not recommended in 
hypertensive patients with multiple metabolic risk factors,d 
due to the increased risk of DM. 
III B 441 
 
ACE-I = angiotensin-converting enzyme inhibitor; ARBs = angiotensin receptor blockers; BP = blood pressure; 2661 
CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; DBP = diastolic blood 2662 
pressure; NNT = number needed to treat; SBP = systolic blood pressure; SCORE = Systematic Coronary Risk 2663 
Estimation. 2664 
aClass of recommendation. 2665 
bLevel of evidence. 2666 
cReference(s) supporting recommendations. 2667 
dOverweight, obesity, dyslipidaemia, impaired glucose tolerance 2668 
 2669 
3a.9.1. Introduction 2670 
High BP is a leading risk factor for disease burden globally, accounting for 9.4 million deaths 2671 
and 7.0% of global disability-adjusted life years (DALYs) in 2010.442 Compared to 1990, the 2672 
impact of high BP has increased by about 2.1 millions deaths.442 Overall, the prevalence of 2673 
hypertension is around 30–45% in adult persons aged 18 years or older, with a steep increase 2674 
with ageing. 2675 
Elevated BP is a risk factor for CAD, HF, cerebrovascular disease, PAD, CKD, and AF. The 2676 
risk of death from either CAD or stroke increases progressively and linearly from BP levels as 2677 
low as 115 mmHg systolic and 75 mmHg diastolic upwards,443 although for absolute risk the 2678 
curves flatten in the lower BP ranges.  2679 
 2680 
3a.9.2 Definition and classification of hypertension 2681 
The definition and classification of hypertension are shown in Table 14.11 2682 
 2683 
Table 14 Definition and classification of blood pressure levelsa 2684 
Category Systolic BP 
(mmHg) 
 Diastolic BP 
(mmHg) 
Optimal < 120 and < 80 
Normal 120–129 and/or 80–84 
High normal 130–139 and/or 85–89 
Grade 1 hypertension 140–159 and/or 90–99 
Grade 2 hypertension 160–179 and/or 100–109 
Grade 3 hypertension ≥ 180 and/or ≥ 110 
Isolated systolic hypertension  ≥ 140 and < 90 
BP = blood pressure.  2685 
a BP levels in untreated individuals.  2686 
 2687 
3a.9.3 Blood pressure measurement 2688 
Office BP is recommended for screening and diagnosis of hypertension, which should be 2689 
based on at least two BP measurements per visit and on at least two visits. If the BP is only 2690 
slightly elevated, repeated measurements should be made over a period of several months to 2691 
achieve an acceptable definition of the individual’s “usual” BP and to decide about initiating 2692 
drug treatment. If BP is more markedly elevated or accompanied by target organ damage, 2693 
other CV factors, or established CV or renal disease, repeated BP measurements are required 2694 
within a shorter period in order to make treatment decisions. 2695 
 2696 
3a.9.4 Office or clinic blood pressure measurement 2697 
Auscultatory or oscillometric semiautomatic sphygmomanometers should be validated and 2698 
checked periodically.444 Measurement of BP at the upper arm is preferred and cuff and 2699 
bladder dimensions should be adapted to the arm circumference. If feasible, automated 2700 
recording of multiple BP readings in the office, with the patient seated in an isolated room, 2701 
might be considered as a means to improve reproducibility and make office BP values closer 2702 
to those provided by daytime ambulatory BP monitoring (ABPM) or home BP measurements 2703 
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(HBPM).445 Note that automated devices are not validated for BP measurement in patients 2704 
with AF. 2705 
3a.9.5 Out-of-office blood pressure monitoring 2706 
Out-of-office BP is commonly assessed by ABPM or HBPM, usually by self-measurement; it 2707 
is usually lower than office BP and the difference increases as office BP increases (Table 15). 2708 
446 2709 
 2710 
Table 15 Blood pressure thresholds for definition of hypertension with different types of BP 2711 
measurement 2712 
 SBP 
(mmHg) 
DBP 
(mmHg) 
Office or clinic 140 90 
24-hour 125–130 80 
Day 130–135 85 
Night 120 70 
Home 130–135 85 
DPB = diastolic blood pressure; SBP = systolic blood pressure. 2713 
 2714 
General principles and remarks should be taken into account: (1) The procedure should be 2715 
adequately explained to the patient, with verbal and written instructions; (2) Interpretation of 2716 
the results should take into account that the reproducibility of out-of-office BP measurements 2717 
is reasonably good for 24 h, day and night BP averages but less for shorter periods: (3) ABPM 2718 
and HBPM provide somewhat different information on the subject’s BP status and risk and 2719 
the two methods should thus be regarded as complementary, rather than competitive; (4) 2720 
Devices should have been validated and regularly calibrated, at least every 6 months.  2721 
Both ABPM and HBPM values are closely related to prognosis.447 Night-time BP seems to be 2722 
a stronger predictor than daytime BP. Out-of office measurement may be useful not only in 2723 
untreated subjects but also in treated patients, with the aim of monitoring the effects of 2724 
treatment and increasing compliance with drug therapy (Table 16). 2725 
 2726 
Table 16 Clinical indications for the use of out-of-office blood pressure measurements (home 2727 
blood pressure measurement, ambulatory blood pressure measurement) 2728 
Suspicion of white-coat or masked hypertension 
 High office BP in individuals without organ damage and at low total CV risk 
 Normal office BP in individuals with organ damage or at high total CV risk 
 Considerable variability of office BP over the same or different visits 
 Autonomic, postural, post-prandial, siesta- and drug-induced hypotension 
 Elevated office BP or suspected pre-eclampsia in pregnant women 
 Identification of true and false resistant hypertension 
Specific indications for ABPM 
 Marked discordance between office BP and home BP 
 Assessment of dipping status 
 Suspicion of nocturnal hypertension or absence of dipping, such as in patients with 
sleep apnoea, CKD, or DM 
 Assessment of BP variability 
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CKD, chronic kidney disease; CV, 2729 
cardiovascular. 2730 
3a.9.6 Diagnostic evaluation in hypertensive patients 2731 
Routine: Laboratory tests: haemoglobin, fasting plasma glucose (HbA1c if not fasting) and 2732 
serum tests for total cholesterol, and HDL-C, triglycerides, potassium, uric acid, creatinine 2733 
(and calculated renal function), thyrotropin (in postmenopausal women); Urine analysis: 2734 
albumin/creatinine ratio, dipstick test, sediment, and quantitative proteinuria if dipstick test 2735 
positive; Electrocardiogram (ECG). Echocardiography and fundoscopy can be considered. 2736 
The routine measurement of additional biomarkers and/or the use of vascular imaging 2737 
methods is not recommended.  2738 
3a.9.7 Risk stratification in hypertension 2739 
The decision to start pharmacological treatment depends not only on the BP level but also on 2740 
total CV risk, outlined in section 2. However, even subclinical hypertensive organ damage 2741 
predicts CV death independently of SCORE, and the combination may improve risk 2742 
prediction, especially in subjects at moderate risk (SCORE 1–4%).448, 449 Echocardiography is 2743 
more sensitive than ECG in diagnosing LVH and in predicting CV risk, and may help in more 2744 
precise stratification of the overall risk and in directing therapy.450 Albumin/creatine ratio 2745 
>30mg/g in urine is also a marker of subclinical damage in hypertensive patients. 2746 
3a.9.8 Who to treat, and when to initiate antihypertensive treatment  2747 
The decision to start antihypertensive treatment depends on the BP level and total CV risk. 2748 
Lifestyle changes are recommended in all patients with suboptimal BP including masked 2749 
hypertension. Prompt initiation of drug treatment is recommended in individuals with grade 3 2750 
hypertension with any level of CV risk.434 Lowering BP with drugs is more frequently 2751 
required when total CV risk is very high and should be considered when the risk is high 2752 
(section 2.3.5).434 Initiation of BP lowering drug treatment may also be considered in grade 1 2753 
or 2 hypertensive patients at low to moderate risk when BP is within this range at several 2754 
repeated visits or elevated by ambulatory BP criteria, and remains within this range despite a 2755 
reasonable period of time with lifestyle measures.450 However, the NNT in this patient 2756 
category is very high, and patients should be informed about this, and their preference must be 2757 
considered. 2758 
Lifestyle measures only with close BP monitoring should be the recommendation in young 2759 
individuals with isolated moderate elevation of brachial SBP451 and in individuals with high 2760 
normal BP who are at low or moderate risk.450 Also in white-coat hypertensives without 2761 
additional risk factors, therapeutic intervention should be limited to lifestyle changes, 2762 
accompanied by close follow-up. Drug treatment may also be considered in white-coat 2763 
hypertensives with a higher CV risk because of metabolic derangements or in the presence of 2764 
organ damage.  2765 
3a.9.9 How to treat 2766 
3a.9.9.1 Lifestyle changes 2767 
Lifestyle interventions, weight control and regular PA alone may be sufficient for patients 2768 
with high-normal and grade 1 hypertension, and should always be advised for patients 2769 
receiving BP lowering drugs as they may reduce the dosage of BP lowering drugs needed to 2770 
achieve BP control. The lifestyle intervention specific to hypertension is salt restriction. At 2771 
the individual level, effective salt reduction is by no means easy to achieve. As a minimum, 2772 
advice should be given to avoid added salt and high-salt food. As the BP-lowering effect of 2773 
increased potassium has been well documented in the DASH diet (rich in fruits, vegetables, 2774 
and low fat diary products with a reduced content of dietary cholesterol as well as saturated 2775 
and total fat), patients with hypertension should generally be advised to eat more fruits and 2776 
vegetables and to reduce intake of saturated fat and cholesterol.450 2777 
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3a.9.9.2 Blood pressure lowering drugs  2778 
The large number of randomized trials of BP lowering therapy, both those comparing active 2779 
treatment versus placebo, and those comparing different compounds, confirm that: a) the main 2780 
benefits of BP lowering treatment are due to lowering of BP per se, and are largely 2781 
independent of the drugs employed; and b) thiazide and thiazide-like diuretics (chlorthalidone 2782 
and indapamide), beta-blockers, calcium antagonists, ACE-I, and ARB can adequately lower 2783 
BP, and reduce risk of CV death and morbidity.434, 435 These drugs are thus all recommended 2784 
for initiation and maintenance of BP control, either as monotherapy or in combination. Some 2785 
aspects should be considered for each of the BP lowering drugs groups. 2786 
The position of beta-blockers as first-choice BP lowering drugs has been questioned. A 2787 
meta-analysis of 147 randomized trials434 reports only a slight inferiority of beta-blockers in 2788 
preventing stroke (17% reduction rather than 29% reduction with other agents), but a similar 2789 
effect in preventing CAD and HF, and higher efficacy in patients with a recent coronary 2790 
event. However, as beta-blockers induce weight gain, have adverse effects on lipid 2791 
metabolism, and increase (compared with other drugs) the incidence of DM, they are not 2792 
preferred in hypertensive patients with multiple metabolic risk factors and conditions that 2793 
increase the risk of new-onset DM (such as obesity, impaired fasting glucose). However, this 2794 
may not apply to vasodilating beta-blockers such as carvedilol and nebivolol, which have less 2795 
or no dysmetabolic action, as well as a reduced incidence of new-onset DM compared with 2796 
conventional beta-blockers.  2797 
Thiazide diuretics also have dyslipidaemic and diabetogenic effects, particularly when used 2798 
in high doses. Thiazides have often been administered together with beta-blockers in trials 2799 
showing a relative excess of new-onset DM.  2800 
ACE-I and ARB are particularly effective in reducing LVH, reducing microalbuminuria and 2801 
proteinuria, and preserving renal function and delaying end-stage renal disease. 2802 
Evidence concerning the benefits of other classes of agents is much more limited. Alpha1-2803 
blockers, centrally acting agents (alpha2-adrenoreceptor agonists and imidazoline-receptor 2804 
agonists), anti-aldosterone drugs and the renin inhibitor aliskiren effectively lower BP in 2805 
hypertension, but there are no data documenting their ability to improve CV outcome. All of 2806 
these agents have frequently been used as added drugs in trials documenting CV protection 2807 
and can thus be used for combination treatment on top of the recommended combinations (see 2808 
below). 2809 
Drugs with 24 h efficacy are preferred. Simplification of treatment improves adherence to 2810 
therapy, while effective 24 h BP control is prognostically important in addition to “office” BP 2811 
control. Long-acting drugs also minimize BP variability, which may offer protection against 2812 
progression of organ damage and risk of CV events. 2813 
Any all-purpose ranking of drugs for general BP lowering usage is infeasible and no evidence 2814 
is available that different choices should be made based on age or sex (except for caution in 2815 
using ACE-I and ARB in women with child-bearing potential because of possible teratogenic 2816 
effects).452 Some agents should be considered as the preferred choice in specific conditions 2817 
because they have been used in trials including patients with those conditions or because of 2818 
greater effectiveness in specific types of organ damage (Table 17).450  2819 
Table 17 Drugs to be preferred in specific conditions  2820 
Condition Drug 
Asymptomatic organ damage  
   LVH ACE-I, calcium antagonist, ARB 
   Asymptomatic atherosclerosis Calcium antagonist, ACE-I 
   Microalbuminuria ACE-I, ARB 
   Renal dysfunction ACE-I, ARB 
Clinical CV event  
   Previous stroke Any agent effectively lowering BP 
   Previous MI BB, ACE-I, ARB 
   Angina pectoris BB, calcium antagonist 
   Heart failure Diuretic, BB, ACE-I, ARB, mineralocorticoid 
receptor antagonist 
   Aortic aneurysm BB 
   Atrial fibrillation: prevention Consider ARB, ACE-I, BB or mineralocorticoid 
receptor antagonist 
   Atrial fibrillation: rate control BB, non-dihydropyridine calcium antagonist 
   ESRD/proteinuria ACE-I, ARB 
   Peripheral artery disease ACE-I, calcium antagonist 
Other  
   ISH (elderly) Diuretic, calcium antagonist 
   Diabetes mellitus ACE-I, ARB 
   Pregnancy Methyldopa, BB, calcium antagonist 
   Blacks Diuretic, calcium antagonist 
 2821 
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BB = beta-blocker; BP 2822 
= blood pressure; CV = cardiovascular; Diuretic = thiazide or thiazide-like; ESRD = end-stage renal disease; ISH 2823 
= isolated systolic hypertension; LVH = left ventricular hypertrophy; MI = myocardial infarction. 2824 
 2825 
3a.9.9.3 Combination treatment 2826 
Combination treatment is needed to control BP in most patients. The addition of a drug from 2827 
another class should thus be regarded as a recommended treatment strategy unless the initial 2828 
drug needs to be withdrawn because of side effects or the absence of any BP-lowering effects. 2829 
The extra BP reduction from combining drugs from two different classes is approximately 2830 
five times greater than doubling the dose of one drug453 and may reduce the side effects 2831 
associated with either drug. The combination of two drugs may also offer advantages for 2832 
treatment initiation, particularly in patients at (very) high risk in whom early BP control may 2833 
be desirable. Trial evidence of outcome reduction has been obtained, particularly for the 2834 
combination of a diuretic with an ACE-I, or an ARB or calcium antagonist.454 2835 
Despite the trial evidence of outcome reduction, the beta-blocker/diuretic combination favours 2836 
the development of DM and should thus be avoided unless required for other reasons. The 2837 
combination of ACE-I and ARB is not recommended.455 Specific benefits of such a 2838 
combination in nephropathic patients with proteinuria (because of a superior anti-proteinuric 2839 
effect) await confirmation in event-based trials and, if used, should be monitored closely. 2840 
In 15–20% of hypertensive patients, a combination of three drugs is needed to achieve BP 2841 
control; thus a combination of three BP lowering drugs at fixed doses in a single tablet may 2842 
be favoured, because reducing the number of daily pills improves adherence, which is low in 2843 
patients with hypertension. The most rational combinations appear to be a blocker of the 2844 
renin–angiotensin system, a calcium antagonist, and a diuretic at effective doses. 2845 
3a.9.10 Blood pressure goals 2846 
There are only a few randomized clinical trials comparing different treatment targets. Hence, 2847 
recommendation on target levels largely derives from observational studies and post-hoc 2848 
analyses of randomized clinical trials, which mostly compared different treatment regimens 2849 
and reported achieved BP levels. 2850 
There is sufficient evidence to recommend that SBP be lowered to < 140 mmHg and diastolic 2851 
BP (DBP) to < 90 mmHg in all non-elderly hypertensive patients. Evidence is missing in the 2852 
elderly hypertensive patient, in whom the benefit of lowering SBP to < 140 mmHg has not 2853 
been tested in randomized trials. 2854 
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A DBP target < 90 mmHg is always recommended, except in patients with DM, in whom 2855 
values < 85 mmHg are recommended. It should nevertheless be considered that DBP values 2856 
between 80 and 85 mmHg are generally safe and well tolerated.398, 399 2857 
Post-hoc analyses of large-scale trials (e.g. ONTARGET, INVEST, and VALUE), although 2858 
suffering from the limitation posed by comparisons of non-randomized groups, suggest that at 2859 
least in high-risk hypertensive patients, there may be no advantage in lowering SBP below 2860 
130 mmHg, except perhaps for risk of stroke. A J-curve phenomenon for achieved SBP below 2861 
130 mmHg cannot be excluded,450 mainly in patients with advanced atherosclerotic diseases 2862 
and/or frailty.  2863 
The publication of the primary results of the Systolic Blood Pressure Intervention Trial 2864 
(SPRINT), which compared the benefit of treatment of SBP to a target of less than 120 2865 
mmHg with treatment to a target of less than 140 mmHg, challenged the above goal 2866 
recommendations in high risk patients without DM.438 Frail elderly were underrepresented in 2867 
this trial. Targeting a SBP of less than 120 mmHg, as compared with less than 140 mmHg 2868 
(average values 121 mmHg and 136 mmHg, respectively at the first year), resulted in lower 2869 
rates of a combined outcome of fatal and nonfatal major CV events and death from any cause. 2870 
However significantly higher rates of serious adverse events, hypotension, syncope, 2871 
electrolyte abnormalities and acute kidney injury or failure but not injurious falls, were 2872 
observed in the intensive-treatment group. The fact that the study was open-label in a strategy 2873 
close to usual care with frequent visits may have helped to adjust the antihypertensive 2874 
treatment if serious side effects occurred and then minimized the risk of events. 2875 
Generalizability of the findings of SPRINT to patients with DM and to frail elderly is 2876 
problematic. 2877 
Based on current data, it may still be prudent to recommend lowering SBP/DBP to values 2878 
within the range 130–139/80–85 mmHg and, possibly, close to lower values in this range, in 2879 
all hypertensive patients. 2880 
3a.9.11 Hypertension in special groups 2881 
3a.9.11.1 Diabetes mellitus  2882 
See section 3a.8.4. 2883 
3a.9.11.2 Elderly  2884 
Large meta-analyses confirm that treatment is highly beneficial in the elderly hypertensive 2885 
patient. The proportional benefit in patients aged > 60 years is no less than that of younger 2886 
patients. 2887 
In patients > 60 years old with SBP ≥ 160 mmHg there is solid evidence to recommend 2888 
reducing SBP to between 140 and 150 mmHg. However, in fit patients < 80 years of age, BP 2889 
lowering treatment may be considered at SBP values ≥ 140 mmHg with a target SBP < 140 2890 
mmHg if treatment is well tolerated.  2891 
Evidence is now available from an outcome trial that BP lowering treatment also has benefits 2892 
in patients aged ≥ 80 years. Because patients in the Hypertension in the Very Elderly Trial 2893 
(HYVET) were generally in a good condition, the extent to which HYVET data can be 2894 
extrapolated to more fragile octogenarians is uncertain. In individuals older than 80 years with 2895 
an initial SBP ≥ 160 mmHg it is recommended to reduce SBP to between 140 and 150 2896 
mmHg, provided they are in good physical and mental condition.439 The decision to treat  2897 
should be taken on an individual basis, and patients should always be carefully monitored 2898 
during treatment, with BP also measured in the standing position. In frail elderly patients, it is 2899 
recommended to be careful and reach a decision based on monitoring of the clinical effects of 2900 
treatment.  2901 
3a.9.12 Resistant hypertension  2902 
The definition of hypertension resistant to treatment is when a therapeutic strategy that 2903 
includes appropriate lifestyle measures plus a diuretic and two other BP lowering drugs 2904 
belonging to different classes at adequate doses (but not necessarily including a 2905 
mineralocorticoid receptor antagonist) fails to lower SBP and DBP values to < 140 and 90 2906 
mmHg, respectively. Depending on the population examined and the level of medical 2907 
screening, the prevalence of resistant hypertension has been reported to range from 5–30% of 2908 
the overall hypertensive population, with figures < 10% probably representing the true 2909 
prevalence. Resistant hypertension is associated with a high risk of CV and renal events.456 2910 
Before a patient is considered treatment resistant, consideration should be given to lack of 2911 
treatment adherence, white-coat effect or high salt or alcohol intake, as well as drug intake 2912 
with potential pressor effect, or the use of recreational drugs or secondary hypertension. In 2913 
these patients physicians should check whether the drugs included in the existing multiple 2914 
drug regimen have any BP lowering effect, and withdraw them if their effect is absent or 2915 
minimal. Anti-aldosterone drugs, amiloride, or the alpha-1-blocker doxazosin should be 2916 
considered as the fourth or fifth drug, if no contra-indication exists (eGFR < 45 mL/min/m2 2917 
and/or serum potassium > 4.5 mmol/L for mineralocorticoid receptor antagonists). 2918 
In the case of ineffectiveness of drug treatment (i.e. resistant hypertension) specialist referral 2919 
should be considered. Any invasive approach in these patients should be considered only for 2920 
truly resistant hypertensive patients, with clinic values ≥ 160 mmHg SBP or ≥ 110 mmHg 2921 
DBP and with BP elevation confirmed by ABPM.  2922 
3a.9.13 Duration of treatment and follow-up 2923 
Generally, BP lowering therapy should be maintained indefinitely. Cessation of therapy in 2924 
hypertensive patients is mostly followed by the return of BP to pre-treatment levels. In some 2925 
patients, in whom treatment is accompanied by an effective BP control for an extended 2926 
period, it may be possible to reduce the number and dosage of drugs. This may be particularly 2927 
the case if BP control is accompanied by healthy lifestyle changes. Reduction of medications 2928 
should be made gradually and the patient should frequently be checked because of the risk of 2929 
reappearance of hypertension. 2930 
Patient follow-up should be carried out by the healthcare team which should include 2931 
physicians, nurses and pharmacists in a concerted activity, although wide variations exist in 2932 
the organization of healthcare systems across Europe. In some countries the task relies more 2933 
on the physicians while in others specially educated and trained nurses have a more prominent 2934 
role. Once the target is reached, a visit interval of a few months is reasonable; there is no 2935 
difference in BP control between 3- and 6-month intervals. The regression of asymptomatic 2936 
organ damage occurring during treatment reflects the treatment-induced reduction of morbid 2937 
and fatal CV events457; however, a cost-effectiveness analysis of which signs of organ damage 2938 
should best be assessed in the follow-up has never been done.450 2939 
 2940 
Gaps in evidence 2941 
• Drug treatment in white-coat hypertension  2942 
• If and when drug treatment should be started in the high normal BP range  2943 
• The optimal office BP values (i.e. the most protective and safe) for patients to achieve by 2944 
treatment in different demographic and clinical conditions  2945 
• The optimal out-of-office (home and ambulatory) BP targets, and whether the treatment 2946 
strategies based on control of out-of-office BP provide an advantage over strategies based 2947 
on conventional (office) BP control  2948 
 2949 
3a.10 Antiplatelet therapy 2950 
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Key messages 2951 
• Antiplatelet therapy is not recommended in individuals free from CVD, due to its 2952 
increased risk of major bleeding. 2953 
 2954 
Recommendations for antiplatelet therapy 2955 
Recommendations Classa Levelb Refc 
In acute coronary syndromes, a P2Y12 inhibitor for 12 months 
is recommended in addition to aspirin,  unless there are 
contraindications such as excessive risk of bleeding.  
I A 458-460 
P2Y12 inhibitor administration for a shorter duration of 3–6 
months after DES implantation may be considered in patients 
deemed at high bleeding risk. 
IIb A 461-464 
P2Y12 inhibitor administration in addition to aspirin beyond 1 
year may be considered after careful assessment of ischaemic 
and bleeding risks of the patient. 
IIb A 465, 466 
In the chronic phase (> 12 months) after MI, aspirin is 
recommended. 
I A 467 
In patients with non-cardioembolic ischaemic stroke or TIA, 
prevention with aspirin only, or dipyridamole plus aspirin or 
clopidogrel alone is recommended. 
I A 468-470 
Prasugrel is not recommended in patients with stable CAD. 
Ticagrelor is not recommended in patients with stable CAD 
without a previous ACS. 
III C 466 
In patients with non-cardioembolic cerebral ischaemic events, 
anticoagulation is not recommended. 
III B 471, 472 
Antiplatelet therapy is not recommended in individuals without 
CVD due to the increased risk of major bleeding. 
III B 467 
MI = myocardial infarction. 2956 
aClass of recommendation. 2957 
bLevel of evidence. 2958 
cReference(s) supporting recommendations. 2959 
 2960 
3a.10.1 Antiplatelet therapy in individuals without cardiovascular disease 2961 
Prevention in individuals without overt CV or cerebrovascular disease was investigated using 2962 
long-term aspirin versus control in a systematic review of six trials including 95,000 2963 
individuals. A risk reduction from 0.57% to 0.51% per year of serious vascular events was 2964 
found by the Antithrombotic Trialists’ Collaboration.467 Major gastrointestinal and 2965 
extracranial bleeds increased by 0.03% per year. Risk of vascular mortality was not changed 2966 
by treatment with aspirin. In a recent Japanese study,473 patients aged 60–85 years presenting 2967 
with hypertension, dyslipidaemia, or DM were randomized to treatment with 100 mg aspirin 2968 
or placebo. The 5-year cumulative primary outcome event rate (death from CV causes) was 2969 
not significantly different between the groups, but treatment with aspirin significantly 2970 
increased the risk of extracranial haemorrhage requiring transfusion or hospitalization 2971 
(P=0.004). In individuals with multiple risk factors, clopidogrel in combination with aspirin 2972 
was tested versus aspirin in the Clopidogrel for High Atherothrombotic Risk and Ischemic 2973 
Stabilisation, Management, and Avoidance (CHARISMA) trial and was not of significant 2974 
benefit.474 The results of the four major ongoing primary prevention trials, two in DM 2975 
patients,475, 476 one in individuals with advanced age,477 and one in individuals with moderate 2976 
CV risk,478 are expected to become available over the next 5 years. 2977 
3a.10.2 Antiplatelet therapy in individuals with cardiovascular or cerebrovascular 2978 
disease 2979 
In the acute state of cerebral ischaemia, aspirin reduced the risk of new vascular events within 2980 
2–4 weeks, by preventing four recurrent strokes and five vascular deaths per 1000 patients 2981 
treated.479  2982 
Following an episode of ACS, dual antiplatelet therapy given for a period of 12 months is a 2983 
standard treatment based on results from the CURE,458 TRITON,459 and PLATO460 studies, 2984 
whereas no clinical studies support use of prasugrel and ticagrelor in patients with stable 2985 
CAD.  2986 
In long-term prevention after MI, stroke, or PAD, aspirin is the most studied drug. In a meta-2987 
analysis of 16 trials comprising 17,000 individuals, the Antithrombotic Trialists’ 2988 
Collaboration,467 aspirin treatment was associated with serious vascular events in 6.7% of 2989 
patients per year versus 8.2% of controls. The risk of total stroke was 2.08% per year versus 2990 
2.59% (P=0.002) and coronary events 4.3% per year versus 5.3% (P=0.0001). Aspirin was 2991 
associated with a 10% reduction in total mortality with a significant excess of major bleeds; 2992 
nevertheless, the benefits of aspirin exceeded the bleeding hazards. 2993 
In patients with prior MI, stroke, or PAD, clopidogrel showed a slight superiority with respect 2994 
to aspirin; the rate of serious vascular events was 5.32% per year with clopidogrel versus 2995 
5.83% with aspirin (P=0.043). There were slightly more bleeds with aspirin.480 2996 
Adding aspirin to clopidogrel in high-risk patients with recent ischaemic stroke or transient 2997 
ischaemic attack was associated with a non-significant difference in reducing major vascular 2998 
events. However, the risk of life-threatening or major bleeding was significantly increased by 2999 
the addition of aspirin481. 3000 
On the other hand, The Clopidogrel in High-risk patients with Acute Non-disabling 3001 
Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel 3002 
and aspirin decreased the 90-day risk of stroke without increasing hemorrhage in comparison 3003 
with aspirin alone in 5170 Chinese patients randomized within 24 hours after symptom onset 3004 
of minor stroke or TIA to clopidogrel-aspirin or to the aspirin alone. Moderate or severe 3005 
hemorrhage did not differ between the study 482.  3006 
In patients with prior non-cardioembolic ischaemic stroke, dual antiplatelet therapy with 3007 
dipyridamole plus aspirin showed superiority over aspirin.468 In such patients, oral vitamin K 3008 
antagonists are not superior to aspirin but are associated with a higher bleeding risk.471, 472 3009 
In patients with ischaemic stroke, a direct comparison of dipyridamole plus aspirin versus 3010 
clopidogrel alone 469 showed similar rates of recurrent stroke, including haemorrhagic stroke. 3011 
There was a higher frequency of major haemorrhagic events with dipyridamole plus aspirin 3012 
(4.1% vs. 3.6%).  3013 
Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin 3014 
through antagonism of PAR-1. In 26,449 patients who had a history of MI, ischaemic stroke, 3015 
or PAD, the primary composite endpoint – CV death, MI or stroke – was significantly 3016 
reduced with vorapaxar in addition to standard antiplatelet therapy, but with increased risk of 3017 
moderate or severe bleeding.483 Vorapaxar cannot be recommended systematically in patients 3018 
with stable atherosclerotic disease. 3019 
 3020 
Gaps in evidence 3021 
• The experience with the new antiplatelet drugs in patients with stable CAD is still limited 3022 
and so is their use in combination with anticoagulant treatment. 3023 
 3024 
3a.11 Adherence to medication 3025 
Key messages 3026 
• Adherence to medication in individuals at high risk and in patients with CVD is low. 3027 
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• Several types of interventions are effective in improving medication adherence. 3028 
• The polypill may increase adherence to treatment and improve CV risk factor control. 3029 
 3030 
Recommendations for achieving medication adherence 3031 
Recommendations Classa Levelb Refc 
Simplifying the treatment regimen to the lowest acceptable 
level is recommended, with repetitive monitoring and 
feedback. In case of persistent non-adherence, multi-
session or combined behavioural interventions are 
recommended. 
I A 484 
It is recommended that physicians assess medication 
adherence, and identify reasons for non-adherence in order 
to tailor further interventions. 
I C  485-487 
The use of the polypill and combination therapy to increase 
adherence to drug therapy may be considered. 
IIb B 488, 489 
aClass of recommendation. 3032 
bLevel of evidence. 3033 
cReference(s) supporting recommendations. 3034 
 3035 
Adherence to medication in individuals at high risk and in patients with CVD is low, resulting 3036 
in worse outcomes and higher healthcare costs.490 One month after AMI, 25–30% of patients 3037 
stop at least one drug, with a progressive decline in adherence over time. After 1 year, only 3038 
50% of patients report persistent use of statins, beta-blockers, or BP lowering therapy.486, 487 3039 
The reasons for poor adherence are multifactorial (Table F in web addenda).486  3040 
Cost-related non-adherence is a relevant problem in many healthcare systems. For example, in 3041 
American veterans, adherence to lipid-lowering medication decreased as co-payment 3042 
increased.491 Depression also independently doubles the risk for non-adherence.492 Reasons 3043 
for non-adherence tend to cluster; for example, complex medication regimens may be 3044 
important in individuals with chronic disease or multiple risk factors. This places high 3045 
demands on caregivers to provide clear advice and continuous care.487 Physicians often fail to 3046 
communicate critical elements of medication use (e.g. possible adverse effects, how long to 3047 
take the medication, and the frequency or timing of dosing).493 Thus there is a need to train 3048 
physicians to identify risk factors for non-adherence and promote adherence to medication. 3049 
Several interventions are effective in improving adherence in chronic conditions.484 Solely 3050 
reducing dosage demands resulted in strong effects, but other interventions such as repetitive 3051 
monitoring and feedback, multi-session information and combined behavioural interventions 3052 
have shown effects ranging from minor to strong.484 Collaboration with pharmacists or 3053 
pharmacist-directed care was superior to standard care with respect to BP, total cholesterol 3054 
and LDL-C levels.494 Knowledge of one’s CAC score may increase risk perception and 3055 
adherence to medication.495. 3056 
In clinical practice, physicians should assess adherence to medication, identify reasons for 3057 
possible non-adherence, and promote adherence according to the following established 3058 
principles:  3059 
- provide clear advice regarding the benefits and possible adverse effects of the medication, 3060 
and the duration and timing of dosing;  3061 
- consider patients’ habits and preferences (shared decision making);  3062 
- simplify the treatment regimen to the lowest feasible level;  3063 
- ask patients in a non-judgemental way how the medication works for them, and discuss 3064 
possible reasons for non-adherence (e.g. side effects, worries);  3065 
- implement repetitive monitoring and feedback; introduce physician assistants and/or 3066 
trained nurses or pharmacists whenever it is necessary and feasible;  3067 
- in case of persistent non-adherence, offer multi-session or combined behavioural 3068 
interventions e.g. for patients after myocardial revascularisation in a cardiac rehabilitation 3069 
(CR) setting. 3070 
3a.11.1 Polypill 3071 
Over a decade ago, Wald and Law quantified the efficacy and adverse effects of a fixed dose 3072 
combination (FDC) from published trials and proposed that a FDC consisting of statin, BP 3073 
lowering agents, aspirin, and folate could potentially reduce CVD by 80% in individuals 3074 
above 55 years of age.496.  3075 
A recent systematic review and meta-analysis488 summarizes nine randomized trials (n = 3076 
7047) on FDCs, largely conducted in higher-risk populations and primarily designed to 3077 
evaluate changes in CV risk factors and adherence. However FDCs included in the analysis 3078 
were single pills of diverse composition and doses (although all contained a statin and at least 3079 
one BP lowering agent) and had a range of comparators (placebo, single drug active 3080 
component, or “usual care”). No convincing evidence of either benefit or risk for FDCs in 3081 
terms of all-cause mortality or CV events was found. FDC therapy improved adherence (only 3082 
one trial) to a multi-drug strategy by 33% (95% CI 26% to 41%) compared with usual care. 3083 
Another international study, not included in the previous meta-analysis, in 695 CAD patients 3084 
randomized to test the effect of an FDC polypill containing aspirin, simvastatin and ramipril, 3085 
or the three drugs separately, showed that FDC improved adherence compared to separate 3086 
medications after 9 months follow-up (adherence 63% vs. 52%; P=0.006).489  3087 
The polypill should not be considered in isolation but as an integral part of a comprehensive 3088 
CVD prevention strategy that includes efforts to reduce tobacco use, increase PA, and 3089 
increase consumption of heart-healthy diets.497 However, potential adverse effects of a single 3090 
drug component of the FDC cannot be specifically corrected and therefore may also affect 3091 
treatment adherence to the other components. Until we have the results of ongoing trials with 3092 
major CVD as endpoints the polypill cannot be recommended in prevention of CVD and 3093 
cannot be prescribed to all individuals. 3094 
 3095 
Gaps in evidence 3096 
• There is limited evidence about which interventions to improve adherence to medication 3097 
are the most effective in whom (e.g. young–old, male–female, high vs. low socio-3098 
economic status). 3099 
• The effect of the polypill as a global strategy to reduce CVD remains uncertain. 3100 
  3101 
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3b. How to intervene at the individual level: disease specific intervention. 3102 
Atrial fibrillation, coronary artery disease, chronic heart failure, 3103 
cerebrovascular disease, peripheral artery disease (web addenda) 3104 
 3105 
3c. How to intervene at the population level 3106 
3c.1 Introduction (healthy lifestyle promotion) 3107 
The population level approach follows the Geoffrey Rose paradigm: small shifts in the risk of 3108 
disease (or risk factor) across a whole population consistently lead to greater reductions in 3109 
disease burden than a large shift in high risk individuals only. This population-wide approach 3110 
has further advantages: it addresses CV health over the entire life-course and reduces health 3111 
inequalities.  3112 
Individual behaviour is enacted in an environment with hierarchical levels, which encompass 3113 
individual choice, family influence, cultural and ethnic grouping, workplace, health care and 3114 
policy at state and global levels (e.g. EU policies and international trade agreements).  3115 
The aim of this section is to provide stakeholders with evidence-based suggestions for the 3116 
most effective interventions to improve CVD risk that can be implemented at a group, 3117 
community, regional, national or global level. Health care professionals play an important role 3118 
in advocating evidence-based population level interventions.  3119 
Strategies such as “nudging” (to push mildly) and “default” have been proposed as tools. By 3120 
changing the context to make healthy decisions default, the individual is “nudged” in the 3121 
healthy direction. A task for both national and local authorities is to create social 3122 
environments which provide healthier defaults. 3123 
The evidence presented here builds on recent comprehensive reviews312, 498-500 and individual 3124 
studies and summarises the “Totality of Evidence”. It is rarely feasible to use an RCT to 3125 
evaluate population level interventions (in contrast to individual level interventions). The 3126 
guidelines committee has chosen to follow the definition of “Level of Evidence” also for 3127 
population level approaches. Thus, consistent findings from several high quality studies were 3128 
considered sufficient to merit strong recommendations.  3129 
 3130 
3c.2 Population-based approaches to diet 3131 
Key messages 3132 
• Structural measures like product reformulation, limitations of marketing and taxes on 3133 
unhealthy foods, subsidizing of costs of healthier foods, and consumer friendly nutrition 3134 
labelling will improve healthy food choices. 3135 
• Healthy environments in the community, at schools and workplaces will stimulate a 3136 
healthy lifestyle. 3137 
 3138 
Recommendations for population-based approaches to diet 3139 
 Recommendations Classa Levelb Refc 
Governmental 
restrictions 
and mandates 
Legislation on composition of foods to reduce 
energy density, salt and saturated fat, and (added) 
sugar content of foods and beverages, and to limit 
portion sizes is recommended. 
 
I B 312, 498, 499, 
501-504 
Elimination of industrially produced transfats is 
recommended 
I A 317 
Facilitating an integrated and coherent policy and 
activities of the (local) governments, non-
governmental organizations, food industry, retail, 
catering, schools, workplaces and other stakeholders 
to promote a healthy diet and to prevent overweight 
is recommended. 
I C 501, 505 
Legislation restricting marketing aimed at children 
of foods that are high in fats, sugar and/or salt, less 
healthy options, junk foods, drinks with alcohol and 
non-alcoholic beverages rich in sugar (e.g. on TV, 
internet, social media and on food packages) is 
recommended. 
I C 312, 498, 506, 
507 
Media and 
education 
Reformulation of foods accompanied by educational 
information campaigns should be considered to 
create awareness on the nutrition quality of foods 
among consumers. 
IIa C 508, 509 
Labelling and 
information 
Mandatory and harmonized simplified front-of-pack 
nutrition labelling is recommended. 
I C 312, 499, 509 
Independently and coherently formulated criteria for 
nutrient profiles should be considered in support of 
health and nutrition claims and front-of-pack logos 
(e.g. traffic lights, healthy choices, key-holes). 
IIa C 312 
Mandatory nutrition labelling for non-pre-packaged 
foods, including  in restaurants hospitals and 
workplaces, should be considered 
IIa C 312, 509 
Economic 
incentives 
Pricing and subsidy strategies are recommended to 
promote healthier food and beverage choices. 
I B 312, 498, 510, 
511 
Taxes on foods and beverages rich in sugar and 
saturated fat, and on alcoholic drinks are 
recommended.  
I B  312, 498, 510, 
511 
Schools At all schools, pre-schools and daycare centres a 
multi-component, comprehensive and coherent 
policy is recommended to promote a healthy diet. 
I B 312, 498, 505, 
507 
 
Availability of fresh drinking water and healthy 
foods in schools, and in vending machines is 
recommended. 
I B 312, 498, 507 
Workplaces At all companies a coherent and comprehensive 
health policy and nutritional education is 
recommended to stimulate the health awareness of 
I B 312, 498, 499, 
512 
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employees. 
Increased availability of fresh drinking water and 
improved nutritional quality of food served and/or 
sold in the workplace, and in vending machines 
should be considered. 
IIa C 312, 499 
Community 
setting 
Regulation of location and density of fast food and 
alcohol purchasing outlets and other catering 
establishments should be considered. 
IIa C 498-500 
aClass of recommendation. 3140 
bLevel of evidence. 3141 
cReference(s) supporting recommendations. 3142 
 3143 
Diet is a powerful determinant of obesity, hypertension, dyslipidemia, DM and CV health. 3144 
Rapid reductions in CV events can be seen after changes in diet at the population level.500, 513 3145 
Stakeholder, including health care professionals, have a shared responsibility for population-3146 
based approaches and can help to promote healthy diets and environments498, 501 (Figure D in 3147 
web addenda).507 3148 
Many EU countries recognize the health benefits of reducing the energy density, salt and 3149 
sugar content and replacement of trans and saturated fat by unsaturated fat in foods and 3150 
drinks.312, 498, 501 These have led to successful reductions in trans fats502 and salt,498, 502-504 the 3151 
latter likely leading to decreases in BP.504 Mandatory upper limits harmonized across the EU 3152 
will ensure that all EU consumers are equally protected.501 3153 
Governments can facilitate nation-wide cooperation between (local) governments, non-3154 
governmental organizations (NGOs), food industry, retail, catering, schools, workplaces and 3155 
other stakeholders. The French EPODE (Ensemble Prévenons l'Obésité des Enfants) project is 3156 
an example of a multi-stakeholder cooperation which can help decrease childhood obesity.505 3157 
Similar projects are in place in Belgium, Spain, the Netherlands, Greece and Australia. 3158 
Educational tools and intervention on media may lead to reduction of childhood obesity, e.g. 3159 
limiting children’s exposure to advertising of unhealthy foods.312, 498, 500, 505, 506 In 2013, the 3160 
European Heart Network (EHN) published a report summarizing recent developments in 3161 
relation to the marketing of unhealthy foods to children.507 Accompanying consumer 3162 
awareness campaigns on healthy foods,508 and nutrition labelling can be effective. Consumers 3163 
understand different systems of labelling and their use has a positive impact on sales.509 EHN 3164 
calls for a simplified, colour-coded, front-of-pack scheme indicating high, medium and low 3165 
levels of nutrients.312, 498, 500 This scheme can be applied to all foods and could be expanded to 3166 
certain restaurants.312 Labelling also stimulates reformulation of foods.507 Thereby it has the 3167 
potential to improve dietary intake and reduce diet-related chronic diseases.  3168 
Pricing strategies can also lead to a decline in sales of unhealthy foods and increase of sales of 3169 
fruits and vegetables. Modelling studies have demonstrated that food taxes could improve 3170 
energy and nutrient intake, BMI and health.498, 510, 511 An increasing number of countries have 3171 
introduced taxes on unhealthy foods and drinks e.g. fat tax in Denmark (10–15% decrease in 3172 
consumption; now repealed) and junk food tax in Hungary (sales declined by 27%).507 3173 
Consideration should be given to balanced economic incentives: subsidy and taxes to 3174 
counteract any unbalanced effect on the socially disadvantaged. 3175 
To tackle obesity, every school and workplace should have a policy to promote a healthy 3176 
environment and provide healthy foods and meals.498, 507 Health education ideally should be 3177 
part of the school curriculum. Workplace dietary modification interventions alone and in 3178 
combination with nutrition education or environmental changes have shown improvements in 3179 
consumption of fruits and vegetables and/or fat.512 3180 
In the community, planning of location and density of fast food outlets, and good access to 3181 
supermarkets, is needed, especially in deprived areas.498 499, 500 3182 
Gaps in evidence 3183 
• Scientific evidence of the impact of food and nutrition policy instruments on outcome 3184 
measures such as food intake and CV health is largely lacking. 3185 
• Cost-effective studies of the impact of different policy options are also limited. 3186 
 3187 
3c.3 Population-based approaches to physical activity  3188 
Key messages 3189 
• Sedentary lifestyle and physical inactivity affects more than half of the population 3190 
worldwide. 3191 
• Regular PA is recommended in all men and women as a lifelong part of lifestyle with at 3192 
least 150 minutes moderate activity per week or at least 75 minutes of vigorous activity 3193 
per week or an equivalent combination thereof. Any activity is better than none, more 3194 
activity is better than some. 3195 
• Population-based interventions are effective in promoting PA. 3196 
• Early childhood education in PA and movement should start at pre-school/ kindergarten. 3197 
• Daily PA at school should be at least 30 minutes, preferably 60 minutes every day at 3198 
school. 3199 
• Good neighbourhoods and safe environment enhances and encourages PA in everyday 3200 
life.  3201 
 3202 
Recommendations for population-based approaches to physical activity 3203 
 Recommendations Classa Levelb Refc 
Governmental 
restrictions 
and mandates 
Consideration of PA when planning new 
landscaping/buildings or towns is recommended. 
I C 312, 514-516  
Media and 
education. 
See also 
section 3c.2 
for multi-
component 
interventions 
Sustained, focused, media and educational 
campaigns, using multiple media modes (e.g. 
apps, posters, flyers and signage) may be 
considered to promote PA.  
IIb C 499 
Short term community-based educational 
programmes and wearable devices promoting 
healthy behaviours, such as walking should be 
considered. 
IIa C 517; 518, 519 
Labelling and 
information 
Point-of-decision prompts should be considered 
to encourage use of stairs. 
IIa B 519, 520 
Exercise prescription for health promotion by 
physicians, especially GPs, similar to drug 
prescription should be considered.,  
IIa  C 520, 521 
Economic 
incentives 
  
  
  
Increased fuel (gasoline) taxes should be 
considered to increase active 
transport/commuting  
IIa C 515, 521 
Tax incentives for individuals to purchase 
exercise equipment or health club/fitness 
memberships may be considered.  
IIb C 515, 521 
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Sustained individual financial incentives may be 
considered for increased activity/fitness or 
weight loss.  
IIb C 515, 516, 521 
Tax incentives to employers to offer 
comprehensive worksite wellness programmes 
with nutrition, PA, and tobacco 
cessation/prevention components may be 
considered.   
IIb C 515, 521 
Schools. See 
also section 
3c.2 for 
multi-
component 
interventions 
  
  
  
Increased availability and types of school 
playground spaces and equipment for  exercise 
activity and sports are recommended. 
I C 515, 522  
 
Regular classroom PA breaks during academic 
lessons should be considered.  
IIa B  514 
Increasing active commuting to school should be 
considered e.g. a walking school bus programme 
with supervised walking routes to and from 
school for safety.  
IIa C 
515, 517 
Increased number and duration of PA classes, 
with revised PA curricula to implement at least 
moderate activity and trained teachers in 
exercise and sports may be considered.  
IIb B  514, 516  
 Workplace. 
See also 
section 3c.2 
for multi-
component 
interventions 
  
Comprehensive worksite wellness programmes 
should be considered with nutrition and PA 
components.  
IIa 
 
B 
 
515, 523-525 
Structured worksite programmes that encourage 
PA and provide a set time for PA during work 
hours should be considered. Improving stairway 
access and appeal, potentially in combination 
with “skip-stop” elevators that skip some floors 
should be considered. 
IIa C 
Promoting worksite fitness centres should be 
considered.  
IIa C 520 
Community 
settings 
Health care providers should consider inquiring 
about PA in every medical encounter and adding 
it to the record. In addition, they should consider 
to motivate the individual and promote PA. 
IIa C 515, 523 
  Improved accessibility of recreation and PA 
spaces and facilities (e.g. building of parks and 
playgrounds, increasing operating hours, use of 
school facilities during non-school hours), 
improved walkability should be considered. 
IIa C 515, 523 
 Improved neighbourhood aesthetics (to increase 
activity in adults) should be considered.  
IIa C 515, 523 
GPs = general practitioners; PA = physical activity. 3204 
aClass of recommendation. 3205 
bLevel of evidence. 3206 
cReference(s) supporting recommendations. 3207 
 3208 
In most countries the majority of adults and children do not achieve the minimum activity 3209 
levels recommended by health organizations: every person should engage in moderate 3210 
exercise for at least 150 minutes per week and/or vigorous activity for at least 75 minutes per 3211 
week or an equivalent thereof.260, 523 For population-based prevention, the statement of “seven 3212 
best investments”515 gives the universal and comprehensive advice to promote PA.515 3213 
Specific national guidelines developed for PA include frequency, intensity, time (duration), 3214 
and type of activity (the FITT acronym) which can influence legislative initiatives, such as 3215 
“active cities” with bicycle lanes and walking paths and re-allocation of road space.  3216 
Focused media and educational campaigns can initiate physical activities.522 Recent 3217 
campaigns from sports medicine societies endorsed PA prescriptions from the GP 3218 
(www.efsma.eu). The PA should be assessed at every medical encounter. 3219 
A simple strategy for increasing daily exercise is to encourage the use of stairs rather than the 3220 
elevator or escalator, along with signage directing people to the stairs and health promotion 3221 
materials endorsing the positive effects of stair climbing.519  3222 
Interestingly, an increase in fuel prices may reduce car driving and increase active commuting 3223 
for those who live within reasonable walking or biking distances with exception of diseased 3224 
or disabled persons.499  3225 
PA education should be started in pre-school/kindergarten and continued for all levels of 3226 
primary and secondary education. For school education, a multicomponent intervention 3227 
should focus on improving life-long PA by trained teachers. At least 3 hours per week, better 3228 
60 minutes daily, sports or PA should be performed during school time.514 Regular activity 3229 
also improves cognitive competence for learning.516, 524 This activity can be supplemented by 3230 
active commuting to school and supervised walking routes to and from school with less 3231 
reliance on buses.517 3232 
Workplaces may offer different opportunities for PA promotion. Some larger companies offer 3233 
a fitness centre on company grounds without fees for employees. Workplace-based 3234 
interventions may increase regular physical exercise for employees but results demonstrate 3235 
that a high proportion of workers do not participate.525 Therefore, supervisors and managers 3236 
should endorse workplace interventions by encouraging employees to undertake PA . 3237 
Improved accessibility to recreation and exercise facilities with increased operating hours and 3238 
utilizing community resources such as school playgrounds may increase regular PA in all age 3239 
groups and reduce socio-economic inequality in access.520 3240 
 3241 
Gaps in evidence 3242 
• Sustainability and long-term outcomes of population-based actions to promote PA.  3243 
 3244 
3c.4 Population-based approaches to smoking and other tobacco products  3245 
 3246 
Key messages 3247 
• Adolescence is the most vulnerable period for uptake of smoking with lifelong 3248 
consequences. 3249 
• High taxes on all tobacco products is the most effective policy measure to reduce smoking 3250 
uptake by the young. 3251 
• Restrictions on smokeless tobacco due to strong evidence of harm.  3252 
• Restrictions on electronic cigarettes due to uncertainty regarding safety and effect 3253 
• Plain packaging is effective to reduce tobacco consumption. 3254 
• Restrictions on advertising, promotion and sponsorship by the tobacco industry. 3255 
• A goal would be to make a common European decision to achieve a smoking-free Europe 3256 
from 2030. 3257 
 3258 
Recommendations for population-based approaches to smoking and other tobacco 3259 
products 3260 
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Risk factor Recommendations Classa Levelb Refc 
Governmental 
restrictions and 
mandates 
Banning smoking in public places is 
recommended to prevent smoking and to 
promote smoking cessation. 
I A 
 
498  
 
Banning smoking in public places, outside 
public entrances, workplaces, in restaurants 
and bars is recommended to protect people 
from passive smoking. 
I 
 
A 499, 526 
 
Prohibit sales of tobacco products to 
adolescents are recommended. 
I A 498 
Banning of tobacco vending machines is 
recommended. 
I A 498 
 
Restrictions on advertising, marketing and 
sale of smokeless tobacco are recommended. 
I A 527-530 
Complete ban on advertising and promotion of 
tobacco products are recommended. 
I 
 
B 
 
499 
 
Reduced density of retail tobacco outlets in 
residential areas, schools and hospitals is 
recommended. 
I B 499 
 
Harmonization of border sales and tax free 
sales of all tobacco products is recommended. 
I B 498 
Restrictions on advertising, marketing and 
sale of electronic cigarettes should be 
considered. 
IIa A 
 
531, 532 
 
Media and 
education 
 
 
 
Telephone and internet based lines for 
cessation counselling and support services are 
recommended. 
I A 499 
 
Media and educational campaigns as part of 
multicomponent strategies to reduce smoking 
and increase quit rates, reduce passive 
smoking and use of smokeless tobacco are 
recommended  
I A 499 
Media and educational campaigns 
concentrating solely on reducing smoking, 
increasing quit rates, reducing passive 
smoking and the use of smokeless tobacco 
should be considered  
IIa 
 
B 
 
498 499 
 
Labelling and 
information 
Cigarette package pictorial and text warnings 
are recommended. 
I B 498 499 
 
Plain packaging is recommended. I B 498, 499 
Economic 
incentives 
Higher taxes and prices on all tobacco 
products are recommended. 
I A 498, 499 
 
Schools 
 
 
Banning smoking in school, pre-school and 
child care to protect from passive smoking is 
recommended. 
I A 498 
Promotion and teaching of a healthy lifestyle IIa B 499 
including tobacco free life should be 
considered in all schools. 
Workplaces 
 
 
Workplace specific bans on smoking to reduce 
passive smoking and increase quit rates are 
recommended. 
I A 498 499 
 
Workplace policy on healthy choices 
including tobacco cessation/prevention is 
recommended. 
I A 499 
Community 
settings 
 
 
It is recommended that health personnel, 
caregivers and school personnel set an 
example by not smoking or using tobacco 
products at work. 
I A 498 499 
 
It is recommended to advise pregnant women 
to be tobacco-free during pregnancy. 
I A 527 
It is recommended to advise parents to be 
tobacco-free when children are present. 
I A 498, 499 
It is recommended to advise parents to never 
smoke in cars and private homes. 
I A 498 499 
Residence-specific restrictions on smoking 
should be considered. 
IIa B 499 
aClass of recommendation. 3261 
bLevel of evidence. 3262 
cReference(s) supporting recommendations. 3263 
 3264 
The WHO Framework Convention on Tobacco Control recommends smoke-free laws: 3265 
protecting people from tobacco smoke and banning smoke in public places, warning about the 3266 
dangers of tobacco, raising taxes on tobacco, and enforcing advertising bans.526 Children and 3267 
low socio-economic groups are sensitive to population-based tobacco intervention. Passive 3268 
smoking increases CVD risk,498, 499 more so in women than in men.533 All smoking, including 3269 
smoking a waterpipe, is deleterious. Smokeless tobacco (in Europe usually snus, a moist 3270 
powder tobacco placed under the upper lip) increases the risk of fatal CVD events 528-530, and 3271 
use of snus during pregnancy increases the risk of stillbirth.534 There is no evidence that snus 3272 
increases smoking cessation more than nicotine replacement products or medication. Many 3273 
smokers use electronic cigarettes (e-cigarettes) to quit. There are many unanswered questions 3274 
about their safety, efficacy for harm reduction and cessation, and impact on public health. 3275 
They should be subjected to the same restrictions as tobacco or pharmaceutical products.531, 3276 
532 International legislation should be harmonized to prevent a new tobacco epidemic.498 3277 
Multi-component strategies are best. Advertising bans reduce tobacco consumption, and mass 3278 
media campaigns reduce smoking uptake by teenagers and increase adult quitting.498 Media 3279 
and educational campaigns in schools reduce smoking and promote smoking cessation. 3280 
Editors should increase the coverage of tobacco and health in the media.535 Telephone or 3281 
internet-based cessation-support reduces tobacco use.499  3282 
Packs with pictorial and text warnings raise awareness of tobacco dangers.498 Plain and 3283 
standardized packaging without brand labels enhances the effectiveness.  3284 
Higher taxes reduce tobacco consumption and quitting, particularly among youth and lower 3285 
socio-economic groups.498, 499  3286 
School-based smoking bans should be implemented.499 Smoking bans at workplaces reduce 3287 
exposure to passive smoking, decrease smoking, and increase quitting rates.498 Tobacco outlet 3288 
density around homes, hospitals and schools should be reduced. Pregnant women should 3289 
avoid tobacco, and parents should be tobacco-free when children are present. Health 3290 
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personnel, caregivers and teachers must set an example by not using tobacco products at 3291 
work. 3292 
 3293 
Gaps in evidence 3294 
• Effect of school-based smoking restrictions.  3295 
• Effect of plain packaging. 3296 
• Health harm of electronic cigarettes.  3297 
• More evidence on environmental smoking is needed as smoke particles may remain in 3298 
rooms for many years. 3299 
 3300 
3c.5 Alcohol abuse protection 3301 
Key messages 3302 
• Excessive alcohol intake is associated with increased CV mortality and alcohol ranks as 3303 
the second-leading cause of DALYs lost in high-income countries. 3304 
• The interventions for addressing the harmful use of alcohol are cost-effective with good 3305 
return, i.e. increasing alcoholic beverage excise taxes, restricting access to alcoholic 3306 
beverages, and implementing comprehensive restrictions and bans on advertising and 3307 
promotion of alcoholic beverages. 3308 
 3309 
Recommendations for protecting against alcohol abuse 3310 
 Recommendations Classa Levelb Refc 
Governmental 
restrictions 
and mandates 
Regulating physical availability of alcoholic 
beverages is recommended, including minimum 
legal purchase age, restrictions on outlet density and 
time and place of sales, public health oriented 
licensing systems, and governmental monopolies of 
retail sales . 
I B 536-540,536, 
537  
 
Drink-driving countermeasures are recommended 
such as lowered blood alcohol concentration limits 
and “zero tolerance”, random breath testing and 
sobriety check points.  
I B 538, 541 
 
Implementing comprehensive restrictions and bans 
on advertising and promotion of alcoholic 
beverages is recommended. 
I C 536 
Media and 
education 
Educational information campaigns may be 
considered to create awareness on the hazardous 
effects of alcohol. 
IIb B 536, 542 
Labelling and 
information 
Labelling alcohol with information on caloric 
content and health warning messages of the harmful 
effects of alcohol may be considered. 
IIb 
 
B 536, 542 
Economic 
incentives 
Taxes on alcoholic beverages are recommended. I B 537 
Schools At every school, pre-school and day care a multi-
component, comprehensive and coherent education 
may be considered to prevent alcohol abuse. 
IIb B 536, 542 
 
Workplaces At every company a coherent and comprehensive 
health policy and nutritional education on 
stimulating the health of employees are 
recommended, including limiting excessive alcohol 
intake. 
I 
 
B 498 
Community 
setting 
Support and empower primary care to adopt 
effective approaches to prevent and reduce harmful 
use of alcohol are recommended. 
I B 543 
Enacting management policies relating to 
responsible serving of alcoholic beverages should 
be considered to reduce the negative consequences 
of drinking. 
IIa B 538, 542 
Planning of location and density of alcohol 
purchasing outlets and other catering establishments 
should be considered. 
IIa C  
aClass of recommendation. 3311 
bLevel of evidence. 3312 
cReference(s) supporting recommendations. 3313 
 3314 
At the population level, alcohol consumption is associated with multiple health risks that 3315 
clearly outweigh any potential benefits. In 2012, about 3.3 million deaths, or 5.9% of all 3316 
global deaths, and 139 million DALYs, or 5.1% of the global burden of disease and injury, 3317 
were attributable to alcohol consumption. The highest numbers of deaths are from CVDs, 3318 
with 33.3% of the alcohol-attributable deaths due to CVDs.538 Ischaemic heart disease 3319 
mortality is 65% higher in men heavy drinkers and more than double in women heavy 3320 
drinkers.544  3321 
The relationship between alcohol consumption and CAD and cerebrovascular diseases is 3322 
complex. It depends on both the level and the pattern of alcohol consumption. Low alcohol 3323 
consumption, ranging from 1–3 alcohol units per day (a unit equates to about 80 mL of wine, 3324 
250 mL of normal strength beer, and 30–50 mL of spirits), in some segments of the 3325 
population is associated with the lowest all-cause mortality, largely due to lower coronary 3326 
mortality.545  3327 
SBP and DBP levels increase as alcohol consumption increases above 3 units per day and 3328 
similarly, the risk of cardiac arrhythmias, cardiomyopathy, sudden death, and haemorrhagic 3329 
stroke.546 The pattern of alcohol use has an effect on CVD risk; binge drinking is associated 3330 
with a higher risk of sudden death and stroke.547 3331 
The following strategies and interventions have the highest level of effectiveness to prevent 3332 
the harmful use of alcohol: age limits for sale and serving,539 drink-driving strategies,541 3333 
government retail monopolies for sale and reducing the hours of sale of alcohol,540 banning 3334 
alcohol advertising, promotion, and sponsorship of events,536 increase in retail price.537, 542 3335 
Labelling alcohol with information on caloric content and health warning messages of the 3336 
harmful effects of alcohol has been shown to have a limited effect 542. 3337 
Alcohol regulations in policies on workplaces, educational centres, and schools are 3338 
effective.536  3339 
Brief intervention in primary care to prevent alcohol abuse has been shown to be effective.543 3340 
In the community, excessive alcohol intake can be limited by restrictions in the number and 3341 
opening hours of outlets, and by increasing the minimum age for sales and servings.498 3342 
 3343 
Gaps in evidence 3344 
• Better quality evidence is needed with regard to potential confounding in studies on the 3345 
effects of alcohol consumption. 3346 
 3347 
3c.6 Healthy environment 3348 
 3349 
Air pollution contributes to the risk of respiratory and CV diseases.548 Important sources of 3350 
fine particles in the EU are motorized road traffic, power plants, and industrial and residential 3351 
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heating using oil, coal or wood. Up to a third of Europeans living in urban areas are exposed 3352 
to levels exceeding EU air quality standards. In particular, young and old individuals and 3353 
subjects with a high risk of CVD are more prone to the detrimental effects of air pollution on 3354 
the circulation and the heart. 3355 
The EU Commission released a policy package to be implemented by the year 2030 with 3356 
measures to reduce harmful emissions from traffic, energy plants and agriculture. Further 3357 
efforts to reduce air pollution should be stimulated and taken by national governments, e.g. 3358 
through appropriate and effective legislation. Patient organisations and health professionals 3359 
have an important role to play in supporting educational and policy initiatives and provide a 3360 
strong voice in the call for action at the governmental level.548 3361 
The media can inform the population on the quality of the air (e.g. by apps) and by providing 3362 
smog alerts. Information on patients’ behaviour during smog is warranted. Economic 3363 
incentives like reduced taxes on electrical and hybrid cars can contribute to the improvement 3364 
of the air quality. New houses and schools can preferably be built in areas remote from 3365 
highways and polluting industries.  3366 
 3367 
 3368 
4a. Where to intervene at the individual level 3369 
 3370 
The question of “where” prevention should take place requires only a simple answer: 3371 
everywhere! Prevention of CVD should be valued and implemented at all levels of society 3372 
and in all healthcare settings. This should include increased spending on prevention in 3373 
healthcare and on actions that make communities healthier. All clinicians should also consider 3374 
prevention and promotion of healthy lifestyles as a professional responsibility with individual 3375 
patients and by supporting policies that promote healthier lifestyles. Patients should also be 3376 
empowered and have the knowledge and support to make informed decisions, and to demand 3377 
robust prevention efforts from healthcare groups and society. 3378 
 3379 
4a.1 Clinical settings and stakeholders 3380 
4a.1.1 Cardiovascular disease prevention in primary care  3381 
Key messages 3382 
• The prevention of CVD should be delivered in all healthcare settings including primary 3383 
care.  3384 
• Where appropriate, all health professionals should assess CV risk factors to determine 3385 
individual total CV risk score. 3386 
• GPs and nurses should work together as teams to provide the most effective 3387 
multidisciplinary care.  3388 
 3389 
Recommendation for cardiovascular disease prevention in primary care 3390 
Recommendation Classa Levelb 
It is recommended that GPs, nurses and allied health professionals within 
primary care deliver CVD prevention for high-risk patients. I C 
aClass of recommendation. 3391 
bLevel of evidence. 3392 
 3393 
The physician in general practice is the key person to initiate, coordinate, and provide long-3394 
term follow-up for CVD prevention. In most countries GPs deliver > 90% of consultations 3395 
and provide most public health medicine, including preventive care and chronic disease 3396 
monitoring. In the case of CVD prevention they have a unique role in identifying individuals 3397 
at risk of CVD and assessing their eligibility for intervention based on their risk profile. How 3398 
to maximise attendance rates and adherence, particularly in those who are at highest risk, 3399 
remains an issue. 3400 
As mentioned in section 2.2, a systematic approach is recommended to risk assessment, 3401 
giving priority to persons with a priori higher risk (such as family history of premature CVD, 3402 
presence of hypertension, etc); opportunistic screening to persons below the age of 40 years 3403 
without CV risk factors is not recommended.  3404 
Intensive and structured intervention in general practice contributes to the prevention of 3405 
recurrent CV events and reduces hospital admission in CAD patients.549  3406 
The successful implementation of CVD prevention guidelines relies heavily on GPs providing 3407 
risk factor evaluation, intervention, and patient education. However, CV targets in general 3408 
practice are often not achieved. The EUROASPIRE III survey (primary prevention arm) 3409 
showed that the lifestyle of people being treated as high CV risk – defined as patients treated 3410 
with BP and lipid lowering drugs as well as anti-diabetes drugs - showed much persistent 3411 
smoking and a high prevalence of both obesity and central obesity. BP, lipid, and glucose 3412 
control is poor with most patients not achieving the targets defined in the prevention 3413 
guidelines. 5  3414 
Surveys done among GPs and physicians in several European regions found that most were 3415 
aware of the European guidelines on CVD prevention, but that only 36–57% were using the 3416 
guidelines in practice, and less than half performed comprehensive risk assessments. The 3417 
main barrier was time, but GPs also cited that there were too many guidelines, unrealistic 3418 
targets for risk factor control, a preference for using their own experience, and lack of 3419 
knowledge regarding comprehensive risk assessment.550-553. Online resources, mobile apps, 3420 
pocket guidelines and summary cards may contribute as a means to overcome the 3421 
implementation challenge. 3422 
Evidence for an effective role for nurses in primary care exists. A study of nurse-coordinated 3423 
preventive cardiology programmes for primary prevention of CVD compared to routine 3424 
practice – conducted in a matched, paired-cluster RCT in six pairs of general practices in six 3425 
European countries – showed more high-risk patients achieved the lifestyle and risk factor 3426 
targets in the nurse-coordinated arm compared with usual care.554 3427 
In 2009, a randomized trial in the Netherlands on CVD risk management and preventive care 3428 
found that practice nurses achieved results equal to GPs after 1 year follow-up.555). A clinical 3429 
trial (n = 525) in the USA has also shown that advanced practice nurses working with 3430 
community health workers can achieve significant improvements in CV risk factors (BP, 3431 
cholesterol, DM control) in underserved inner-city populations compared to enhanced usual 3432 
care, and was cost-effective.556  3433 
 3434 
Gaps in evidence 3435 
• Further research is needed in order to explore what is the best strategy to improve 3436 
implementation of CVD prevention guidelines in general practice, taking into account 3437 
heterogeneity among countries in terms of health systems and local resources.  3438 
  3439 
 3440 
4a.1.2 Acute hospital admission setting 3441 
 3442 
Recommendations for CVD prevention strategies in the acute hospital admission setting 3443 
Recommendations Classa Levelb Refc 
It is recommended to implement strategies for prevention in 
CVD patients, including lifestyle changes, risk factor 
I  A 302, 557 
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management and pharmacological optimization, after an acute 
event before hospital discharge to lower risk of mortality and 
morbidity. 
aClass of recommendation. 3444 
bLevel of evidence. 3445 
cReference(s) supporting recommendations. 3446 
 3447 
The importance of starting appropriate prevention before hospital discharge cannot be over-3448 
emphasised, as prevention treatment tends to decrease rather than increase post-3449 
hospitalization, with proportions of patients on appropriate therapy declining over time and 3450 
patients not reaching risk factor targets.297, 558  3451 
The acute care team should: (1) emphasize the importance of the preventive measures directly 3452 
to the patient, because failure to do so may suggest that these measure are valueless; and (2) 3453 
interact with the other health professionals, e.g. physicians, nurses, to ensure that prevention 3454 
strategies initiated during hospitalization are sustained and supported in other settings.  3455 
Thus patients while in acute care should receive appropriate interventions to optimize 3456 
prevention strategies. These include full clinical assessment to guide optimization of medical 3457 
therapy, individualised behavioural education for risk factor modification, and referral to 3458 
exercise-based CR.  3459 
Education should be person-centred with full participation of patients and carers, providing 3460 
explanations for each intervention, while early mobilization and physical conditioning 3461 
programmes should vary according to the individual’s clinical status.  3462 
 3463 
4a.1.3 Specialized prevention programmes  3464 
 3465 
Recommendations for specialized prevention programmes 3466 
Recommendations Classa Levelb Refc 
Participation in a CR programme for patients hospitalized 
for an acute coronary event or revascularization, and for 
patients with HF, is recommended to improve patient 
outcomes 
I  A 559, 560 
Preventive programmes for therapy optimisation, adherence 
and risk factor management are recommended for stable 
patients with CVD to reduce disease recurrence  
I B 561-564 
Methods to increase referral to and uptake of CR should be 
considered such as electronic prompts or automatic 
referrals, referral and liaison visits, structured follow-up by 
physicians, nurses or therapists, and early starts to 
programmes after discharge. 
IIa B 561, 562 
Nurses and allied health professional led programmes 
should be considered to deliver CVD prevention across 
healthcare settings 
IIa B 554-556, 565 
CR=cardiac rehabilitation. CVD= cardiovascular disease; HF = heart failure. 3467 
aClass of recommendation.  3468 
bLevel of evidence. 3469 
cReference(s) supporting recommendations. 3470 
 3471 
Specialized prevention programmes are delivered as CR or other prevention programmes for 3472 
all patients with CVD or at high risk for CVD. The core components and goals of CR have 3473 
been standardized,566 but the structure, length and type of the programme offered differs 3474 
widely by country, affected by national guidelines and standards, legislation, and payment 3475 
factors.567  3476 
CR is a comprehensive programme involving exercise training, risk factor modification, 3477 
education and psychological support. An overview of six Cochrane systematic reviews of CR 3478 
(148 RCTs, n = 98,093) concluded that for low to moderate risk patients with HF, or who are 3479 
post-MI or revascularization, exercise-based CR decreased hospital admissions and improved 3480 
health-related quality of life (HRQoL) compared to usual care, and may reduce mortality 3481 
longer-term.559 A limitation of current reviews is the inclusion of trials prior the modern 3482 
treatment, differing patients groups, and heterogeneous programmes of CR. Thus more 3483 
research is needed to determine the optimal intervention. A number of recent controlled 3484 
cohort studies have found a survival benefit for patients receiving CR compared to no CR. An 3485 
on-going meta-analysis of CR in the modern era may provide more definitive results 3486 
regarding patients programmes and outcomes. At present the benefit of CR appears to be both 3487 
through direct physiological effects of exercise training, and CR’s effects on risk factors, 3488 
behaviours and mood.559 CR also provides an opportunity for social support and to screen 3489 
patients for psychosocial risk factors.  3490 
Referral and participation in CR varies widely across countries: many CR programmes do not 3491 
include unstable patients, patients with HF, devices or PAD, and referral and retention of 3492 
women and older, higher risk patients remain sub-optimal.567, 568 Referrals to CR can be 3493 
increased through electronic prompts or automatic referrals, while patient uptake may be 3494 
improved by structured follow-up by nurses or therapists and early starts to programmes after 3495 
discharge.561, 562, 569 3496 
Nurse-led programmes can also deliver effective preventive programmes in patients with 3497 
CVD. The EUROACTION trial used a 16-week family centred approach that led to healthier 3498 
lifestyle changes in activity and diet, and more effective control of risk factors in patients and 3499 
their partners compared to usual care.554 The Randomised Evaluation of Secondary 3500 
Prevention by Outpatient Nurse Specialists (RESPONSE) trial randomized patients after ACS 3501 
to usual care or to nurse-coordinated prevention intervention of outpatient visits over 6 3502 
months: at 1 year patients in the intervention group had better control of risk factor, fewer 3503 
readmissions and emergency department visits, and a predicted relative risk of mortality 3504 
(using SCORE) 17% lower than the control group.565 3505 
 3506 
4a.1.4 Alternative rehabilitation models  3507 
Key message 3508 
• Home-based rehabilitation with and without tele-monitoring holds promise for increasing 3509 
participation and supporting behavioural change. 3510 
 3511 
CR has predominantly been implemented in hospitals or in community centres with trained 3512 
staff. Home-based rehabilitation programmes have the potential to increase patient 3513 
participation by offering greater flexibility and options for activities. A systematic review of 3514 
12 trials (n = 1978 patients) of home versus centre-based rehabilitation found no difference in 3515 
outcomes, adherence or in cost between the two in the short-term and up to 24 months.570 The 3516 
majority of studies recruited low-risk, predominantly male patients and activities were self-3517 
regulated with intermittent support usually by telephone. Home-based rehabilitation thus 3518 
offers an alternative for some patients, although relatively few programmes in Europe offer 3519 
it.567.  3520 
4a.1.4.1 Tele-rehabilitation 3521 
Tele-rehabilitation, i.e. the use of electronic communication and information technologies to 3522 
provide and support remote clinical care after an acute event, has been found more effective 3523 
than usual care in achieving behavioural change, and as equally effective as a CR 3524 
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programme.561, 571 Simple tele-monitoring including ECG transmission by telephone in 3525 
patients with CVD has been found to be safe and acceptable to patients, and to result in 3526 
improvements in physical capacity.572 Recent studies are also using smartphone applications 3527 
for monitoring and delivery of content and support with improvements in uptake, adherence 3528 
and completion of rehabilitation in younger patients.573 3529 
Thus tele-rehabilitation could further widen participation to more patients, and provide 3530 
monitoring and greater individualized behavioural support, but large-scale randomized trials 3531 
are needed. 3532 
4a.1.5 Maintaining lifestyle changes 3533 
Maintaining healthy behaviours after a specialized prevention programme is problematic for 3534 
many patients.  3535 
Specialized prevention programmes and patient consultations should use a patient-centred 3536 
approach that focuses on the patient’s priorities and goals and incorporates lifestyle changes 3537 
within the context of the patient’s life. Behavioural change of personal value to the individual 3538 
is more likely to be maintained (see section 3a.1). 3539 
Longer term support for behaviour change may be needed and community maintenance 3540 
programmes may be useful. In the Global Secondary Prevention Strategies to Limit Event 3541 
Recurrence After MI (GOSPEL) trial, 3241 patients were randomized post-CR programme to 3542 
an intensive multi-factorial intervention over 3 years, or usual care. Patients in the 3543 
intervention group received monthly exercise and counselling sessions for 6 months, then 3544 
every 6 months for 3 years. Compared to usual care, the intervention group had improved PA, 3545 
diet, and total cholesterol maintained throughout the study. The intervention significantly 3546 
decreased several combined end points, such as CV mortality plus non-fatal MI and stroke by 3547 
33%, cardiac death plus non-fatal MI by 36%, and non-fatal MI by 48% compared to usual 3548 
care 574.  3549 
 3550 
Gaps in evidence 3551 
• The optimal CR programme in the era of modern cardiology, and the incremental benefits 3552 
of various components of CR programmes, especially for under-served patient groups. 3553 
• Alternative and cost-effective models of CR are needed to ensure participation globally, 3554 
including low and middle-income countries. 3555 
 3556 
 3557 
4a.2 How to monitor preventive activities 3558 
Key message 3559 
• Standards of performance in CVD prevention may serve as vehicles to accelerate 3560 
appropriate translation of scientific evidence into clinical practice.  3561 
 3562 
Recommendation for monitoring preventive strategies 3563 
Recommendation Classa Levelb 
Systematically monitoring the process of delivery of cardiovascular 
disease prevention activities as well as outcomes may be considered. 
IIb C 
aClass of recommendation. 3564 
bLevel of evidence. 3565 
 3566 
Candidates for measures of performance are some of those processes of care that are 3567 
recommended by the Guideline either as Class I, which identifies recommended 3568 
procedures/treatments, or Class III, which identifies procedures/treatments that are not 3569 
recommended.  3570 
The development of standards of performance involves identification of a set of measures that 3571 
target a specific patient population observed over a particular time period. Thus, these 3572 
performance measures are aimed at any clinician or healthcare professional who sees adult 3573 
subjects (age 18 years and older) at risk for CVD. Table 18 provides examples of prevention 3574 
of CVD performance measurement. Detailed specification for each performance measure 3575 
including the numerator, denominator, period of assessment, method of reporting, and sources 3576 
of data, should be developed at the local level. An optimal target of 100% is recommended for 3577 
all standards. If this is not achievable an interim local target could be set.  3578 
 3579 
Table 18 Examples of prevention of cardiovascular disease performance measurement  3580 
• Subjects identified as tobacco users who received cessation intervention. 
• Subjects for whom sedentary habits have been recorded and are counselled to increase 
PA. 
• Subjects for whom unhealthy diet/nutritional habits have been recorded and are 
counselled to improve diet. 
• Subjects for whom weight and BMI and/or waist circumference is documented above 
normal limits and are counselled on weight management.  
• Subjects >40 years old with at least one lipid profile performed within the past 5 years. 
• Patients <60 years old and with hypertension (not DM) who had a recorded BP 
reading at their most recent visit of <140/90 mm Hg 
• Patients with DM who had a recorded HbA1c <7.0% (<53 mmol/mol) at the most 
recent visit. 
• Patients with a qualifying event/diagnosis who have been referred to an in-patient CR 
or out-patient CR programme before hospital discharge. 
BMI = body mass index; BP = blood pressure; CR = cardiac rehabilitation; HbA1c = glycated haemoglobin; PA 3581 
= physical activity. 3582 
4b. Where to intervene at the population level 3583 
 3584 
Key message  3585 
• Governmental and non-governmental organisations (NGOs) such as heart foundations and 3586 
other health promoting organisations can be a powerful force in promoting a healthy 3587 
lifestyle and healthy environments in CVD prevention.  3588 
 3589 
4b.1 Government and public health 3590 
 3591 
Recommendations for population-based interventions to promote CV health are described in 3592 
section 3c. These preventive strategies to address unhealthy diets, smoking and physical 3593 
inactivity must take place at different levels. At each level, different clusters of stakeholders 3594 
are concerned and responsible for the interventions498: 3595 
• International level (e.g. WHO, World Trade Organization, EU); 3596 
• National level (e.g. government departments, health authorities, health promoting 3597 
agencies, consumer organizations, health NGOs, industries); 3598 
• Regional and local level (e.g. local governmental departments, communities, schools, 3599 
workplaces, health professionals, catering sector, retailers, NGOs). 3600 
At the EU level as well as at the level of national governments, legislation should be 3601 
developed on, for example, the nutritional composition of foods, nutrition labelling, smoke-3602 
free policies and environments, restrictions on marketing of unhealthy foods, alcohol and 3603 
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tobacco products, and environments that encourage PA in everyday life.312 Also policy 3604 
measures to reduce air pollution should be developed. Both levels also may use economic 3605 
instruments like taxes and subsidies to support strategies on food and nutrition, tobacco and 3606 
alcohol. It is not necessarily exclusively the responsibility of governments to ensure the 3607 
availability of and accessibility to PA opportunities and healthy foods: this should be a joint 3608 
effort by government, industry and businesses. Health authorities should monitor 3609 
improvements and if voluntary efforts by the industry prove inadequate, governments must 3610 
intervene. 3611 
4b.2 Non-governmental organizations  3612 
NGOs are important partners to healthcare workers in promoting CV prevention and 3613 
advocates for the development and maintenance of public health policies.  3614 
Several Brussels based NGOs aim at improving CV health of the public and patients, 3615 
including EHN, health and medical professionals (ESC, European Chronic Disease Alliance 3616 
(ECDA), and consumer organizations (Bureau Européen des Unions de Consummateurs 3617 
(BEUC). 3618 
CV patients’ organizations provide their patient members with the opportunity to obtain 3619 
support from their peers. They produce patient information in the form of booklets and web-3620 
based materials and promote CR. 3621 
Stakeholders such as NGOs and health professionals (e.g. cardiologists, internists and GPs) 3622 
have a responsibility in agenda setting and monitoring interventions, and can initiate mass 3623 
media campaigns to improve health.  3624 
In creating healthy and active environments, especially in schools, workplaces and the 3625 
community, stakeholders such as teachers and parent organizations, the catering sector, 3626 
employers organizations, trade unions, sport clubs and fitness centres, organizations 3627 
promoting cycling, walking, public transport, or involved in urban planning and mobility, can 3628 
play a role. An example is the French EPODE-project aimed at reducing overweight in 3629 
children 505.  3630 
 3631 
3632 
Figure list 3633 
1. SCORE chart: 10-year risk of fatal CVD in populations at high CVD risk based on the 3634 
following risk factors: age, sex, smoking, systolic blood pressure, total cholesterol. CVD 3635 
= cardiovascular disease; SCORE = Systematic Coronary Risk Estimation.  3636 
2. SCORE Chart: 10-year risk of fatal CVD in populations at low CVD risk based on the 3637 
following risk factors: age, sex, smoking, systolic blood pressure, total cholesterol. CVD 3638 
= cardiovascular disease; SCORE = Systematic Coronary Risk Estimation. 3639 
3. Relative risk chart. Conversion of cholesterol: mmol/L mg/dL: 8 = 310, 7 = 270, 6 = 3640 
230, 5 = 190, 4 = 155. 3641 
4. SCORE chart (for use in high risk European regions) illustrating how the approximate risk 3642 
age can be read off the chart. SCORE = Systematic Coronary Risk Estimation. 3643 
 3644 
Web Figures 3645 
A. Predicted vascular deaths avoided over 5 years from reductions in LDL-C with statin 3646 
treatment at different levels of CVD risks  3647 
B. Lifetime risk calculator based on the JBS3 web-based tool  3648 
C. Modified World Health Organization (WHO) smoking cessation algorithm. 3649 
D. How can governments support healthy food preferences? 3650 
  3651 
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Table list  3652 
1. Impact of combinations of risk factors on risk  3653 
2. Current cardiovascular disease risk estimation systems 3654 
3. Advantages and limitations in using the SCORE risk charts 3655 
4. Examples of risk modifiers that are likely to have reclassification potential  3656 
5. Risk categories 3657 
6. Risk factor goals and target levels for important cardiovascular risk factors 3658 
7. Core questions for the assessment of psychosocial risk factors in clinical practice 3659 
8. Principles of effective communication to facilitate behavioural change 3660 
9. Ten strategic steps to facilitate behaviour change  3661 
10. Classification of physical activity intensity and examples of absolute intensity levels 3662 
11. The “Five As” for a smoking cessation strategy for routine practice 3663 
12. Healthy diet characteristics 3664 
13. Possible intervention strategies as a function of total cardiovascular risk and low-3665 
density lipoprotein cholesterol level. 3666 
14. Definition and classification of blood pressure levels 3667 
15. Blood pressure thresholds for definition of hypertension with different types of blood 3668 
pressure measurement 3669 
16. Clinical indications for the use of out-of-office blood pressure measurements (home 3670 
blood pressure measurement, ambulatory blood pressure measurement) 3671 
17. Drugs to be preferred in specific conditions 3672 
18. Examples of prevention of cardiovascular disease performance measurement 3673 
 3674 
Web Table 3675 
A. Table for different risk factor combinations for more accurate estimation of risk ages  3676 
B. Self-assessment questionnaires PAR-Q & YOU 3677 
C. World Health Organization classification of body weight according to body mass 3678 
index in adults  3679 
D. Measures of general obesity and abdominal adiposity 3680 
E. Selected drugs that may increase risk of myopathy and rhabdomyolysis when used 3681 
concomitantly with statin (CYP3A4 inhibitors/substrates or other mechanisms) 3682 
F. Reasons for medication non-adherence according to the World Health Organization 3683 
3684 
Abbreviation list 3685 
ABI  ankle–brachial (blood pressure) index 3686 
ABPM  ambulatory blood pressure monitoring 3687 
ACCORD Action to Control Cardiovascular Risk in Diabetes  3688 
ACE-I  angiotensin-converting enzyme inhibitor 3689 
ACS  acute coronary syndromes 3690 
ADVANCE Action in Diabetes and Vascular disease: PreterAx and Diamicron MR 3691 
Controlled Evaluation  3692 
AF  atrial fibrillation 3693 
AMI  acute myocardial infarction 3694 
apoA1  apolipoprotein A1  3695 
apoB  apolipoprotein B 3696 
ARB  angiotensin receptor blocker 3697 
BEUC  Bureau Européen des Unions de Consummateurs 3698 
BMI  body mass index (weight(kg)/height(m2) 3699 
BP  blood pressure 3700 
CAC  coronary artery calcium  3701 
CAD  coronary artery disease 3702 
CAPRIE Clopidogrel versus Aspirin in Patients at Risk for Ischaemic Events 3703 
CARDS Collaborative Atorvastatin Diabetes Study 3704 
CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilisation, 3705 
Management, and Avoidance 3706 
CI  confidence interval  3707 
CKD  chronic kidney disease 3708 
CR  cardiac rehabilitation 3709 
CT  computed tomography 3710 
CTT  Cholesterol Treatment Trialists' Collaboration 3711 
CURE  Clopidogrel vs. Placebo in Patients with ACS without ST-segment elevation 3712 
CV  cardiovascular 3713 
CVD  cardiovascular disease 3714 
DALYs  disability-adjusted life years 3715 
DASH  Dietary Approaches to Stop Hypertension 3716 
DBP  diastolic blood pressure 3717 
DCCT  Diabetes Control and Complications Trial 3718 
DHA  docosahexaenoic acid 3719 
DM  diabetes mellitus 3720 
DPP-4  dipeptidyl peptidase-4 inhibitors 3721 
eGFR   estimated glomerular filtration rate 3722 
ECDA  European Chronic Disease Alliance 3723 
ECG  electrocardiogram 3724 
ED  erectile dysfunction 3725 
EHN  European Heart Network 3726 
EMA  European Medicines Agency 3727 
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EPA  eicosapentaenoic acid 3728 
EPIC  European Prospective Investigation into Cancer and Nutrition 3729 
EPODE Ensemble Prévenons l'Obésité des Enfants   3730 
ESC  European Society of Cardiology 3731 
EU  European Union 3732 
FDA  Food and Drug Administration (USA) 3733 
FDC  fixed dose combination 3734 
FH  familial hypercholesterolaemia 3735 
GLP-1  glucagon-like peptide 1 3736 
GP  general practitioner 3737 
GOSPEL Global Secondary Prevention Strategies to Limit Event Recurrence After 3738 
Myocardial Infarction 3739 
HbA1c  glycated haemoglobin  3740 
HBPM  home blood pressure measurements 3741 
HDL-C  high-density lipoprotein cholesterol  3742 
HF  heart failure 3743 
HF-ACTION Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training 3744 
HOPE  Heart Outcomes Prevention Evaluation 3745 
HPS  Heart Protection Study 3746 
HRQoL health-related quality of life 3747 
HR  heart rate  3748 
hsCRP  high-sensitivity C-reactive protein 3749 
HYVET Hypertension in the Very Elderly Trial 3750 
ICD  International Classification of Diseases 3751 
IMT  intima–media thickness 3752 
INVEST International Verapamil-Trandolapril Study 3753 
LDL-C  low-density lipoprotein cholesterol 3754 
Lp(a)  lipoprotein(a)  3755 
LV  left ventricle/left ventricular 3756 
LVH  left ventricular hypertrophy 3757 
MET  metabolic equivalent 3758 
MHO  metabolically healthy overweight/obesity 3759 
MI  myocardial infarction 3760 
MUFA monounsaturated fatty acids 3761 
NGO  non-governmental organization 3762 
NHS  National Health Service (UK) 3763 
NICE  National Institute for Health and Care Excellence  3764 
NNT  number needed to treat 3765 
NRI  net reclassification index 3766 
NRT  nicotine replacement therapy 3767 
OASIS Organization to Assess Strategies in Acute Ischemic Syndromes 3768 
ONTARGET ONgoing Telmisartan Alone and in combination with Ramipril Global 3769 
Endpoint Trial 3770 
OSAS  obstructive sleep apnoea syndrome 3771 
PA  physical activity 3772 
PAD  peripheral artery disease 3773 
PLATO Ticagrelor vs. Clopidogrel in Patients with ACS with and without ST-segment 3774 
elevation 3775 
PCOS  polycystic ovary syndrome  3776 
PCSK9 proprotein convertase subtilisin/kexin type 9 3777 
PROactive Prospective Pioglitazone Clinical Trial in Macrovascular Events 3778 
PROGRESS Perindopril Protection Against Recurrent Stroke Study 3779 
PROCAM Prospective Cardiovascular Munster Study 3780 
PWV  pulse wave velocity 3781 
RA  rheumatoid arthritis 3782 
RCT  randomized controlled trial 3783 
RESPONSE Randomised Evaluation of Secondary Prevention by Outpatient Nurse 3784 
Specialists  3785 
RM  repetition maximum 3786 
ROS  reactive oxygen species 3787 
RPE  rating of perceived exertion 3788 
RR  relative risk 3789 
SBP  systolic blood pressure 3790 
SGLT2 Sodium-glucose co-transporter-2 3791 
SNP  single nucleotide polymorphism  3792 
SCORE  Systematic Coronary Risk Estimation 3793 
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels 3794 
TIA   transient ischaemic attack 3795 
TRITON Prasugrel vs. Clopidogrel in Patients with ACS  3796 
UKPDS  United Kingdom Prospective Diabetes Study 3797 
VADT  Veterans Affairs Diabetes Trial 3798 
VALUE Valsartan Antihypertensive Long-Term Use Evaluation 3799 
VLDL  very low-density lipoprotein 3800 
V̇O2  oxygen uptake  3801 
WHO  World Health Organization 3802 
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3b. How to intervene at the individual level: disease specific 5876 
intervention. Atrial fibrillation, coronary artery disease, 5877 
chronic heart failure, cerebrovascular disease, peripheral 5878 
artery disease 5879 
3b.1 Atrial Fibrillation 5880 
Key message 5881 
• Hypertension in atrial fibrillation (AF) patients doubles risk of cardiovascular complications and must 5882 
be treated in all grades 5883 
 5884 
Recommendations for atrial fibrillation 5885 
Recommendations Classa Levelb  Refc 
It is recommended to assess stroke risk by CHA2DS2-VASc score or 
CHADS2 score, bleeding risk (HAS-BLED) and consider antithrombotic 
therapy  
I A (1, 2) 
In patients > 65 years or diabetes screening by pulse palpation, followed 
by ECG if irregular pulse, to detect atrial fibrillation is recommended 
I B (1, 2) 
ECG = electrocardiogram. 5886 
aClass of recommendation. 5887 
bLevel of evidence. 5888 
cReference(s) supporting recommendations. 5889 
3b.1.1 Prevention of cardiovascular complication in atrial fibrillation 5890 
AF is the most common arrhythmia with an estimated lifetime risk of 25%. AF is associated with 5891 
increased risk of death, stroke, heart failure (HF), thromboembolism, cognitive dysfunction, 5892 
hospitalizations and reduced quality of life.(3) AF is associated with about a two-fold increased risk of 5893 
AMI. Twenty per cent of strokes are caused by AF and the stroke risk is about 60% higher in women 5894 
than in men. AF can be readily detected. It is recommended that in patients 65 years or older or in 5895 
diabetes, opportunistic screening by pulse palpation for at least 30 seconds is performed, followed by an 5896 
ECG in those with an irregular pulse.(1, 2)  5897 
Management of AF patients is aimed at preventing severe CVD complications associated with AF and 5898 
relies on antithrombotic therapy with vitamin K antagonist therapy or non-vitamin K antagonist oral 5899 
anticoagulants. Recommendations for antithrombotic therapy should be based on risk factors for stroke 5900 
and thromboembolism in addition to risk of bleeding. Stroke risk assessment with the CHA2DS2-VASc 5901 
score or CHADS2 score include the most common stroke risk factors. A bleeding risk assessment with 5902 
HAS-BLED score is recommended for all AF patients. Residual high risk of death in anticoagulated AF 5903 
patients remains a CVD prevention issue. Regarding rate and rhythm control in AF patients, we refer to 5904 
the Guidelines for the Management of Atrial Fibrillation.(1, 2)  5905 
3b.1.2 Prevention of cardiovascular disease risk factors in atrial fibrillation patients 5906 
Many classic CVD risk factors are risk factors for AF, particularly age, smoking, sedentary habits, 5907 
obesity, hypertension and diabetes.(4) Hypertension and AF often coexist and lead to doubling of all 5908 
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CVD complications and mortality in AF patients. Other clinical conditions associated with AF occurrence 5909 
are hyperthyroidism, obstructive sleep apnoea, chronic kidney disease, inflammation, uric acid, major 5910 
surgery, alcohol and coffee consumption, high endurance physical activity.(3) BP measurement in AF 5911 
patients should be performed with a standard auscultatory BP monitor, because automated BP monitors 5912 
are inaccurate in measuring BP in AF patients. Antihypertensive treatment may contribute to reduce the 5913 
risk in these high risk patients, in addition to antithrombotic therapy. The main goal is BP reduction per 5914 
se, and there is insufficient data to recommend specific drugs. (5) However, ACE-I and ARBs should be 5915 
considered first choice in AF patients,(1) followed by beta-blockers and mineralocorticoid antagonists. 5916 
Obesity and diabetes in AF patients increase CVD risk by creating a pro-thrombotic state. Diabetes is 5917 
included in the score for stroke risk assessment, while obesity is not. It is not known which obesity 5918 
intervention is most cost effective in AF patients. Lifestyle risk interventions in AF patients have largely 5919 
targeted physical activity which should probably be encouraged, but studies have not shown the effect 5920 
of physical activity on CVD in AF patients.(6) Presence of ischaemic heart disease and smoking 5921 
increases the CVD risk despite antithrombotic therapy. Smoking cessation is therefore crucial. Less 5922 
evidence is available on the effects of statins on major CVD outcomes in AF patients. These patients 5923 
should be treated according to the SCORE recommendations and not merely because they have AF.  5924 
3b.1.3 Lone atrial fibrillation  5925 
In AF subjects < 65 years, without heart disease or hypertension (“lone AF”) and without risk factors 5926 
implying antithrombotic therapy, AF is not associated with increased risk of stroke or death and 5927 
antithrombotic therapy is not recommended. Lone AF is a diagnosis of exclusion. The risk of stroke in 5928 
young patients with lone AF increases with advancing age or development of hypertension, underlining 5929 
the importance of regular re-assessment of risk factors over time. (1, 2)  5930 
 5931 
 5932 
3b.2 Coronary artery disease 5933 
Key message 5934 
• Prevention is crucial for short- and long-term outcome in CAD, and it should be started as soon as 5935 
possible, with a multidimensional approach that combines feasibility and efficacy. An appropriate 5936 
discharge planning should be considered. 5937 
 5938 
Recommendations for managing coronary artery disease 5939 
 Recommendations Classa Levelb  Refc 
Patient 
assessment 
Clinical history taking, including the conventional risk factors 
for the development of CAD (such as for example glycaemic 
state) with revision of the clinical course (uncomplicated or 
complicated) of ACS is recommended. 
I A 
 
(7-9) 
Physical examination is recommended, I C (9) 
The ECG is predictive of early risk: It is recommended to 
obtain a 12-lead ECG and to have it interpreted by an 
experienced physician. It is recommended to obtain an 
I B (9-
11) 
 147 
6JTF_Mastercopy_Web 20160105 CONFIDENTIAL DOCUMENT 148 
 
additional 12-lead ECG in case of recurrent symptoms or 
diagnostic uncertainty. 
Additional ECG leads (V3R, V4R, V7–V9) are recommended if 
on-going ischemia is suspected when standard leads are 
inconclusive. 
I C  
A resting transthoracic echocardiogram is recommended in all 
patients for: a) exclusion of alternative causes of angina; b) 
regional wall motion abnormalities suggestive of CAD; c) 
measurement of LVEF for d) evaluation of diastolic function. 
I B (9-
11) 
Chest X-ray should be considered in patients with suspected 
heart failure. 
IIa C  
Arrhythmic burden assessment (ventricular arrhythmias, AF 
and other supraventricular tachy-arrhythmias, and 
bradycardia, AV block, and intra-ventricular conduction 
defects) is recommended. 
I A (7-9, 
12, 
13) 
Ambulatory monitoring should be considered in patients in 
whom arrhythmias are suspected 
IIa C  
Exercise stress testing should be considered to evaluate the 
efficacy of medical treatment or after revascularization, or to 
assist prescription of exercise after control of symptoms.  
IIa B (9, 
14) 
 
Exercise capacity and ischaemic threshold assessment 
should be considered by exercise maximal stress test 
(ergospirometry if available) to plan the exercise training 
programme. 
IIa B (9, 
14) 
 An imaging stress test is recommended in patients with 
resting ECG abnormalities which prevent accurate 
interpretation of ECG changes during stress. 
I B (13) 
 An imaging stress test should be considered to assess the 
functional severity of intermediate lesions on coronary 
arteriography. 
IIa B (13) 
Physical 
activity 
counselling 
In the presence of exercise capacity > 5 METs without 
symptoms, return to routine physical activity is recommended; 
otherwise, the patient should resume physical activity at 50% 
of maximal exercise capacity and gradually increase. 
Physical activity should be a combination of activities like 
walking, climbing stairs, cycling and supervised medically 
prescribed aerobic exercise training.  
I B (9, 
15, 
16) 
Exercise 
training 
In low risk patients, at least 2 hours/week aerobic exercise at 
55–70% of the maximum work load (METs) or heart rate at 
I B (9, 
17-
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the onset of symptoms (> 1500 kcal/week) are recommended. 
In moderate to high risk patients, an individualised programme 
is recommended, that starts with < 50% maximum workload 
(METs), resistance exercise at least 1 hour/week, 10 – 15 
repetitions per set to moderate fatigue . 
(refer also to section 3a.3). 
19) 
Diet / 
nutritional 
counselling 
Caloric intake is recommended to be balanced by energy 
expenditure (physical activity) to achieve and maintain healthy 
BMI  
Diet poor in cholesterol and saturated fat is recommended.  
(refer also to section 3a.5). 
I C (9, 
15, 
20) 
Weight control 
management 
Normal-weight CAD patients should be advised to avoid 
weight gain. On each patient visit, it is recommended to 
consistently encourage weight control through an appropriate 
balance of physical activity, caloric intake, and formal 
behavioural programmes when indicated to achieve and 
maintain a healthy BMI  
If waist circumference is ≥ 80 cm in women or ≥ 94 cm in men, 
it is recommended to initiate lifestyle changes and consider 
treatment strategies as indicated (refer also to section 3a.6). 
I B (9, 
15, 
20-
23) 
Lipid 
management 
According to lipid profile, statin therapy is recommended. 
(refer also to section 3a.7)  
I B (9, 
20, 
21) 
 Annual control of lipids, glucose metabolism and creatinine 
are recommended. 
I C  
BP monitoring  A structured approach is recommended (refer to section 
3a.9). 
I B (9, 
20, 
24) 
Smoking 
cessation 
A structured approach is recommended (refer to section 3a.4). I B (9, 
20) 
Psychosocial 
management 
Psychosocial risk factor screening should be considered (refer 
to section 2.4.2) 
IIa B (9, 
16, 
20) 
Multimodal behavioural interventions is recommended (refer 
to section 3a.2) 
I A (9, 
16, 
20) 
ACS = acute coronary syndrome; BMI = body mass index; BP = blood pressure; LVEF = left ventricular 5940 
ejection fraction; MET = metabolic equivalent; PCI – percutaneous coronary intervention. 5941 
aClass of recommendation. 5942 
bLevel of evidence. 5943 
cReference(s) supporting recommendations. 5944 
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 5945 
Acute manifestation of CAD, associated complications and successive management and surveillance 5946 
should be administered according to guidelines. (7, 8, 10-14, 25) Beyond that, survivors need a 5947 
structured support to restore their quality of life and to maintain or improve functional capacity.(20) A 5948 
comprehensive professional lifestyle intervention based on behavioural models of change with different 5949 
strategies, from the more basic, family-based to the more structured and complex modalities, according 5950 
to CV risk assessment and concomitant diseases, is recommended. (9, 10, 20). Risk factor 5951 
management in terms of effective risk factor control, physical activity advice, psychosocial supports and 5952 
appropriate prescription of and adherence to cardio-protective drugs are integral parts,(15-17, 21-24, 26, 5953 
27) to help patients regain as full a life as possible. In short, CAD patients are at high risk and preventive 5954 
measures are keystone. 5955 
The prescription and adherence to behavioural recommendations in the immediate post-event care of 5956 
CAD patients should have as high a priority as other preventive medications and invasive strategies, 5957 
and justify an investment in establishing programmes that systematically enhance early lifestyle 5958 
modification and prevention. In a large cohort of CAD patients from several countries enrolled in the 5959 
Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS) 5 randomized clinical trial,(26) 5960 
adherence to behavioural advice (diet, physical activity, and smoking cessation) after acute 5961 
manifestation of CAD was associated with a substantially lower risk of recurrence. Benefits were seen 5962 
early (< 6 months), and each behaviour modification was additive. Hence, clinical assessment, risk 5963 
factor control and behavioural policies should start as soon as possible, in the acute setting . 5964 
Unfortunately, large proportions of patients still do not achieve the lifestyle, risk factor, and therapeutic 5965 
targets,(28) and attendance at preventive programmes is still low.(29) To properly connect the acute 5966 
and post-acute phase and to favour continuity of care and prevention, the discharge planning is 5967 
fundamental, as it selects and arranges the best next care setting and healthcare services, promotes 5968 
patient and family preventive and education issues, and organizes follow-up. A dedicated discharge 5969 
letter can contribute to implementation(30): beyond primary and secondary diagnosis, procedures and 5970 
clinical progress description, preventive concepts and recommendations oriented to general and 5971 
individual risk factor control, lifestyle intervention, medicine reconciliation, and follow-up arrangements 5972 
should be clearly announced. 5973 
 5974 
Gaps in evidence 5975 
• Although in CAD patients, prevention strategies have been demonstrated in observational studies, 5976 
the best comprehensive tactic, setting and timing are still to be defined. 5977 
 5978 
 5979 
3b.3 Chronic heart failure  5980 
Key message 5981 
• CVD prevention in HF patients should start as soon as possible, and requires a multi-faceted 5982 
integrated tactic. 5983 
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Recommendations for chronic heart failure 5984 
 Recommendations Classa Levelb  Refc 
 The control of fluid status throughout the assessment of 
symptoms and signs is recommended 
I B (11, 
31) 
Patient 
assessment 
 
Identification of precipitating CV and non-CV factors is 
recommended. 
I B (11, 
31, 32) 
Transthoracic echocardiography is the method of choice 
for assessment of myocardial systolic and diastolic 
function of both left and right ventricles. 
I A (11,31, 
33) 
12-lead ECG is recommended in all patients with HF in 
order to determine heart rhythm, heart rate, QRS 
morphology and duration, and to detect other relevant 
abnormalities. This information is needed to plan and 
monitor treatment. 
I C  
The following diagnostic tests are recommended for initial 
assessment of a patient with newly diagnosed HF in order 
to evaluate the patient‘s suitability for particular therapies, 
to detect reversible/treatable causes of HF and co-
morbidities interfering with HF: blood testing (natriuretic 
peptides, complete blood count -haemoglobin/hematocrit, 
WBC and platelet counts- potassium, sodium- creatinine -
with estimated GFR-, C-reactive protein, uric acid, liver 
function tests fasting glucose, HbA1c, fasting lipid profile, 
TSH, ferritin, TSAT = iron/TIBC),  
I B (11, 
31, 33) 
 
Additional laboratory tests should be considered in 
patients admitted due to acute HF based on clinical 
indications 
IIa C  
Chest radiograph (X-ray) is recommended in patients with 
HF to detect/exclude alternative pulmonary or other 
diseases, which may contribute to dyspnoea. It may also 
identify pulmonary congestion/oedema and is more useful 
in patients with suspected HF in the acute setting. 
I C  
Exercise testing (ergospirometry if available) should be 
considered in patients with HF to prescribe adequate 
exercise training program and to discriminate the origin of 
unexplained dyspnea  
IIa C 
 
(34) 
Exercise testing (ergospirometry if available) may be 
considered in patients with HF 
to detect reversible myocardial ischaemia 
IIb C 33 
Exercise testing (ergospirometry if available) is 
recommended in patients with HF as a part of the 
evaluation of patients for heart transplantation and/or 
I C  
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mechanical circulatory support 
Other imaging and non- imaging diagnostic tests should 
be considered in selected clinical situations. 
IIa B (11, 
31, 32) 
Physical activity counselling is recommended. I B (11, 
31, 
32), 
Exercise 
training 
 
Aerobic exercise training is recommended. I A (35, 
36) 
High intensity interval training may be considered in 
selected patients. 
IIb B (37) 
Respiratory training should be considered. IIa B (17, 
38) 
Resistance training may be considered. IIb C (17, 
38) 
Weight control, cachexia and obesity management is recommended (refer 
also to section 3a.6). 
I C (11, 
31, 32) 
Diet/nutritional counselling should be considered (refer also to section 
3a.5). 
IIa C (11, 
31, 32) 
Psychosocial 
management 
Psychosocial screening should be considered (refer to 
section 2.4.2) 
IIa C (11, 
31, 32) 
Psychosocial management is recommended (refer to 
section 3a.2) 
I A (11, 
31, 32) 
Self-care management should be considered. IIa B (11, 
32) 
Home care monitoring should be considered. IIa B (11, 
32) 
CV = cardiovascular. HbA1c = glycated haemoglobin; HF=heart failure;; TIBC = total iron-binding 5985 
capacity; TSAT = transferrin saturation; TSH = thyroid-stimulating hormone; WBC=white blood cells. 5986 
aClass of recommendation. 5987 
bLevel of evidence. 5988 
cReference(s) supporting recommendations. 5989 
HF is a common, disabling and deadly disease, that leads to frequent hospital admissions due to CV 5990 
events (39): HF patients are at high risk, and they deserve special attention throughout a multifaceted 5991 
and multidisciplinary intervention, to start as soon as possible during (26) and after (31) hospital 5992 
admission in order to develop a life-long structured prevention course. In-hospital, clinical management 5993 
and risk assessment are decisive,(11, 32) and selection of a test in daily practice should consider 5994 
availability, local expertise, advantages/disadvantages, and, in the case of several questions to address, 5995 
which test could best answer several of them. CV prevention extends also to physical activity 5996 
counselling, psychological support, and patient/caregiver management education. (31) Clinical stage 5997 
may impact recommendations for preventive measures, as advanced HF might be associated with low 5998 
BP and lipid profile, concomitant CV and non-cardiovascular diseases (such as atrial fibrillation, 5999 
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ventricular arrhythmia, non-revascularizable CAD, previous stroke/TIA, diabetes, anaemia, iron 6000 
deficiency, COPD, renal failure, liver dysfunction, sleep apnoea, cognitive impairment, depression, etc), 6001 
and future strategies (device therapy, heart transplantation and mechanical circulatory support) that 6002 
advocate specialized interventions.(11)  6003 
Although congestion management is critical to improving symptoms and readmission risk, management 6004 
extends beyond diuresis alone, and prevention of adverse CV events requires reducing cardiac injury, 6005 
inhibiting maladaptive systemic responses, and controlling relevant co-morbidities. Lifesaving HF 6006 
therapies should be prescribed as recommended. (11) While the patient’s condition and clinical progress 6007 
are informative, monitoring systems that rely less on patient input are attractive.(40) Since most 6008 
readmissions for HF exacerbations are attributable, at least in part, to poor self-care, non-adherence to 6009 
medications and diet counsels, and failure to act upon escalating symptoms, effective self-care is 6010 
essential for CV prevention. (41)  6011 
Before leaving the hospital, several issues should be considered, and discussed with the patient and 6012 
carers. A discharge plan should be organized to build up an appropriate management strategy aiming to 6013 
prevent CV readmissions: congestion should be absent and a stable oral diuretic regimen established 6014 
for at least 48 hours (11). Long-term disease-modifying therapy should be optimized as much as 6015 
possible and appropriate education provided to the patient and family/caregivers. Pre- and post-6016 
discharge management should follow the standards of care and goals of treatment suggested by ESC 6017 
guidelines.(11) 6018 
Exercise training (ET) should be prescribed in out-patients as a fundamental preventive action in 6019 
stable HF. (35, 36) Since HF patients experience exercise intolerance due to several maladaptive 6020 
changes even on optimal HF medical therapy, (42, 43) exercise training dominates symptoms and 6021 
impacts outcome. The HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of 6022 
Exercise Training) trial showed a 7% reduction in all-cause mortality and all-cause hospitalization, even 6023 
after adjustment for pre-specified predictors of mortality. (36) However, adherence is crucial (44) and 6024 
exercise intensity should be a balance between efficacy and safety. (45) ET protocols vary in most trials 6025 
(see also section 3a.3), even though moderate-vigorous intensity exercise (50–60% peak V̇O2) is 6026 
frequently employed, leading to an average 17% improvement in peak oxygen consumption. (46) In 6027 
selected stable patients, “high intensity interval training” may yield even greater improvements in peak 6028 
V̇O2.(37) Before commencing any ET programme, clinical stability and functional evaluations are 6029 
warranted (17, 38), and a comprehensive flowchart has been proposed.(38)  6030 
Prevention recommendations and intervention modalities in HF with preserved left ventricular ejection 6031 
fraction HF are similar to that of HF with reduced ejection fraction; in particular exercise training therapy 6032 
has shown to be effective as should be recommended. (47-49)  6033 
 6034 
Gaps in evidence 6035 
• Biomarkers may guide therapy in HF hospitalized patients, but further evidence is needed. 6036 
 6037 
 6038 
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3b.4 Cerebrovascular disease 6039 
 6040 
Key message 6041 
• CV risk management in patients with previous TIA or ischaemic stroke is generally comparable to 6042 
that in patients with other ischaemic complications of atherosclerosis. However, treatments may 6043 
differ between stroke types (ischaemic stroke, intracerebral haemorrhage, subarachnoid 6044 
haemorrhage, or cerebral venous sinus thrombosis) and causes. 6045 
 6046 
Recommendations for cerebrovascular disease 6047 
Recommendations Classa Levelb  Refc 
In patients with TIA or stroke, it is recommended to investigate the 
cause of the event and a cardiovascular disease prevention 
program tailored to type and cause of stroke (specific guidelines are 
available). 
I A (2, 
50-
53) 
TIA = transient ischaemic attack. 6048 
aClass of recommendation. 6049 
bLevel of evidence. 6050 
cReference(s) supporting recommendations. 6051 
 6052 
CV risk management in patients with previous TIA or ischaemic stroke is generally comparable to that in 6053 
patients with other ischaemic complications of atherosclerosis. However, treatment may differ between 6054 
stroke types (ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, or cerebral 6055 
venous sinus thrombosis) and causes (e.g., cardio-embolism, large artery atherosclerosis, or small 6056 
vessel disease as the most important of many potential causes of ischaemic stroke). Details can be 6057 
found in recent practice guidelines. (2, 50-53) This paragraph will discuss some aspects specific to 6058 
patients with TIA or stroke.  6059 
In patients with TIA or stroke included in the randomised HPS or SPARCL (Stroke Prevention by 6060 
Aggressive Reduction in Cholesterol Levels) trials, either 40 mg of simvastatin or 80 mg of atorvastatin 6061 
reduced the long-term risk of major CV events, but only atorvastatin reduced the risk of recurrent stroke. 6062 
(54, 55) Most of the included patients had had an ischaemic brain event, and the number of patients 6063 
with prior intracerebral or subarachnoid haemorrhage included in statin trials was too small to 6064 
recommend either starting a statin or to withdraw any statin the patient is using at the time of the 6065 
haemorrhage.(51) This also applies to patients with TIA or ischaemic stroke of cardioembolic origin. 6066 
Despite earlier suggestions of the opposite, there is no evidence that the use of statins is associated 6067 
with an increased risk of intracerebral haemorrhage.(56) There are insufficient data on the effects of 6068 
other statins or other cholesterol-lowering treatments in patients with TIA or stroke, and there are also 6069 
no relevant data supporting the benefit of aiming for a specific LDL-C target in this population.(50) 6070 
Starting BP reduction in the first 48 hours after stroke onset generally does not improve outcome, (57, 6071 
58) probably except in patients who had a spontaneous intracerebral haemorrhage within the previous 6 6072 
hours and who have a systolic blood pressure of 150 mm Hg or above. In these patients, intensive blood 6073 
pressure lowering (with a target systolic level of <140 mm Hg reached within 1 hour) likely has a modest 6074 
benefit. (59)  6075 
In patients with stroke or TIA that has occurred more than 1 week earlier, the use of BP-lowering drugs 6076 
reduces the risk of CAD or (recurrent) stroke. (60) The optimal drug regimen in this population is 6077 
uncertain because just a few strategies have been tested in sufficiently large trials. The evidence of 6078 
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benefit is largest for diuretics alone or diuretics in combination with an ACE-I (50, 61) . In the Perindopril 6079 
Protection Against Recurrent Stroke Study (PROGRESS), the relative reduction in the risk of recurrent 6080 
stroke with the combination of indapamide and perindopril was independent of the baseline BP (62) and 6081 
the risk reduction was larger with larger reductions in SBP. (63) However, data are limited and the 6082 
evidence is not conclusive. For this reason, it appears reasonable to base the choice of a specific drug 6083 
and BP target on individual patient characteristics as described elsewhere in this guideline. 6084 
In patients with TIA or ischaemic stroke of presumed atherosclerotic origin, the combination of aspirin 6085 
30–300 mg daily and dipyridamole 200 mg twice daily is associated with a larger reduction in the risk of 6086 
a major CV event than aspirin alone. (64) Clopidogrel 75 mg once daily is as effective as the 6087 
combination of aspirin and dipyridamole, but is associated with fewer side effects. (65) Patients with TIA 6088 
or ischaemic stroke of presumed cardioembolic origin or stenosis of the carotid or vertebral artery 6089 
should be treated according to the relevant guidelines. (2, 50) 6090 
There is a marked lack of evidence on CVD prevention in patients with unruptured intracranial 6091 
aneurysms and on secondary prevention after intracerebral haemorrhage during treatment with oral 6092 
anticoagulation or subarachnoid haemorrhage, and randomized trials for these conditions are 6093 
warranted. 6094 
 6095 
Gaps in evidence 6096 
• For patients with cryptogenic stroke, it is uncertain whether non-vitamin K antagonist oral 6097 
anticoagulants reduce the risk of future CV events more than antiplatelet drugs. 6098 
• The optimal secondary prevention strategy after subarachnoid haemorrhage is uncertain.  6099 
 6100 
 6101 
3b.5 Peripheral artery disease  6102 
 6103 
Key message 6104 
• PAD is asymptomatic in a large cohort of patients.  6105 
• Preventive treatment is identical with coronary and carotid prevention treatment, but specific studies 6106 
for PAD population and specific treatment targets are lacking 6107 
 6108 
Recommendations for peripheral artery disease 6109 
Recommendations Classa Levelb  Refc 
In all PAD patients BP values controlled to values below 140/90 mmHg are 
recommended.  
I A (66-
68) 
Antiplatelet therapy is recommended  I A (69) 
Statin therapy is recommended  I A (70) 
ACE-I therapy is recommended in patients with symptomatic PAD in patients with 
hypertension.  
I A (66) 
Exercise training is recommended in all patients with PAD  I A (71) 
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It is recommended that all patients with PAD who smoke should be advised to stop 
smoking. 
I B (72) 
ACE-I therapy is should be considered in patients with symptomatic PAD without 
hypertension. 
IIa A (66) 
Beta-blockers should be considered  IIa B (73) 
ACE-I = Ace-inhibitors; BP = blood pressure; CAD = coronary artery disease; LDL-C = low-density 6110 
lipoprotein cholesterol; PAD = peripheral artery disease. 6111 
aClass of recommendation. 6112 
bLevel of evidence. 6113 
cReference(s) supporting recommendations. 6114 
The primary non-invasive test for the diagnosis of lower extremity PAD is the ankle–brachial index (ABI). 6115 
In healthy persons, the ABI is > 1.0. Usually an ABI < 0.90 is used to define PAD. The actual sensitivity 6116 
and specificity have been estimated, respectively, at 79% and 96% (74). For diagnosis in primary care, 6117 
an ABI < 0.8 or the mean of three ABIs < 0.90 had a positive predictive value of ≥ 95%; an ABI > 1.10 or 6118 
the mean of three ABIs > 1.00 had a negative predictive value of ≥ 99% (75). 6119 
The German Epidemiologic Trial on Ankle Brachial Index Study Group included 6880 patients ≥ 65 6120 
years of age and demonstrated that 21% of the cohort had either asymptomatic or symptomatic PAD 6121 
(76). 6122 
The level of ABI also correlates with PAD severity, with high risk of amputation when the ABI is < 0.50. 6123 
An ABI change > 0.15 is generally required to consider worsening of limb perfusion over time, or 6124 
improving limb perfusion after revascularization. 6125 
Smoking is an important risk factor for PAD. In the general population smoking increased the risk of 6126 
PAD between two- and six-fold (72). 6127 
Statins reduce the risk of mortality, CV events, and stroke in patients with PAD with and without CAD 6128 
(70). The Antithrombotic Trialists’ Collaboration meta-analysis (69) combined data from 42 randomized 6129 
studies of 9706 patients with intermittent claudication and/or peripheral arterial bypass or angioplasty. 6130 
The incidence of vascular death, non-fatal MI, and non-fatal stroke at follow-up was significantly 6131 
decreased, by 23%, by antiplatelet drugs with respect to placebo. The efficacy of clopidogrel compared 6132 
with aspirin was studied in the randomized Clopidogrel versus Aspirin in Patients at Risk for Ischaemic 6133 
Events (CAPRIE) trial, including a subgroup of 6452 patients with PAD.(77) At 1.9-years follow-up, the 6134 
annual combined incidence of vascular death, non-fatal MI, and non-fatal stroke in the PAD group was 6135 
3.7% and 4.9%, respectively, in the clopidogrel and aspirin groups, with a significant 23.8% decrease 6136 
with clopidogrel, with no major differences in terms of safety . 6137 
Treatment with ACE-I has shown a beneficial effect beyond a BP decrease in high-risk groups. In the 6138 
Heart Outcomes Prevention Evaluation (HOPE) trial, ramipril significantly reduced cardiovascular events 6139 
by 25% in patients with symptomatic PAD without known low ejection fraction or heart failure. (66) The 6140 
ONTARGET trial showed equivalence of telmisartan to ramipril in these patients (67). 6141 
Importantly, beta-blockers are not contraindicated in patients with PAD. A meta-analysis of 11 6142 
randomized controlled studies found that beta-blockers did not adversely affect walking capacity or 6143 
symptoms of intermittent claudication in patients with mild to moderate PAD(73). 6144 
Symptoms can be treated conservatively or invasively. In patients with PAD, training therapy is effective 6145 
in improving symptoms and increasing exercise capacity. In meta-analyses (71) compared with usual 6146 
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care or placebo, exercise significantly improved maximal walking time, with an overall improvement in 6147 
walking ability. The types of exercise varied from strength training to polestriding and upper or lower 6148 
limb exercises, generally supervised sessions, at least twice a week. Cilostazol, naftidrofuryl and 6149 
pentoxyfilline improve pain-free distanc. For other options please refer to ESC Guidelines on the 6150 
diagnosis and treatment of peripheral arterial disease.(70) 6151 
 6152 
Gaps in evidence 6153 
• There are few studies specific for the PAD population. Most of the data comes from CAD patients 6154 
with concomitant PAD. More specific data on the PAD population are needed 6155 
  6156 
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Web Figures  6157 
 6158 
A. Predicted vascular deaths avoided over 5 years from reductions in LDL-C with statin treatment at 6159 
different levels of CVD risks [Jackson R, Kerr A, Wells S. Vascular risk calculators essential but 6160 
flawed clinical tools? Circulation. 2013 May 14;127(19):1929-31] 6161 
B. Lifetime risk calculator based on the JBS3 web-based tool  6162 
C. Modified World Health Organization (WHO) smoking cessation algorithm. 6163 
D. How can governments support healthy food preferences? 6164 
 6165 
  6166 
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 6167 
 6168 
 6169 
Figure A Predicted vascular deaths avoided over 5 years from reductions in LDL-C with statin treatment 6170 
at different levels of CVD risks [Jackson R, Kerr A, Wells S. Vascular risk calculators essential but 6171 
flawed clinical tools? Circulation. 2013 May 14;127(19):1929-31] 6172 
6173 
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 6174 
 6175 
Figure B Lifetime risk calculator based on the JBS3 web-based tool.  6176 
 6177 
6178 
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 6179 
 6180 
Figure C. Modified World Health Organization (WHO) smoking cessation algorithm. 6181 
6182 
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 6183 
 6184 
Figure D. How can governments support healthy food preferences? 6185 
6186 
 162 
6JTF_Mastercopy_Web 20160105 CONFIDENTIAL DOCUMENT 163 
 
Web Tables 6187 
A. Table for different risk factor combinations for more accurate estimation of risk ages 6188 
B. Self-assessment questionaires PAR-Q & YOU 6189 
C. World Health Organization classification of body weight according to body mass index in adults  6190 
D. Measures of general obesity and abdominal adiposity 6191 
E. Selected drugs that may increase risk of myopathy and rhabdomyolysis when used concomitantly 6192 
with statin (CYP3A4 inhibitors/substrates or other mechanisms) 6193 
F. Reasons for medication non-adherence according to the World Health Organization  6194 
6195 
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Table A. Table for different risk factor combinations for more accurate estimation of risk ages.  6196 
 6197 
6198 
WOMEN MEN
Non-Smokers Smokers Age Non-Smokers Smokers
180 78 80 >80 >80 >80 180 >80 >80 >80 >80 >80 180 >80 >80 >80 >80 >80 180 >80 >80 >80 >80 >80
160 73 75 76 78 80 160 >80 >80 >80 >80 >80 65 160 76 79 >80 >80 >80 160 >80 >80 >80 >80 >80
140 69 70 72 74 76 140 76 78 80 >80 >80 140 70 73 75 78 >80 140 >80 >80 >80 >80 >80
120 65 66 68 69 71 120 72 73 75 77 79 120 65 67 70 72 75 120 75 77 >80 >80 >80
180 72 73 75 76 78 180 79 >80 >80 >80 >80 180 76 78 >80 >80 >80 180 >80 >80 >80 >80 >80
160 68 69 70 72 74 160 75 76 78 80 >80 60 160 70 72 75 78 80 160 80 >80 >80 >80 >80
140 64 65 66 68 70 140 70 72 73 75 77 140 65 67 69 72 75 140 74 77 80 >80 >80
Systolic 120 60 61 63 64 66 120 66 68 69 71 73 120 60 62 64 67 69 120 69 71 74 77 80
Blood
Pressure 180 66 67 68 70 71 180 72 74 75 77 79 180 69 71 74 76 79 180 79 >80 >80 >80 >80
(mmHg) 160 62 63 64 66 67 160 68 69 71 73 74 55 160 64 66 68 71 74 160 73 76 79 >80 >80
140 58 59 61 62 64 140 64 65 67 69 70 140 59 61 63 66 68 140 68 70 73 76 79
120 55 56 57 59 60 120 61 62 63 64 66 120 55 57 59 61 64 120 63 65 68 70 73
180 59 60 62 63 64 180 65 66 68 69 71 180 62 64 67 69 72 180 71 74 77 80 >80
160 56 57 58 59 61 160 62 63 64 66 67 50 160 58 60 62 64 67 160 66 68 71 74 77
140 53 54 55 56 58 140 58 59 61 62 64 140 54 56 58 60 62 140 61 64 66 68 71
120 50 51 52 53 55 120 55 56 57 59 60 120 50 52 54 56 58 120 57 59 61 64 66
180 53 54 55 56 57 180 58 59 60 62 63 180 56 58 60 62 64 180 64 66 68 71 74
160 50 51 52 53 54 160 55 56 57 59 60 45 160 52 54 55 57 60 160 59 61 63 66 68
140 48 48 49 50 52 140 52 53 54 55 57 140 48 50 52 54 56 140 55 57 59 61 64
120 45 46 47 48 49 120 49 50 51 52 54 120 45 47 48 50 53 120 51 53 55 57 59
180 47 48 49 50 51 180 51 52 53 54 55 180 49 51 52 54 56 180 56 58 60 62 65
160 45 46 46 47 48 160 49 49 50 51 53 40 160 46 47 49 51 53 160 52 54 56 58 60
140 43 43 44 45 46 140 46 47 48 49 50 140 43 44 46 47 49 140 48 50 52 54 56
120 40 41 42 43 44 120 44 45 45 46 48 120 40 41 43 44 46 120 45 47 49 51 52
4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8
Total Cholesterol (mmol/l) Total Cholesterol (mmol/l)
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Table B. Self-assessment questionaires PAR-Q & YOU 6199 
 6200 
 6201 
 6202 
 6203 
Link: http://www.csep.ca/cmfiles/publications/parq/par-q.pdf) 6204 
  6205 
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Table C World Health Organization classification of body weight according to body 6206 
mass index in adults  6207 
 6208 
Adults (> 18 years of age) BMI (kg/m2) 
Underweight < 18.5 
Normal 18.5–24.9 
Overweight 25–29.9 
Obese ≥ 30 
 Class 1 30–34.9 
 Class 2 35–39.9 
 Class 3 ≥ 40 
BMI = body mass index. 6209 
   6210 
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Table D Measures of general obesity and abdominal adiposity 6211 
 6212 
A. Measures of general obesity 
– body mass index 
B. Measures of abdominal adiposity  
– waist circumference 
– waist:hip ratio 
– waist:height ratio 
C. Direct measures of fat mass 
– bioelectrical impedance analysis 
– skinfold thicknesses 
D. Measures of general obesity and abdominal adiposity 
 – dual-energy X-ray absorptiometry 
 – ultrasound 
 – computed tomography 
 – magnetic resonance imaging 
 6213 
 6214 
  6215 
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Table E. Selected drugs that may increase risk of myopathy and rhabdomyolysis when used 6216 
concomitantly with statin (CYP3A4 inhibitors/substrates or other mechanisms) 6217 
 6218 
CYP3A4 Inhibitors/substrates Others 
Cyclosporine, tacrolimus, sirolimus Digoxin 
Macrolides (azithromycin, clarithromycin, erythromycin, 
telithromycin) 
Fibrates (gemfibrozil) 
Azole antifungals (fluconazole, itraconazole, ketoconazole, 
posaconazole)  
Niacin 
Calcium antagonists (mibefradil, diltiazem, verapamil)  
Nefazodone  
HIV protease inhibitors (amprenavir, atazanavir, darunavir, 
fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, 
saquinavir) 
 
Hepatitis C drugs (boceprevir, telaprevir)  
Danazol  
Amiodarone  
Grapefruit juice  
Sildenafil  
Warfarin  
 6219 
6220 
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Table F. Reasons for medication non-adherence according to the World Health Organization  6221 
 6222 
Category of non-adherence Example 
Health system Poor quality of provider–patient relationship; poor 
knowledge on medication and/or low acceptance of 
guidelines; poor communication (e.g. limited, complex or 
confusing advice); lack of access to healthcare; lack of 
continuity of care. 
Condition Asymptomatic chronic disease (lack of physical cues); co-
morbid mental health disorders (e.g. depression). 
Patient Physical impairments (e.g. vision problems or impaired 
dexterity); cognitive impairment; psychological/behavioural 
factors (e.g. lack of motivation, low self–efficacy, 
impulsivity); younger age. 
Therapy Complexity of regimen; side-effects. 
Socioeconomic Low literacy; high medication costs; poor social support. 
  6223 
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